Synthetic neuromodulatory peptides
By developing synthetic neuromodulatory peptide compositions that regulate GABA-A receptors and voltage-gated calcium channels, the specificity and side effects of existing treatment methods for depression and anxiety are solved, and safe and effective relief in a short period of time symptom.
Patent Information
- Application Number
- CN202080021130.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-14
- Filing Date
- 2020-03-13
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-03-13
AI Technical Summary
The existing treatment methods for depression and anxiety are mostly inconsistent, and are ineffective in about 40% of patients. They have great side effects. It takes several weeks for traditional drugs to show results, and it is difficult to relieve symptoms safely and effectively in a short period of time. .
A composition containing specific synthetic neuromodulatory peptides was developed to treat depression and anxiety by regulating GABA-A receptors and voltage-gated calcium channels, including tetrapeptides FQSE, DKTE and WDQV, etc., designed by computer and in vitro and in vitro experiments to verify its anti-anxiety and anti-depressive activities.
The composition showed significant anti-anxiety and antidepressant effects in animal models, could show therapeutic effects in a shorter time, and had better safety and specificity than traditional drugs, without causing sedative side effects.
Smart Images

Figure BDA0003261373470000471 
Figure BDA0003261373470000481 
Figure BDA0003261373470000641
Abstract
Description
[0001] priority
[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 818,458, filed on March 14, 2019, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to compositions comprising proteins, such as peptide therapeutics, to treat depression and other psychiatric disorders.
[0004] Description of the electronically submitted text file
[0005] The contents of the electronically submitted text file are incorporated herein by reference in their entirety: Computer readable format copy of the Sequence Listing (File Name: LACT-001PC_ST25.txt; Record Date: March 13, 2020; File Size: 5,862 bytes). Background Art
[0006] Depression, which occurs among a variety of conditions that affect the subject's mood, affects millions of people worldwide and its treatment remains generally insufficient. Although a variety of drugs have been developed to treat depression and related conditions, these drugs are generally not specific enough and are ineffective for about 40% of patients. At the same time, it usually takes several weeks for patients to benefit from the therapeutic effects of the drug. In addition, many known drugs have multiple side effects. Although anxiety disorders are different from depression, they are often accompanied by depression. Many antianxiety drugs have similar problems to antidepressants. One challenge in the discovery of effective treatments for depression and anxiety is to identify suitable targets for upregulation or downregulation. Another challenge is to design safe, low-cost therapies that are specific to these targets and can relieve depression and anxiety symptoms in a relatively short period of time.
[0007] Therefore, there remains a need to develop effective and safe therapies for treating depression and related disorders. Summary of the invention
[0008] In various aspects, the present invention provides compositions and methods that can be used to treat a variety of psychiatric, behavioral, affective, neurological and emotional diseases, including depression, anxiety and stress-related diseases. In some aspects, synthetic neuromodulatory peptides in the form of pharmaceutical compositions, such as tetrapeptides, can be used to treat depression and other emotional diseases. In some embodiments, a composition is provided, which comprises a synthetic neuromodulatory peptide defined by the general formula I: R1R2R3R4 (I), wherein R1 is selected from amino acids W, F and D, R2 is a hydrophilic amino acid, R3 is a hydrophilic amino acid, and R4 is selected from amino acids V and E. In some embodiments, the synthetic neuromodulatory peptide consists of amino acids F, Q, S and E. In some embodiments, the synthetic neuromodulatory peptide consists of amino acids D, K, T and E. In some embodiments, the synthetic neuromodulatory peptide consists of amino acids W, D, Q and V. According to the embodiment, the synthetic neuromodulatory peptide or its analog does not contain proline. In some embodiments, R1 is different from Y and R2 is different from L.
[0009] The neuromodulatory peptides and their analogs described herein are developed to modulate GABA-A receptors. In addition, in some embodiments, the neuromodulatory peptides and their analogs described herein can modulate voltage-gated calcium channels (VGCC). In view of the known connection between GABA-A receptors and psychiatric disorders (including anxiety and depression), the neuromodulatory peptides disclosed herein can effectively prevent or treat a variety of depression-anxiety spectrum disorders and neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Non-limiting examples of conditions that can be treated using the neuromodulatory peptides include anxiety disorders, such as separation anxiety disorder, selective mutism, specific phobia (SP), social anxiety disorder (SAD), panic disorder, agoraphobia, substance / medication-induced anxiety disorders and anxiety disorders attributed to another medication condition, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), major depressive disorder (MDD), treatment-resistant depression (TRD), postpartum depression (PPD), bipolar disorder or bipolar depression, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), and schizophrenia. disorder, ADHD), social phobia, agitation in Alzheimer's disease, aggression in Alzheimer's disease, and obsessive-compulsive disorder.
[0010] In some aspects, the tetrapeptide can be optionally chemically modified. The chemical modification can be selected from amidation, methylation and acetylation of one or more amino acids. Other chemical modifications can include the addition of formyl, pyroglutamyl (pGlu), one or more fatty acids, urea, carbamate, sulfonamide, alkylamine or any combination thereof. The composition can include a pharmaceutically acceptable carrier. In some embodiments, the composition can further include a delivery vehicle, which can be, for example, a liposome, a nanoparticle or a polysaccharide. The composition can be administered to a subject determined to need treatment by various routes, and in some aspects, the composition is formulated for intranasal administration.
[0011] BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1A , 1B and 1C shows 1.25 mg / kg ( Figure 1A ) and 5mg / kg( Figure 1B and Figure 1C ) doses of diazepam on behavioral parameters of zebrafish (Daniorerio). Figure 1A : Time spent in and out of social or "shoal" areas. Figure 1B : Time spent in and out of social or "shoal" areas. Figure 1C : Time spent in the light chamber. The ordinate represents the time in seconds ( Figure 1A and 1B ) or the percentage of the control group ( Figure 1C ). Data are shown as mean values, error bars indicate standard error of the mean, “*” indicates p < 0.05, “**” indicates p < 0.01, and “****” indicates p < 0.0001 according to Mann-Whitney U-test.
[0013] Figure 2 This is a perspective view of a system for testing fish behavior used in an open field test.
[0014] Figure 3 A perspective view of a system for testing fish behavior used in a Light / Dark preference test.
[0015] Figure 4 A perspective view of a fish behavior test system used in a shoaling behavior test.
[0016] Figure 5A , 5Band 5C show the effects of a 10 mg / kg dose of diazepam on behavioral parameters in zebrafish. Figure 5A : The number of transitions between the light and dark compartments of the experimental light-dark box. The ordinate represents the number of transitions. Figure 5B : Latency of retreating from the dark compartment to the light compartment. The ordinate represents the time in seconds. Figure 5C : Average distance covered in the open field test. The ordinate represents the length in centimeters. Data are shown as mean values, error bars represent standard error of the mean, "*" indicates p < 0.05, "**" indicates p < 0.01 according to the Mann-Whitney U-test.
[0017] Fig. 6A and 6B It is shown that 5 mg / kg ( Fig. 6A ) and 10mg / kg( Figure 6B ) doses of fluvoxamine on the time spent on the surface of the aquarium in the open field test. The ordinate represents the time in seconds. Data are shown as means, error bars represent standard errors of the mean, and "**" indicates p < 0.01 according to the Mann-Whitney U-test.
[0018] Fig. 7A and 7B Shown are the effects of α-Casozepine-10 (ACZ-10) at a dose of 0.6 mg / kg on behavioral parameters of zebrafish. Fig. 7A : Time spent near social areas. Figure 7B : Time spent on the surface in the open field test. The ordinate represents the time in seconds. Data are shown as mean values, error bars represent standard error of the mean, "*" represents p<0.05, and "**" represents p<0.01 according to the Mann-Whitney U-test.
[0019] Fig. 8A and 8B Shown are the effects of 5 mg / kg dose of Beta-Casomorphin-7 (BCM-7) on behavioral parameters of zebrafish. Fig. 8A : Time spent in the "social zone". The vertical axis represents the time in seconds. Figure 8B : Average length covered in the open field test. The ordinate represents the length in centimeters. Data are shown as mean values, error bars represent standard error of the mean; and according to the Mann-Whitney U-test, "*" indicates p<0.05.
[0020] Fig. 9Shown are the average lengths covered in the open field test by groups of fish exposed to diazepam at doses of 1.25 mg / kg ("Diaz 1.25"), 5 mg / kg ("Diaz 5"), and 10 mg / kg ("Diaz 10") and the corresponding controls ("Control-diaz 1.25", "Control-diaz 5", and "Control-diaz 10"), as well as groups of fish exposed to fluvoxamine at doses of 5 mg / kg ("Fluv 5") and 10 mg / kg ("Fluv 10") and the corresponding controls ("Control-fluv5") and ("Control-fluv 10") . In fish administered ACZ-10 (0.6 mg / kg) and BCM-7 (5 mg / kg), the corresponding controls were Control-ACZ10 and Control-BCM-7, respectively. The ordinate represents the length in centimeters. The data are shown as the mean, and the error bars represent the standard error of the mean. According to Mann-Whitney U-test, p=0.1 and p=0.07 were classified as statistically significant.
[0021] Fig. 10A and 10B Shown is the effect of the neuromedin FQSE (SEQ ID NO: 10) on zebrafish behavior in the open field test. Fig. 10A : Time spent in the upper part of the aquarium. Fig. 10B : Latency to leave the bottom. The ordinate represents the time in seconds. Data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05.
[0022] Fig.11A and 11B Shown is a comparison of the effects of ACZ10, FQSE (SEQ ID NO: 10), and fluvoxamine on zebrafish behavior in the open field test. Fig.11A : Time spent in the upper part of the aquarium, expressed as % relative to the control group. Fig. 11B : Latency to leave the bottom, expressed as % relative to the control group. The ordinate represents the % value relative to the control group. Data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p < 0.05.
[0023] Fig. 12A and 12B Shown is the effect of FQSE (SEQ ID NO: 10) on zebrafish behavior in a light / dark box (LDB) test. Fig. 12A : Time spent in the light compartment of the LDB. Fig. 12B: Time spent in the dark compartment of the LDB. The ordinate represents the time in seconds. The data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05.
[0024] Fig.13A and 13B Shown is a comparison of the effects of test substances on zebrafish behavior in a light / dark test. Fig.13A : Time spent in the light compartment of the LDB, expressed as % relative to the control group. Fig. 13B : Time spent in the dark compartment of LDB, expressed as % relative to the control group. The ordinate represents the % value relative to the control group. Data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05, and "**" represents p<0.01.
[0025] Fig.14A and 14B Shown is the effect of FQSE (SEQ ID NO: 10) on zebrafish behavior in a shoaling test. Fig.14A : Time spent outside the shoaling compartment. Fig. 14B : Latency to leave the cluster compartment. The ordinate represents the time in seconds. Data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05.
[0026] Fig.15A and 15B Shown is a comparison of the effects of test substances on zebrafish behavior in a swarming assay. Fig.15A : Time spent outside the group area, expressed as % relative to the control group. Fig. 15B : Delay period to leave the cluster compartment, expressed as % relative to the control group. The ordinate represents the % value relative to the control group. Data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05, and "**" represents p<0.01.
[0027] Fig.16A and 16B Shown is a comparison of the effects of test substances on zebrafish behavior in the open field test. Fig.16A : Time spent near the water surface. Fig. 16B: Comparison of the effects of FQSE (SEQ ID NO: 10) (1 mg / kg) and fluvoxamine (10 mg / kg), time spent near the water surface, expressed as % relative to the control group. The ordinate represents the % value relative to the control group. Data are shown as means, error bars represent standard error of the mean, and "*" represents p<0.05 according to the Mann-Whitney U-test.
[0028] Fig.17A and 17B Comparison of the effects of test substances on zebrafish behavior in the open field test is shown. Fig. 17A: Latency to come to the water surface. Fig. 17B : Comparison of the effects of FQSE (SEQ ID NO: 10) (1 mg / kg) and fluvoxamine (10 mg / kg), latency to the water surface, expressed as % relative to the control group. The ordinate represents the % value relative to the control group. Data are shown as mean values, error bars represent standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05, and "**" represents p<0.01.
[0029] Fig.18 Shown are the average track lengths in the open field test for groups of fish administered diazepam at doses of 1.25 mg / kg ("Diazepam 1,25"), 5 mg / kg ("Diazepam 5") and 10 mg / kg ("Diazepam 10"), and the corresponding control groups ("Contr-diaz 1,25", "Contr-diaz 5" and "Contr-diaz 10"), as well as for groups of fish treated with 5 mg / kg ("Fluvoxamine 5") and 10 mg / kg ("Fluvoxamine 10"), and the corresponding control groups ("Control-fluv 5" and "Control-fluv 10"). For the fish group administered with 0.6 mg / kg ACZ-10 ("ACZ-10 0,6"), the control group was named "Control-ACZ,-10 0,6" accordingly; BCM-7 5 mg / kg was "BCM-7 5" and "Control-BCM-7 5" accordingly; tetrapeptide FQSE (SEQ ID NO: 10) doses of 1 mg / kg and 10 mg / kg ("FQSE 1" and "FQSE 10") - "Control-FQSE 1" and "Control-FQSE 10". The ordinate represents the length in centimeters. The data are shown as the mean, and the error bars represent the standard error of the mean.
[0030] Fig.19A , 19B 19C and 19C show behavioral parameters of zebrafish injected with a 1 mg / kg dose of FLPY (SEQ ID NO: 36). Fig.19A : Time spent near the surface (open field). Fig.19B : Time spent in the light compartment of the LDB. Fig.19C : Time spent outside the gathering area. The ordinate represents the time in seconds. The data are shown as the mean, and the error bars represent the standard error of the mean.
[0031] Fig. 20A , 20B 20C show behavioral parameters of zebrafish injected with a 10 mg / kg dose of FLPY (SEQ ID NO: 36). Fig. 20A : Time spent near the surface (open field). Fig. 20B : Time spent in the light compartment of the LDB. Fig. 20C : Time spent outside the gathering area. The ordinate represents the time in seconds. The data are shown as the mean, and the error bars represent the standard error of the mean.
[0032] Fig.21A , 21B 21C show the behavioral parameters of zebrafish injected with 1 mg / kg dose of DKTE (SEQ ID NO: 26) in a grouping assay. Fig.21A : Time spent outdoors in group areas. Fig.21B : Latency to visit the swarming compartment. Figure 21: Time spent near the swarming compartment. The ordinate represents time in seconds. Data are shown as mean values, error bars represent standard error of the mean, "*" indicates p < 0.05, and "**" indicates p < 0.01 according to the Mann-Whitney U-test.
[0033] Fig. 22 Shown are measured values of latency to visit the bottom in the open field test for a control group ("Control") and a group administered 1 mg / kg DKTE (SEQ ID NO: 26) ("DKTE 1"). The ordinate represents time in seconds.
[0034] Fig.23A comparison of the effects of test substances on zebrafish behavior in a grouping test is shown. The time spent outside the grouping area is shown as a % relative to the control group. The following groups are shown: 1.25 mg / kg diazepam ("diazepam 1,25"), 1.25 mg / kg control diazepam ("control-diaz 1,25"), 10 mg / kg FQSE (SEQ ID NO: 10) ("FQSE 10"), 10 mg / kg control FQSE (SEQ ID NO: 10) ("control-FQSE"), 1 mg / kg DKTE (SEQ ID NO: 26) ("DKTE1"), and 1 mg / kg control DKTE (SEQ ID NO: 26) ("control-DKTE 1"). The ordinate represents the change in time, expressed as a % relative to the control group. The data are shown as the mean, the error bars represent the standard error of the mean, and according to the Mann-Whitney U-test, "*" represents p<0.05, and "**" represents p<0.01.
[0035] Fig.24A and 24B Shown are parameters of locomotor activity in the open field test at a dose of 1 mg / kg of DKTE (SEQ ID NO: 26). Fig.24A : The length of the trajectory along the ordinate axis, in cm. Fig. 24B : Average velocity, the vertical axis shows the velocity in cm / sec. The data are shown as the mean, and the error bars represent the standard error of the mean.
[0036] Fig.25A , 25B 25A and 25C show behavioral parameters of zebrafish injected with a 10 mg / kg dose of DKTE (SEQ ID NO: 26). Fig.25A : Time spent near the surface (open field). Fig.25B : Time spent in the light compartment of the LDB. Fig.25C : Time spent outside the gathering area. The ordinate represents the time in seconds.
[0037] Fig.26A , 26B 26C and 26C show behavioral parameters of zebrafish injected with WDQV (SEQ ID NO: 14) at a dose of 1 mg / kg. Fig.26A : Time spent near the surface (open field). Fig.26B : Time spent in the light compartment of the LDB. Fig.26C : Time spent outside the gathering area. The ordinate represents the time in seconds. The data are expressed as the mean, and the error bars represent the standard error of the mean.
[0038] Fig.27A , 27B , 27C and 27D show the behavioral parameters of zebrafish injected with WDQV (SEQ ID NO: 14) at a dose of 10 mg / kg in the light / dark box test. Fig.27A : Time spent in the bright compartment of the LDB (total), expressed in seconds. Fig.27B : Time spent in the bright compartment of the LDB (dynamic within minutes of the experiment), expressed in seconds. Fig.27C : Time spent in the dark chamber of the LDB (total), expressed in seconds. Fig.27D : Time spent in the dark compartment of the LDB (dynamic within a few minutes of the experiment), expressed in seconds. The axis coordinates represent the time expressed in seconds. Data are expressed as mean values, error bars define the standard error of the mean value, and according to the Mann-Whitney U-test, "*" indicates p<0.05.
[0039] Fig.28A and 28B Shown are the effects of WDQV (SEQ ID NO: 14) at a dose of 10 mg / kg in the light / dark test compared to the effects of diazepam (5 mg / kg) and FQSE (SEQ ID NO: 10) (10 mg / kg) and corresponding controls. Fig.28A : Time spent in the bright compartment of the LDB, expressed in seconds. Fig.28B : Time spent in the dark chamber of the LDB, expressed in seconds. Data are presented as mean values, error bars define standard error of the mean, and "*" indicates p<0.05 according to the Mann-Whitney U-test.
[0040] Fig.29Shown are the average track lengths in the open field test for groups of fish administered diazepam at doses of 1.25 mg / kg ("Diazepam 1,25"), 5 mg / kg ("Diazepam 5"), and 10 mg / kg ("Diazepam 10"), as well as the corresponding control groups ("Contr-diaz 1,25", "Control-diaz5", and "Control-diaz 10"), and for groups of fish administered fluvoxamine at doses of 5 mg / kg ("Fluvoxamine 5") and 10 mg / kg ("Fluvoxamine 10"), as well as the corresponding control groups ("Control-fluv 5" and "Control-fluv 10"). For the group of fish administered 0.6 mg / kg ACZ-10 ("ACZ-10 0,6"), the corresponding control group was "Control-ACZ-10"; for the group of fish administered 5 mg / kg BCM-7 ("BCM-75"), the corresponding control group was "Control-BCM-7"; and for the group of fish administered a 10 mg / kg dose of the tetrapeptide WDQV (SEQ ID NO: 14) ("WDQV 10"), the corresponding control group was "Control-WDQV 10".
[0041] Fig.30 Total distances in cm for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg in an open field test in mice are shown. Each bar represents the mean total distance ± SEM. Significant differences are indicated by a "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0042] Fig.31 The number of rearings in an open field test in mice is shown for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg, and 20 mg / kg. Each bar represents the mean number of rearings ± SEM for each group. Significant differences are indicated by a "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0043] Fig.32 The number of center entries in the open field test in mice is shown for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg. Each bar represents the mean number of center entries for each group ± SEM. Significant differences are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0044] Fig.33 The total distance in the elevated plus maze test in mice is shown for 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg concentrations of FQSE (SEQ ID NO: 10) peptide, expressed in cm. Each bar represents the mean total distance ± SEM. Significant differences from the control group are indicated by a "*" symbol, and significant differences from the diazepam group are indicated by a "#" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0045] Fig.34 Shown is the immobility in the elevated plus maze test in mice for 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg concentrations of FQSE (SEQ ID NO: 10) peptide, expressed in seconds. Each bar represents the mean immobility time ± SEM for each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0046] Fig.35 The time on open arms in the elevated plus maze test in mice is shown for 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg concentrations of FQSE (SEQ ID NO: 10), expressed in seconds. Each bar represents the mean open arm time ± SEM for each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0047] Fig.36 The number of open arm entries in the elevated plus maze test for FQSE (SEQ ID NO: 10) peptide at 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg concentrations is shown. Each bar represents the mean number of open arm entries for each group ± SEM. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0048] Fig.37 The number of occurrences of risky behaviors in the elevated plus maze test for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg is shown. Each bar represents the mean number of risky behaviors ± SEM for each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0049] Fig.38 Anxiety index in the elevated plus maze test for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg is shown. Each bar represents the mean anxiety index ± SEM of each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0050] Fig.39 The results of the marble burying test (number of buried beads) are shown for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg. Each bar represents the mean number of buried beads ± SEM for each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0051] Fig.40 Immobility in the Porsolt swim test (two-day modification) is shown for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg, expressed in seconds. Each bar represents the mean total duration of immobility for each group ± SEM. Significant differences from the control group are indicated with a "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0052] Fig.41 Passive swimming duration in the Porsolt swim test (two-day correction) is shown for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg, expressed in seconds. Each bar represents the mean passive swimming duration ± SEM for each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0053] Fig.42The active swimming duration in the Porsolt swim test (two-day correction) is shown for FQSE (SEQ ID NO: 10) peptide at concentrations of 1 mg / kg, 5 mg / kg, 10 mg / kg and 20 mg / kg, expressed in seconds. Each bar represents the mean passive swimming duration ± SEM for each group. Significant differences from the control group are indicated by the "*" symbol (one-way ANOVA followed by Fisher's LSD test; p<0.05).
[0054] Fig.43A , 43B and 43C show the behavior of rats in the OF test. Fig.43A : Effects of different doses of FQSE (SEQ ID NO: 10) and diazepam (DZ) on central zone time (expressed in seconds). Fig.43B : Effects of different doses of FQSE (SEQ ID NO: 10) and diazepam (DZ) on the number of central zone entries. Fig.43C : Effect of different doses of FQSE (SEQ ID NO: 10) and diazepam (DZ) on total distance traveled (cm). Each bar represents the mean ± SEM. *-p < 0.05 compared to vehicle (0), #-p < 0.05 compared to diazepam (DZ). One-way ANOVA with Fisher's least significant difference (Least Significant Difference, LSD) post hoc test was used.
[0055] Fig.44 Shown are the effects of different doses of FQSE (SEQ ID NO: 10) and diazepam (DZ) on the percentage (%) of time spent in the open arms in the EPM. * - p < 0.05 compared to vehicle (0). One-way ANOVA with Fisher's least significant difference (LSD) post hoc test was used.
[0056] Fig.45A and 45B The behavior of rats in the FST is shown. Fig.45A : Effect of different doses of FQSE (SEQ ID NO: 10) and ketamine (10 mg / kg, K10) on immobility time (expressed in seconds). 45B: Effect of different doses of FQSE (SEQ ID NO: 10) and ketamine (10 mg / kg, K10) on activity time (expressed in seconds). Each bar represents the mean ± SEM. *-p < 0.05 compared to vehicle (0). One-way ANOVA with Fisher's least significant difference (LSD) post hoc test was used.
[0057] Fig.46The experimental schedule is shown. SPT-Sucrose Preference Test, Sucrose Solution Preference Test, CUMS-Chronic Mild Stress test, Chronic Unpredictable Mild Stress, EPM-Elevated Plus Maze, Elevated Plus Maze test, SI-Social Interaction, Social Interaction test, FUST-Female Urine Sniffing Test, Female Urine Sniffing Test, NSFT-Novelty Suppressed Feeding Test, Suppression of Food Consumption in a New Environment, FST-Forced Swim Test.
[0058] Fig.47A and 47B Shown are the behaviors of rats in the EPM test after CUMS and one drug injection. Fig.47A : Time spent in open arms, expressed in seconds. Fig.47B : Freezing time, expressed in seconds. Each bar represents mean ± SEM. *p<0.05 represents significant difference from control group, #-p<0.05-significant difference from CUMS+veh group, $-p<0.05 compared with diazepam group. Kruskal-Wallis and Dunn multiple comparison tests were used.
[0059] Fig.48 Shown is the duration of social interaction in the SI test after CUMS and four injections of drug (expressed in seconds). Each column represents the mean ± SEM. *-p<0.05 represents a significant difference from the control group, and #-p<0.05-significantly different from the CUMS+veh group. One-way ANOVA with Fisher LSD test was used.
[0060] Fig.49Female urine preference index (expressed in %) in FUST after CUMS and 8 drug injections is shown. Each column represents mean ± SEM. *-p<0.05 represents significant difference from control group, and #-p<0.05-significant difference from CUMS+veh group. One-way ANOVA with Fisher LSD test was used.
[0061] Fig.50 Kaplan-Mayer survival curves are shown. On the x-axis - latency to start eating (expressed in seconds), Y - proportion of animals that did not start eating. The introduction of the substance was carried out for eleven days. *-p<0.05 represents a significant difference from the control group, and #-p<0.05-significant difference from the CUMS+veh group. Chi-square criterion and Cox-Mantel test were used.
[0062] Fig.51 The sucrose preference index (expressed in %) after CUMS and 16 injections of the investigated substances is shown. Each bar represents the mean ± SEM. * - p < 0.05 - significantly different from the control group. Kruskal-Wallis with Dunn's multiple comparison test was used.
[0063] Fig.52 Shown are the immobility times (in seconds) in the FST after CUMS and 18 injections of the study substance. Each column represents the mean ± SEM. *-p<0.05 represents a significant difference from the control group, and #-p<0.05-is significantly different from the CUMS+veh group. Kruskal-Wallis and Dunn multiple comparison tests were used.
[0064] Fig.53A , 53B 53A and 53C show the behavior of rats in predator odor stress exposure and conditioned place aversion paradigm. Fig.53A : Display of conditioned place aversion after exposure to predator odor or no odor. Tests were performed 24 hours post-conditioning. Fig.53B : Conditioned place aversion after exposure to no odor in the group that was pretreated after no odor exposure and before the test conducted 24 h after treatment. Fig.53C: Conditioned place aversion after exposure to predator odor in the group pretreated after odor exposure and before the test performed 24 hours after treatment. Each bar represents the mean ± SEM. *- p < 0.05 between groups. One-way ANOVA with Student Newman-Keuls test was used.
[0065] Fig.54 The latency duration in the OF test in the LH paradigm is shown, expressed in seconds. The results are shown as a box plot with maximum and minimum values. *-significantly different from the control group, #-significantly different from the LH group, p≤0.05. Kruskal-Wallis with Dunn's multiple comparison test was used.
[0066] Fig.55A and 55B Shown are the behaviors of rats in the OF test in the LH paradigm. Fig.55A : Duration of the animal's vertical motor activity (hind limbs), expressed in seconds. Fig.55B : Horizontal motor activity (mileage), sector number. Results are shown as box plots with maximum and minimum values. *-Significantly different from the control group. One-way ANOVA with Tukey test was used.
[0067] Fig.56A and 56B Shown is the behavior of rats in the EPM test in the LH paradigm. Fig.56A : Time spent in open arms, expressed in seconds. Fig.56B : Number of stretch-attended postures at the closed arms of the maze, N. The results are shown as box plots with maximum and minimum values.
[0068] Fig.57A and 57B Shown are the behaviors of rats in the FST in the LH paradigm. Fig.57A : Duration of immobility, expressed in seconds. Fig.57B : Active swimming duration, expressed in seconds. Each bar represents the mean ± SEM. *-significantly different from the control group; &-different from the control group at the trend level (p < 0.1); #-significantly different from the LH group, p ≤ 0.05. One-way ANOVA with Fisher LSD post hoc test was used.
[0069] Fig.58Basal corticosterone levels in rat plasma are shown, nmol / L. Each bar represents mean ± SEM. *-p<0.1-statistically significant trend compared to the control group, #p<0.05-significant difference compared to the LH group. One-way ANOVA with Fisher LSD post hoc test was used.
[0070] Fig.59 Stress-induced changes in rat plasma corticosterone after acute stress and administration of saline / dexamethasone (DXM), nmol / L. Each bar represents the mean ± SEM. *-p<0.05-significantly different from the corresponding "stress+veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0071] Fig.60 Shown are the total distance traveled (squares) in the OFT for animals after CRS and drug treatment. Each bar represents the mean ± SEM.
[0072] Fig.61A and 61B Shown are the performances of rats after CRS and drug treatment in the FST. Fig.61A : Time spent active (active swimming + climbing), expressed in seconds. Fig.61B : Time spent inactive swimming (passive swimming + immobility), expressed in seconds. Each bar represents the mean ± SEM. *- Statistically significant difference at p ≤ 0.05; #- p < 0.05 compared to the "CRS + Veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0073] Fig.62 Examples of Western blot results in cortical and hippocampal homogenate samples from Sprague-Dawley rats following CRS and treatment are shown.
[0074] Fig.63A and 63B The integrated area of GAPDH obtained by Western blotting (normalized to total protein) compared with the control group is shown and expressed as %. Fig.63A : GAPDH content in the cerebral cortex. Fig.63B : GAPDH content in hippocampus. Each bar represents the mean ± SEM.
[0075] Fig.64A and 64B The integrated area of BDNF obtained by Western blotting (normalized to total protein) compared with the control group is shown and expressed as %. Fig.64A : BDNF content in the cerebral cortex. Fig.64B: BDNF content in hippocampus. Each bar represents mean ± SEM. *-p<0.05 compared with control group, and #-p<0.05 compared with "CRS+veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0076] Fig.65A and 65B The integrated area of p70s6k (Thr421 / Ser424) obtained by Western blotting compared with the control group (normalized to total protein) is shown and expressed as %. Fig.65A :p70s6k(Thr421 / Ser424) content in cerebral cortex. Fig.65B : p70s6k (Thr421 / Ser424) content in hippocampus. Each bar represents mean ± SEM. *-p<0.05 compared with control group, and #-p<0.05 compared with "CRS+veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0077] Fig.66A and 66B The integrated area of p-ERK1 (Thr202) obtained by Western blotting compared with the control group (normalized to total protein) is shown and expressed as %. Fig.66A :p-ERK1(Thr202) content in cerebral cortex. Fig.66B : p-ERK1 (Thr202) content in hippocampus. Each bar represents mean ± SEM. *-p<0.05 compared with control group, and #-p<0.05 compared with "CRS+veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0078] Fig.67A and 67B The integrated area of p-ERK 2 (Tyr204) obtained by Western blotting (normalized to total protein) compared with the control group is shown and expressed as %. Fig.67A : p-ERK 2(Tyr204) content in cerebral cortex. Fig.67B : p-ERK 2 (Tyr204) content in hippocampus. Each bar represents mean ± SEM. *-p<0.05 compared with control group, and #-p<0.05 compared with "CRS+veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0079] Fig.68A and 68B The integrated area of p-PKC (PKCγThr514) obtained by Western blotting (normalized to total protein) compared with the control group is shown and expressed as %. Fig.68A : p-PKC (PKCγThr514) content in the cerebral cortex. Fig.68B : p-PKC (PKCγThr514) content in hippocampus. Each bar represents mean ± SEM. *-p<0.05 compared with control group, and #-p<0.05 compared with "CRS+veh" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0080] Fig.69A and 69B The integrated area of p-GSK3β(Ser9) obtained by Western blotting (normalized to total protein) compared with the control group is shown and expressed as %. Fig.69A :p-GSK3β(Ser9) content in the cerebral cortex. Fig.69B : p-GSK3β (Ser9) content in hippocampus. Each bar represents mean ± SEM. *-p < 0.05 compared with control group. One-way ANOVA with Fisher LSD post hoc test was used.
[0081] Fig.70 The results show that SR 95531 and FQSE (SEQ ID NO: 10) have an in vitro 3 Effects of [H]-SR 95531 binding to GABA receptors in rat cerebral cortex.
[0082] Fig.71 The in vitro effects of FQSE (SEQ ID NO: 10) and ketanserin on [ 3 [H]-FQSE (SEQ ID NO: 10) binding to the cortical site of binding of FQSE (SEQ ID NO: 10). Using the ketanserin curve as an example, similarly all selected ligands had IC50>100 μmol / L.
[0083] Fig.72 The in vitro effects of FQSE (SEQ ID NO: 10) and GABA on [ 3 Effect of [H]-FQSE binding to the specific site of FQSE (SEQ ID NO: 10) in rat cortex. Using the GABA curve as an example, similarly, all selected ligands had IC50>100 μmol / L.
[0084] Fig.73 The in vitro effects of FQSE (SEQ ID NO: 10), diazepam and pregnenolone on [ 3H]-FQSE (SEQ ID NO: 10) binding to the FQSE (SEQ ID NO: 10) specific binding site in rat mesocortex.
[0085] Fig.74 The in vitro effects of FQSE (SEQ ID NO: 10) and isotetrahydronicotinic acid (Isoguvacine) on [ 3 Effect of [H]-FQSE (SEQ ID NO: 10) binding to the cortical FQSE (SEQ ID NO: 10) binding site. Using the isothiahydronicotinic acid curve as an example, similarly all selected ligands had IC50 > 100 μmol / L.
[0086] Fig.75A , 75B , 75C shows the behavior of mice treated with FQSE (SEQ ID NO: 10), bicuculine, and bicuculine + FQSE (SEQ ID NO: 10) in the elevated plus maze test. Fig.75A : Time spent in open arms, s. Fig.75B : Number of open arm entries. Fig.75C : Anxiety index (AI), %. Results are expressed as mean ± SEM. *p<0.05 indicates significant difference compared with the control group, #p<0.05 - compared with the "bicuculline" group, $p<0.05 - compared with the "bicuculline + FQSE (SEQ ID NO: 10)" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0087] Fig.76 The time spent in active swimming in the Porsolt forced swim test (two-day correction) after treatment with FQSE (SEQ ID NO: 10), bicuculline and bicuculline + FQSE (SEQ ID NO: 10) is shown, s. The results are expressed as mean ± SEM. *p < 0.05 indicates a significant difference compared to the control group, #p < 0.05 - compared to the "bicuculline" group, $p < 0.05 - compared to the "bicuculline + FQSE (SEQ ID NO: 10)" group. One-way ANOVA with Fisher LSD post hoc test was used.
[0088] Fig.77FQSE (SEQ ID NO: 10) is shown to inhibit LPS-induced TNFa, 11-1b and IL-6 mRNA expression levels in mouse primary glial cells. Results are expressed as mean ± SEM. All LPS groups showed significant differences compared to the control without LPS. #-p<0.05 compared to LPS control. *-p<0.05 compared to control. Statistical analysis was performed using unpaired t-test.
[0089] Fig.78 It is shown that in mouse primary glial cells, IKKb mRNA expression levels are neither LPS-dependent nor FQSE (SEQ ID NO: 10). The results are expressed as mean ± SEM. DETAILED DESCRIPTION
[0090] Provided herein are peptide compositions that can be used, for example, to treat depression, anxiety, related mood conditions, and stress-related diseases. In some aspects, peptide-based neuromodulatory therapeutic compositions for a variety of psychiatric conditions for various depression and anxiety conditions are developed. Central nervous system (CNS) targets are selected to achieve high specificity and efficacy of neuromodulatory peptide compositions. Combined with the expected safety profile of the peptides, the compositions described in the present disclosure provide safe and effective treatments.
[0091] In the embodiments described in the present disclosure, the GABA-A receptor, which is an ionotropic receptor, is selected as the target of the neuromodulatory peptides of the group. The endogenous ligand of GABA-A is γ-aminobutyric acid (GABA), which is the main inhibitory neurotransmitter in the central nervous system. The GABA-A receptor is the main type of GABA receptor in the brain. The GABA-A receptor contains 5 subunits. It is divided into α, β, γ, δ, ε and σ subunits (among which α, β and γ are more fully studied) and there are at least 19 different isoforms of subunits encoded by different genes. See Nutt (2006). GABA-A Receptors: Subtypes, Regional Distribution, and Function. Journal of clinical sleep medicine, 2: S7-11. The active site of the GABA-A receptor is the binding site for GABA and several drugs, and GABA binds to the junction between subunits α and β. GABA-A receptors can be modulated by a variety of therapeutic agents, including benzodiazepines, barbiturates, anesthetics, ethanol, zinc, and neurosteroids. Benzodiazepines (BDZ) bind to the so-called benzodiazepine binding site located at the interface between the α- and γ-subunits of the GABA-A receptor containing α- and γ-subunits. Barnard (1998) Subtypes of gamma-aminobutyric acid Areceptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50(2):291–313. Thus, benzodiazepines bind to a receptor site on the GABA-A receptor protein complex that is distinct from the GABA binding site. Once benzodiazepines bind to the site on the GABA-A receptor, they allosterically change the conformation of the GABA-A receptor, increasing the affinity of the GABA-A receptor for GABA. At the same time, neurosteroids bind to the GABA-A receptor at a site that is distinct from the recognition site for GABA, benzodiazepines, and barbiturates. This results in allosteric modulation of GABA binding or channel gating. The lack of subunit-selective neurosteroid modulation suggests that neurosteroids bind to a site that is conserved in most members of the GABA-A receptor family. The effects of neurosteroids on GABA-A-receptors depend on the type of steroid (agonist or antagonist), the type of receptor (synaptic or extrasynaptic), the subunit composition, and the intrinsic structure of the steroid.Wang,M.(2011).Neurosteroids andGABA-A receptorfunction.Front.Endocrinol.2,44.
[0092] The inventors of the present disclosure have discovered neuromodulatory peptides having a novel structure and having the ability to bind to the allosteric BDZ site between the α- and γ-subunits, and / or another allosteric regulatory site of the GABA-A receptor, such as the binding site between the α- and β-subunits, and / or to the neurosteroid site of the GABA-AR. The anxiolytic and antidepressant activity of these peptides has been found to be comparable to that of diazepam and fluvoxamine. This has been demonstrated by experiments in zebrafish (Danio rerio) and rodents, as discussed in more detail in the Examples below.
[0093] In some embodiments, the neuromodulatory peptides described in various embodiments of the present disclosure can modulate voltage-gated calcium channels (VGCC), also known as voltage-dependent calcium channels (VDCC), which are found in the membranes of excitable cells (e.g., muscles, glial cells, neurons, etc.) and are sensitive to calcium ions Ca 2+ A group of voltage-gated calcium channels with permeability. See Yamakage et al. Calcium channels--basic aspects of their structure, function and gene encoding; anesthetic action on the channels--a review. Canadian Journal of Anaesthesia. 2002. 49(2):151–64. At physiological or resting membrane potentials, VGCCs are normally closed; and they are activated (i.e., open) at depolarized membrane potentials. Extracellular Ca 2+ ions are often thousands of times higher than inside the cell, and activation of VGCCs allows Ca 2+ Flow into cells, which, depending on the cell type, can lead to activation of calcium-sensitive potassium channels, muscle contraction, neuronal excitation, upregulation of gene expression, or release of hormones or neurotransmitters. Wilson et al. Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca 2+ Entry and Ca 2+sensitization:Rho-associated kinase-mediated phosphorylation ofMYPT1 at Thr-855,but not Thr-697.The Biochemical Journal.2005.389(Pt3):763–74。
[0094] THDOC (tetrahydrodeoxycorticosterone; 3α,21-dihydroxy-5α-pregnane-20-one), DHEA (dehydroepiandrosterone) and pregnenolone were shown to act as VGCC antagonists by reversibly blocking VGCC in adult mammalian hippocampal neurons. Reddy & Kulkarni, Development of neurosteroid-based novel psychotropic drugs. Prog Med Chem. 2000; 37: 135-75. THDOC is a positive allosteric modulator of GABAA receptors and has sedative, anxiolytic and anticonvulsant effects. Reddy & Rogawski. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. The Journal of Neuroscience. 200. 22(9): 3795–805. Benzodiazepines, such as diazepam, flurazepam and desalkylflurazepam, and other positive GABAAR modulators have been shown to directly inhibit the activity of L-type VGCC (L-VGCC). Earl & Tietz. Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1): 301-311. Gabapentinoid drugs (eg, gabapentin and pregabalin) are GABA analogs that work by directly inhibiting VGCCs. Pateletal. Mechanisms of the gabapentinoids and α2δ-1 calcium channelsubunit in neuropathic pain. Pharmacol Res Perspect. 2016. Feb 27; 4(2).
[0095] The inventors of the present disclosure generated a group of peptides by computer, wherein it is assumed that the peptides in the group are GABA-A allosteric modulators with affinity for the BDZ and neurosteroid (NS) binding sites of GABA-A. Another set of experiments evaluated another binding site between the α- and β-subunits (called the alpha-beta or α-β binding site). A three-dimensional docking algorithm was used to select more related peptides from the peptide group. Thus, a tetrapeptide family with a new sequence was identified. In some aspects, multiple tetrapeptides were generated by computer as potential drugs, and a subset of tetrapeptides was tested. In some aspects, in vivo behavioral experiments have confirmed that three exemplary peptides FQSE (SEQ ID NO: 10), DKTE (SEQ ID NO: 26) and WDQV (SEQ ID NO: 14) have both anxiolytic and antidepressant activity comparable to diazepam and fluvoxamine, as discussed in more detail below.
[0096] The inventors of the present disclosure designed and evaluated neuromodulatory peptides predicted to have binding ability to the BDZ (α-γ) site and / or to the α-β site and / or neurosteroid site of GABA-AR. In some aspects, the inventors of the present disclosure performed computer analysis and experiments in the animal models described herein, and thereby identified a group of tetrapeptides defined by the following general formula: R1R2R3R4 (I).
[0097] In some respects, R l It is an amino acid located at the BDZ site or the α-β binding site of GABA-AR or the neurosteroid site. The N-terminus of the peptide may be located at the BDZ site or the α-β binding site of GABA-AR or the neurosteroid site, or adjacent to the BDZ site or the α-β binding site of GABA-AR or the neurosteroid site. Alternatively, the C-terminus of the peptide may be located at the BDZ site or the α-β binding site of GABA-AR or the neurosteroid site. In the following description herein, the peptide is defined as a sequence extending from the N-terminus to the C-terminus. In some aspects, the tetrapeptide described in the present disclosure does not include proline.
[0098] In some embodiments, the peptide is defined such that R l is an amino acid different from Y, R2 is an amino acid different from L, and the isoelectric point of the peptide is less than 6.
[0099] The inventors evaluated the efficacy of three exemplary peptides FQSE (SEQ ID NO: 10), DKTE (SEQ ID NO: 26) and WDQV (SEQ ID NO: 14) as well as other (known) test substances tested using in vivo and in vitro models, as discussed in more detail in the Examples section below.
[0100] It has been previously observed that increased anxiety in zebrafish is associated with increased time spent in the dark compartment of a light / dark box (scototaxis - increased desire to stay in the dark shelter), and with an exacerbation of the shoaling reflex, which is manifested as a desire to come into close contact with other zebrafish. Increased time spent on the top (or decreased time spent on the bottom) in the novel aquarium test has also been associated with anxiolysis in fish: such changes in zebrafish behavior under the influence of the antidepressant fluoxetine (SSRI) have been described previously. See Egan, RJ (2009). Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain. Res., 205(1):38-44. Increased scototaxis has been shown to be caused by a shift in the explore-hide motivation balance toward hiding, and the shoaling reflex is a fundamental protective response of shoaling fish to predators. Maximino (2011) Pharmacological analysis of zebrafish (Danio rerio) scototaxis. Prog Neuropsychopharmacol Biol Psychiatry 35:624–631; Nguyen (2014) Aquatic blues: Modeling depression and antidepressant action in zebrafish. Prog Neuro-Psychopharmacology Biol. Psychiatry 55:26–39. Therefore, zebrafish is a suitable model for evaluating potential anxiolytic substances.
[0101] The findings of the inventors of the present disclosure are consistent with the published data on the subject, according to which zebrafish behavior in the context of open field, light / dark box, and apparatus for assessing flocking reflexes is a suitable model for assessing anxiety-like behavior and the effects of antidepressants and anxiolytics (Maximino (2014). Fingerprinting of Psychoactive Drugs in Zebrafish Anxiety-Like Behaviors. PLoS One. 9. P. e103943). FQSE (SEQ ID NO: 10) appears as a leading peptide in the zebrafish assay, which has robust anxiolytic activity and does not show sedative effects.
[0102] Administration of FQSE (SEQ ID NO: 10) to mice (via intraperitoneal injection) resulted in a significant anxiolytic-like effect, based on the results obtained in the open field test (OFT), elevated plus maze (EPM) test, and buried bead (MB) test. In the forced swimming test (FST), administration of the peptide resulted in an antidepressant-like effect.
[0103] The inventors observed the effects of different doses of FQSE (SEQ ID NO: 10) on the behavior of Sprague-Dawley rats in the open field, elevated plus maze and forced swim tests after intranasal administration. The behavioral changes after FQSE (SEQ ID NO: 10) administration partially recapitulated those observed in diazepam-treated rats in the OF and EPM tests and in ketamine-treated rats in the FST. According to the behavioral paradigm, the most significant anxiolytic-like and antidepressant-like effects of the peptide were seen at doses of 0.5 mg / kg and 0.01 mg / kg. The results showed a dose-dependent activity of FQSE (SEQ ID NO: 10), with maximum efficacy at an intranasal dose of 0.5 mg / kg.
[0104] FQSE (SEQ ID NO: 10) at doses of 0.05 and 0.5 mg / kg showed antidepressant-like effects in multiple behavioral tests in the chronic mild unpredictable stress (CUMS) model. Meanwhile, FQSE (SEQ ID NO: 10) at a dose of 0.05 mg / kg showed anxiolytic effects in the novelty suppressed food intake test (NSFT) and a mild anxiolytic-like effect in the EPM without signs of sedation.
[0105] The present inventors' findings showed that FQSE (SEQ ID NO: 10) at a dose of 0.5 mg / kg significantly attenuated predator odor-induced place aversion to a greater extent than doxazosin (DOX).
[0106] Studies on the effects in the learned-Helplessness (LH) paradigm showed that FQSE (SEQ ID NO: 10) had a dose-dependent anxiolytic-like effect in OF and EPM tests, and an antidepressant-like effect in FST and dexamethasone test (DXMT). FQSE (SEQ ID NO: 10) administration prevented the overactivation and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which is manifested in animals responding to stress.
[0107] FQSE (SEQ ID NO: 10) was found to have positive neurotropic effects after chronic administration in the Chronic Restraint Stress (CRS) model. The present inventors compared the molecular mechanism of action results obtained for FQSE (SEQ ID NO: 10) with the activity of the GABAA modulators.
[0108] Unlabeled FQSE (SEQ ID NO: 10) specifically replaces [ 3 H]-FQSE (SEQ ID NO: 10): found in rat cortical membranes [ 3 H]-FQSE (SEQ ID NO: 10) specific binding site IC50 = 2*10 -6 M. also found that diazepam and pregnenolone (both GABAAR ligands) have an effect on the [ 3 H]-FQSE (SEQ ID NO: 10) binding site has a certain degree of affinity (IC50 ~ 10 -4 M).
[0109] FQSE (SEQ ID NO: 10) has been shown to inhibit the expression of LPS-induced proinflammatory cytokines TNF-α, IL-1b and IL-6 in mouse primary glial cells, which may indicate its role in regulating neuroinflammation. The data obtained are highly consistent with the Western blot results shown previously, which showed that FQSE (SEQ ID NO: 10) was able to normalize stress-induced ERK1 / 2 (MAPK pathway participant) phosphorylation levels. The suppressed expression of proinflammatory cytokines observed in this study can also be considered as a result of GABAA-triggered MAPK inhibition (Lee (2013). Neurotransmitters and microglial-mediated neuroinflammation. Curr. Prot. Pept. Sci., 14 (1), 21-32).
[0110] The inventors' findings revealed that FQSE (SEQ ID NO: 10) is able to cross the blood-brain barrier. The greatest affinity for the peptide FQSE (SEQ ID NO: 10) was found in the olfactory bulb, where its content was significantly higher than in other brain regions. It was also found that higher levels of the peptide FQSE (SEQ ID NO: 10) were present in the prefrontal cortex, hippocampus, and hypothalamus compared to other brain regions.
[0111] In some aspects, a composition is provided comprising a synthetic neuromodulatory peptide defined by the general formula I: R1R2R3R4(I), wherein R1 is selected from amino acids W, F and D; R2 is a hydrophilic amino acid; R3 is a hydrophilic amino acid; and R4 is selected from amino acids V and E.
[0112] In some embodiments, R l is W. In other embodiments, R l is F. In a further embodiment, R l It is D.
[0113] In some embodiments, R2 is a hydrophilic amino acid selected from polar and positively charged hydrophilic amino acids, polar and neutrally charged hydrophilic amino acids, and polar and negatively charged hydrophilic amino acids. In some embodiments, the polar and neutrally charged hydrophilic amino acids are amino acids other than L, and the positively charged hydrophilic amino acids are selected from R and K, H. In some embodiments, the polar and neutrally charged hydrophilic amino acids are selected from N, Q, S, T, and C. In some embodiments, the polar and negatively charged hydrophilic amino acids are selected from D and E, C, Y.
[0114] In some embodiments, R2 can be selected from D, Q, and K, such that R2 can be any one of D, Q, and K.
[0115] In some embodiments, R3 is a hydrophilic amino acid selected from polar and positively charged hydrophilic amino acids, polar and neutrally charged hydrophilic amino acids, and polar and negatively charged hydrophilic amino acids. In some embodiments, polar and positively charged hydrophilic amino acids are selected from R and K. In some embodiments, polar and neutrally charged hydrophilic amino acids are selected from N, Q, S, T, and C. In some embodiments, polar and negatively charged hydrophilic amino acids are selected from D and E. In some embodiments, R3 is selected from Q, S, and T.
[0116] In some embodiments, R4 is selected from V and E.
[0117] In some embodiments, R1 is selected from W, F and D, R2 is selected from D, Q and K, R3 is selected from Q, S and T, and R4 is selected from V and E. In such embodiments, the synthetic neuromodulatory peptide can include any of the above amino acids. Thus, in some embodiments, R1 is W, R2 is D, R3 is Q, and R4 is V. In such embodiments, the composition is capable of binding to the benzodiazepine and neurosteroid binding sites of the GABA-A receptor. In addition, the composition is capable of binding to the alpha-beta binding site of the GABA-A receptor.
[0118] In some embodiments, R1 is F, R2 is Q, R3 is S, and R4 is E. In such embodiments, the composition is capable of binding to the benzodiazepine and neurosteroid binding sites of the GABA-A receptor. Additionally, in such embodiments, the composition is capable of binding to the α-β binding site of the GABA-A receptor.
[0119] In some embodiments, R1 is D, R2 is K, R3 is T, and R4 is E. In such embodiments, the composition is capable of binding to the benzodiazepine and neurosteroid binding sites of the GABA-A receptor. Additionally, in such embodiments, the composition is capable of binding to the α-β binding site of the GABA-A receptor.
[0120] The neuromedin of any of the embodiments described herein has an isoelectric point (pi) value of less than about 6. In some embodiments, the neuromedin has an isoelectric point (pi) value between about 3.5 and about 4.5. In further embodiments, the neuromedin has an isoelectric point (pi) value between about 3.3 and about 4.2.
[0121] In some aspects, a composition is provided comprising a synthetic neuromodulatory peptide defined by Formula Ia:
[0122] R1R2R3R4 (Ia),
[0123] wherein R1 is selected from amino acids W, F, and D, R2 is selected from amino acids D, Q, and K, R3 is a polar and neutrally charged hydrophilic amino acid, and R4 is selected from amino acids V and E. In some embodiments, R3 is a polar and neutrally charged hydrophilic amino acid selected from N, Q, S, T, P, and C.
[0124] In at least some embodiments, R1 is F, R2 is Q, R3 is S and R4 is E. In at least some embodiments, R1 is D, R2 is K, R3 is T, and R4 is E. In at least some embodiments, R1 is W, R2 is D, R3 is Q, and R4 is V.
[0125] The neuromodulatory peptides disclosed herein may be in the form of a pharmaceutical composition. The composition may be administered to a subject in need of treatment, such as a subject diagnosed with a condition manifested by depression and / or anxiety.
[0126] In some embodiments, one or more peptides described in the present disclosure can be included in food as an active ingredient. In these embodiments, the peptides can be included in a composition as a food product. The food composition can include any inactive ingredients. In addition, in addition to the peptides described in the present disclosure, the food composition can also include other active ingredients that do not affect the effectiveness of the peptides.
[0127] In some embodiments, the peptide described in the present disclosure is the active ingredient of the composition. In other embodiments, the active ingredient of the composition is an analog of the peptide, which can be an analog of an N-terminal modification or an analog of a C-terminal modification. The peptide described in the present disclosure is optionally chemically modified. In some embodiments, the chemical modification is selected from amidation, methylation and acetylation of one or more of R1, R2, R3 and R4, as described herein for Formula I or Ia. In other embodiments, other various types of peptide backbone and / or side chain modifications can be performed. In some embodiments, the chemical modification may include the addition of formyl, pyroglutamylamino (pGlu), one or more fatty acids, urea, carbamate, sulfonamide, alkylamine or any combination thereof.
[0128] For example, in some embodiments, the peptide may be a "pseudo-peptide" in which the conventional peptide bond (CO-NH) is replaced by one of the isosteric or isoelectronic analogs. For example, a reduced amide (CH2-NH) may be introduced isosterically into a peptide. In some embodiments, the peptide may be prepared in the form of an azapeptide in which the α-carbon of the peptide backbone is replaced by nitrogen (without changing the amino acid residue). As a further example of chemical modification, the synthetic neuromodulatory peptide described in the present disclosure may be a retro-inverso peptide in which D-amino acids are used in reverse order. As another example, in some embodiments, the synthetic neuromodulatory peptide described in the present disclosure may be a peptide mimetic in which the side chain is attached to the nitrogen atom of the peptide backbone instead of the α-carbon. Thus, in some embodiments, the synthetic neuromodulatory peptide may be a peptoid or a poly-N-substituted glycine.
[0129] In some embodiments, the synthetic neuromodulatory peptides can be optionally modified by introducing non-natural amino acids into certain positions in the peptide. Non-limiting examples of non-natural amino acids include D-amino acids, N-methylated (or N-alkylated) amino acids, α-substituted α-amino acids, β-substituted α-amino acids, β-amino acids, and γ-amino acids.
[0130] In some embodiments, the synthetic neuromodulatory peptides can be modified by cyclization of the peptide. In some embodiments, the synthetic neuromodulatory peptides can be modified such that the peptide is a beta-turn mimetics peptide. In some embodiments, the phenylalanine (F) in the peptide, if present, can be replaced by nitro-, amino-, fluoro-phenylalanine or other protease inhibitors.
[0131] In some embodiments, the compositions described herein comprise a pharmaceutically acceptable carrier.
[0132] In some embodiments, the compositions described in the present disclosure include a delivery vehicle. The delivery vehicle can be selected from liposomes, nanoparticles, and polysaccharides. In some embodiments, the polysaccharide can be selected from cyclodextrin, chitosan, cellulose, and alginate.
[0133] The compositions described in the present disclosure can be formulated for a variety of administration routes. Non-limiting examples of administration routes include inhalation, intranasal, oral, intravenous, intramuscular, and subcutaneous.
[0134] In some embodiments, the composition is formulated for intranasal administration. The composition formulated for intranasal administration may include at least one inhibitor of nasal mucosal proteases. Non-limiting examples of inhibitors include one or more compounds selected from the following: bestatine, comostate amylase, leupeptin, aprotinin, bacitracin, amastatine, boroleucine, puromycin, bile salts (bilesalt) and fusidic acid (e.g., disodium ethylene-diaminetetraacetate). Intranasal delivery is a non-invasive route of administration of therapeutic peptides and provides an alternative to intravenous or subcutaneous injection.
[0135] In some embodiments, the composition is formulated for administration by inhalation. In some embodiments, the composition formulated for administration by inhalation can be administered using a dry powder intranasal device.
[0136] In some embodiments, the compositions are formulated for intravenous administration.
[0137] In some embodiments, the composition modulates gamma-aminobutyric acid A (GABA-A) receptors.
[0138] In some embodiments, a pharmaceutical composition is provided according to any embodiment or combination of any embodiment described herein, comprising a therapeutically effective amount of the composition and at least one pharmaceutically acceptable carrier, diluent or excipient. Physiological saline, carbonate or bicarbonate buffer, and other possible diluents, can be used to dissolve the composition.
[0139] In some embodiments, a method of modulating a gamma-aminobutyric acid A (GABA-A) receptor in a cell is provided. The method comprises contacting the cell with a composition according to any embodiment or combination of any embodiments described herein.
[0140] In some embodiments, a method for treating an emotional disorder in a patient in need thereof is provided. The method comprises administering to a patient in need thereof a therapeutically effective amount of a composition according to any embodiment or a combination of any embodiments described herein. The emotional disorder may be depression. In some embodiments, depression may be pediatric depression or adolescent depression. In some embodiments, depression is selected from major depressive disorder, dysthymia, breakthrough depression, treatment-refractory depression, and depression associated with Parkinson's disease, depression associated with post-traumatic stress disorder, postpartum depression, and bipolar depression. In some embodiments, the emotional disorder may be a stress-related disease.
[0141] In some embodiments, the mood disorder is an anxiety disorder. In some embodiments, the anxiety disorder is a pediatric anxiety disorder or an adolescent anxiety disorder. The anxiety disorder may be selected from separation anxiety disorder, selective mutism, specific phobia (SP), social anxiety disorder (SAD), panic disorder, agoraphobia, substance / medication-induced anxiety disorder and anxiety disorder due to another medication condition, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), major depressive disorder (MDD), treatment-resistant depression (TRD), postpartum depression (PPD), bipolar disorder or bipolar depression, obsessive-compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD), social phobia, agitation in Alzheimer's disease, and attention deficit hyperactivity disorder (ADHD). In some embodiments, the mood disorder is schizophrenia. In some embodiments, the mood disorder is post-traumatic stress disorder.
[0142] In some embodiments, there is provided a method of treating a mood disorder according to any embodiment or combination of any embodiments described herein, further comprising administering an antidepressant.The antidepressant is optionally selected from the group consisting of a serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, a combined action SSRI / SNRI, a serotonin-2 antagonist / reuptake inhibitor, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin / norepinephrine / dopamine reuptake inhibition, an antidepressant with norepinephrine and dopamine reuptake inhibition, a 5-HT-1alpha antagonist, a 5-HT-1beta antagonist, a 5-HT1A receptor agonist, a 5-HT1A receptor agonist and antagonist, a 5-HT2 receptor antagonist, viloxazine hydrochloride, dehydroepiandosterone, an NMDA receptor antagonist, an AMPA receptor enhancer, potentiator), substance P antagonist / neurokinin-1 receptor antagonist, nonpeptide substance P antagonist, neurokinin 2 antagonist, neurokinin 3 antagonist, corticotropin-releasing factor receptor antagonist, antiglucocorticoid medication, glucocorticoid receptor antagonist, cortisol blocker, nitric oxide synthesis inhibitor, phosphodiesterase inhibitor, enkephalinase inhibitor, GABA-A receptor agonist, free radical trapping agent, atypical MAOI MAOI's), selective MAOI inhibitors, hormones, folinic acid, leucovorin, tramadol, and tryptophan in combination with an antipsychotic selected from the group consisting of an atypical antipsychotic and a dopamine system stabilizer.
[0143] In some embodiments, provided is a method of treating a mood disorder according to any embodiment or combination of any embodiments described herein, further comprising administering an additional depression treatment optionally selected from one or more other agents.
[0144] In some embodiments, the present invention provides compositions and methods of the present invention further comprising additional agents and methods of administering additional agents to a subject. In some embodiments, the present invention relates to co-administration and / or co-formulation. Any composition described herein can be co-formulated and / or co-administered.
[0145] In various embodiments, the additional pharmaceutical agent is one or more of: CYMBALTA oral, LEXAPRO oral, EFFEXOR XR oral, ZOLOFT oral, CELEXA oral, TRAZODONE oral, PROZAC oral, WELLBUTRIN XL oral, CITALOPRAM oral, PRISTIQ oral, AMITRIPTYLINE oral, SAVELLA oral, VIIBRYD oral, PAXILCR oral, WELLBUTRIN oral, PAXIL oral, SERTRALINE oral, REMERON oral, NORTRIPTYLINE oral, VENLAFAXINE oral, FLUOXETINE oral, BUPROPION HCL oral, MIRTAZAPINE oral, RITALIN oral, PAROXETINE oral, WELLBUTRIN SR oral, DOXEPIN oral, METHYLPHENIDATE oral, SYMBYAX oral, ESCITALOPRAM oral OXALATE oral, PAMELOR oral, IMIPRAMINE oral, BRINTELLIX oral, DULOXETINE oral, NARDIL oral, FETZIMA oral, EMSAM TRANSDERMAL, PARNATE oral, PEXEVA oral, BRISDELLE oral, CLOMIPRAMINE oral, ANAFRANIL oral, TOFRANIL oral, FLUVOXAMINE oral, ZYBAN oral, DESIPRAMINE oral, SARAFEM oral, PROZAC WEEKLY oral, APLENZIN oral, METHYLIN oral, NEFAZODONE oral, QUILLIVANT XR oral, TOFRANIL-PM oral, NORPRAMIN oral, REMERONSOLTAB oral, BUPROPION HBR oral, OLEPTRO ER oral, DESVENLAFAXINE SUCCINATE oral, BUPROBAN oral, IMIPRAMINE PAMOATE oral, VILAZODONE oral, MILNACIPRAN oral, PAROXETINEMESYLATE oral, SURMONTIL oral, MAPROTILINE oral, PROTRIPTYLINE oral, PHENELZINE oral, MARPLAN oral, OLANZAPINE-FLUOXETINE oral, TRANYLCYPROMINE oral, SELEGILINETRANSDERMAL, AMOXAPINE oral, FORFIVOXL oral, ISOCARBOXAZID oral, DESVENLAFAXINE oral, KHEDEZLA oral, LEVOMILNACIPRAN oral, VORTIOXETINE oral, and DESVENLAFAXINE FUMARATE oral.
[0146] In some embodiments, a method of treating a mood disorder according to any embodiment or combination of any embodiments described herein is provided, the method further comprising administering an additional anxiety treatment agent optionally selected from one or more of the following agents: benzodiazepines selected from alprazolam (XANAX), clonazepam (KLONOPIN), diazepam (VALIUM), lorazepam (ATIVAN), oxazepam (SERAX) and chlordiazepoxide (librium); beta blockers selected from propranolol (pr opranolol (INDERAL) and atenolol (TENORMIN); tricyclic antidepressants selected from imipramine (TOFRANIL), desipramine (NORPRAMIN, PERTOFRANE), nortriptyline (AVENTYL or PAMELOR), amitriptyline (ELAVIL), doxepin (SINEQUAN or ADAPIN), clomipramine (ANAFRANIL); monoamine oxidase inhibitors (monoamine oxidase inhibitor (MAOI), selected from phenelzine (NARDIL), tranylcypromine (PARNATE); selective serotonin reuptake inhibitor (SSRI), selected from fluoxetine (PROZAC), fluvoxamine (LUVOX), sertraline (ZOLOFT), paroxetine (PAXIL), escitalopram oxalate (LEXAPRO), citalopram (CELEXA); serotonin-norepinephrine reuptake inhibitor (SNRI), selected from venlafaxine (EFFEXOR), venlafaxine extended release (EFFEXORXR) and duloxetine (CYMBALTA); mild sedative (mild tranquilizer) tranquilizers, such as buspirone (BUSPAR);and an anticonvulsant selected from valproate (DEPAKOTE), pregabalin (LYRICA) and gabapentin (NEURONTIN). ;
[0147] In various embodiments, additional agents may be combined with the peptides described herein.
[0148] In a number of embodiments, the composition of the present invention can be fused with other parts such as additional agents or a part to extend the half-life in vivo. In addition to increasing stability, such parts can also increase the solubility of the molecule fused thereto. The part that increases solubility (e.g., prevents aggregation) can make the composition easier to handle, and especially improves stability and shelf life. A well-known example of such parts is PEG (polyethylene glycol). This part is particularly related to because it can be used as a linker and a solubilizing part. Other examples include peptides and proteins or protein domains, or even complete proteins (e.g., GFP). In this regard, it should be noted that, like PEG, a part can have different functions or effects. For example, the flag tag (DYKDDDDK) is a peptide part that can be used as a tag, but due to its charge density, it also enhances solubility. PEGylation has often been shown to increase the solubility of biopharmaceuticals (e.g., Veronese and Mero (2008) The impact of PEGylation on biological therapies, BioDrugs; 22 (5) 315-29). Adding peptide, polypeptide, protein or protein domain tags to a molecule of interest has been widely described in the art. Examples include, but are not limited to, peptides derived from: synuclein (e.g., Park et al., Protein Eng. Des. Sel. 2004; 17: 251-260), SET (solubility enhancement tag, Zhang et al., Protein Expr Purif 2004; 36: 207-216), thioredoxin (TRX), glutathione-S-transferase (GST), maltose-binding protein (MBP), N-Utilization substance (NusA), small ubiquitin-like modifier (SUMO), ubiquitin (Ub), disulfide bond C (DsbC), seventeen kilodalton protein (Seventeen kilodalton protein) ... protein, Skp), bacteriophage T7 protein kinase fragment (T7PK), protein GB1 domain, protein A IgG ZZ repeat domain and bacterial immunoglobulin binding domain (Hutt et al., J Biol Chem; 287(7):4462-9, 2012). The nature of the tag will depend on the application, which can be determined by the skilled person.For example, for transgenic expression of molecules described herein, the molecule can be fused to a larger domain to prevent premature degradation of the cellular machinery. Other applications can involve fusion with a smaller solubilizing tag (e.g., less than 30 amino acids, or less than 20 amino acids, or even less than 10 amino acids) to not change the properties of the molecule too much. Other chemical modifications can include the addition of formyl, pyroglutamyl (pGlu), one or more fatty acids, urea, carbamate, sulfonamide, alkylamine, or any combination thereof.
[0149] In addition to extending the half-life, the compositions of the present invention can be fused with parts that change other or additional pharmacokinetic and pharmacodynamic properties. For example, it is known that fusion with albumin (e.g., human serum albumin), albumin binding domains, or synthetic albumin binding peptides can improve the pharmacokinetics and pharmacodynamics of different therapeutic proteins (Langenheim & Chen (2009). Improving the pharmacokinetics / pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J. Endocrinol., 203 (3): 375). Another frequently used part is the fragment crystallizable region (Fc) of an antibody. The properties of these parts can be determined by those skilled in the art according to the application.
[0150] In some embodiments, the peptides of the disclosure may be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination does not cause unacceptable side effects.
[0151] The amount of active ingredient to be administered in the treatment of one or more conditions can vary according to considerations such as the specific peptide and dosage unit employed, the mode of administration, the duration of treatment, the age, weight and sex of the patient being treated, and the nature and extent of the condition being treated. The compositions described in the present disclosure can be administered to a subject by a particular route at an appropriate dose.
[0152] In some embodiments, the dosage of the peptide to be administered is generally within the range of about 0.001 mg / kg to about 200 mg / kg body weight, about 0.01 mg / kg to about 100 mg / kg body weight, about 0.01 mg / kg to about 50 mg / kg body weight, about 0.01 mg / kg to about 40 mg / kg body weight, about 0.01 mg / kg to about 30 mg / kg body weight, about 0.01 mg / kg to about 20 mg / kg body weight, about 0.01 mg / kg to about 5 mg / kg body weight, about 0.01 mg / kg to about 10 mg / kg body weight, about 0.1 mg / kg to about 10 mg / kg body weight, about 0.1 mg / kg to about 20 mg / kg body weight, about 0.1 mg / kg to about 30 mg / kg body weight, about 0.1 mg / kg to about 40 mg / kg body weight, about 0.1 mg / kg to about 50 mg / kg body weight. A clinically useful dosing schedule is one to three times daily administration. The pharmaceutical composition containing the neuromodulator peptide described herein can also be administered in a single dose. Due to the safety and effectiveness of the composition, a single dose of the composition can effectively alleviate depression or anxiety related symptoms. A treatment plan can also be formulated for a longer treatment process. For example, in some embodiments, the pharmaceutical composition described in the embodiments of the present disclosure can be administered in more than one day, such as 2 days to 60 days, or 2 days to 50 days, or 2 days to 40 days, or 2 days to 30 days, and the daily dose can be in any of the above ranges. More than one day of administration can be used to treat chronic symptoms or diseases, which can be a variety of mental, behavioral, emotional, neurological and emotional diseases, including depression, anxiety and stress-related diseases (stress-relateddisorder) any one.
[0153] A "subject" is a mammal, such as a human (e.g., a female or male human), mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey, and the terms "subject" and "patient" are used interchangeably herein.
[0154] The peptides described herein can be administered in the form of a spray, such as an intranasal spray.
[0155] The present invention further provides a kit that can simplify the administration of any medicament described herein. The illustrative kit of the present invention comprises any composition described herein in unit dosage form. In one embodiment, the unit dosage form is a container, such as a prefilled syringe, which can be sterile, containing any medicament described herein and a pharmaceutically acceptable carrier, diluent, excipient or vehicle. The kit may further include a label or printed instructions for the use of any medicament described herein. The kit may also include a lid speculum, a local anesthetic and a cleaning agent for the application site. The kit may also further include one or more additional medicaments described herein. In one embodiment, the kit comprises a container containing an effective amount of a composition of the present invention and an effective amount of another composition, such as those compositions described herein.
[0156] The present disclosure is further illustrated by the following non-limiting examples.
[0157] Example
[0158] Example 1: Computational design of peptides
[0159] A group of peptides from milk hydrolysate was divided into 5 types and converted into a group of all possible tetrapeptides by computer by sliding the window by a step size of 1 amino acid. A total of 341 unique tetrapeptides were generated. For each peptide, the peptide was fitted to the BDZ site of the GABA-A receptor and the interface between the α and β subunits of the GABA-A receptor using a 3D docking algorithm, which resulted in up to 20 possible conformations for each peptide. A total of 5650 unique peptide positions were generated. All positions were combined and the frequency of atoms (aromatic carbon, hydrogen bond donors / acceptors, etc.) of a specific type being located in a given region was calculated. Each conformation was weighted according to the spatial density map and standardized relative to the number of atoms and residues. A docking site greater than the BDZ site was selected, and therefore, for the convenience of evaluating the results, a peptide score greater than the BDZ site was specified to be 0.0. All common interactions (such as electrostatics, hydrogen bonds, etc.) were considered in the docking / fitting stage. In addition, 100 tetrapeptides were preselected based on their scores.
[0160] Example 2: Selection of four peptides for testing
[0161] 2.1 Research objectives
[0162] A computational approach was used to identify the tetrapeptide with the greatest affinity for the benzodiazepine site of the GABA-A receptor among the given peptides.
[0163] 2.2 Results
[0164] A given set of peptides from milk hydrolysate classified into 5 types was converted into a set of tetrapeptides. All possible tetrapeptides were generated from each peptide by sliding the window with a step size of 1 amino acid. A total of 341 different tetrapeptides were generated.
[0165] Each peptide was modified in the following manner: an acetyl "plug" was added to the N-terminus, while a methyl plug was added to the C-terminus.
[0166] For each peptide, docking with the BZD site of the GABA-A receptor was performed, generating up to 20 conformations. A total of 5650 different peptide positions were obtained. Subsequently, all results were merged, and the frequency of this type of atom (aromatic carbon, hydrogen bond donor / acceptor, etc.) entering a given area was analyzed. Each conformation was weighted according to this spatial density map, and the number of relative atoms and residues was standardized. Therefore, a statistical analysis was performed. Since the docking unit (dockingcell) is definitely larger than the BZD site, in order to facilitate the evaluation of the results, an evaluation score of 0.0 was assigned to the peptide outside the BZD site. The description of common interactions (such as electrostatics, hydrogen bonds, etc.) of a clear form occurs in the docking stage.
[0167] Thus, about 100 evaluation function values ≥ 0.7 were found:
[0168] Abbreviation: Pose name, energy sequence ID
[0169] YLQY YLQY_out_model16.pdb 1.00 SEQ ID NO:1
[0170] YQLY YQLY_out_model9.pdb 0.99 SEQ ID NO:2
[0171] YQLY YQLY_out_model11.pdb 0.94 SEQ ID NO:2
[0172] YLQY YLQY_out_model5.pdb 0.93 SEQ ID NO:1
[0173] YLEQ YLEQ_out_model10.pdb 0.92 SEQ ID NO:3
[0174] QYLY QYLY_out_model10.pdb 0.92 SEQ ID NO:4
[0175] YLKY YLKY_out_model9.pdb 0.90 SEQ ID NO:5
[0176] YLKY YLKY_out_model19.pdb 0.89 SEQ ID NO:5
[0177] YLKT YLKT_out_model4.pdb 0.89 SEQ ID NO:6
[0178] YQLY YQLY_out_model3.pdb 0.86 SEQ ID NO:2
[0179] FLLY FLLY_out_model10.pdb 0.86 SEQ ID NO:7
[0180] YQLY YQLY_out_model20.pdb 0.86 SEQ ID NO:2
[0181] YQKF YQKF_out_model2.pdb 0.86 SEQ ID NO:8
[0182] YLQY YLQY_out_model4.pdb 0.85 SEQ ID NO:1
[0183] YLKY YLKY_out_model6.pdb 0.84 SEQ ID NO:5
[0184] LYQE LYQE_out_model8.pdb 0.84 SEQ ID NO:9
[0185] FQSE FQSE_out_model5.pdb 0.84 SEQ ID NO:10
[0186] FLLY FLLY_out_model7.pdb 0.83 SEQ ID NO:7
[0187] QYLY QYLY_out_model11.pdb 0.82 SEQ ID NO:4
[0188] FYQK FYQK_out_model5.pdb 0.82 SEQ ID NO:11
[0189] LYQE LYQE_out_model2.pdb 0.82 SEQ ID NO:9
[0190] FLLY FLLY_out_model11.pdb 0.81 SEQ ID NO:7
[0191] YLGY YLGY_out_model15.pdb 0.81 SEQ ID NO:12
[0192] YLQY YLQY_out_model12.pdb 0.80 SEQ ID NO:1
[0193] PFTE PFTE_out_model11.pdb 0.80 SEQ ID NO:13
[0194] WDQV WDQV_out_model11.pdb 0.80 SEQ ID NO:14
[0195] PEVF PEVF_out_model16.pdb 0.80 SEQ ID NO:15
[0196] FLLY FLLY_out_model13.pdb 0.80 SEQ ID NO:7
[0197] YLQY YLQY_out_model13.pdb 0.79 SEQ ID NO:1
[0198] LSRY LSRY_out_model12.pdb 0.79 SEQ ID NO:16
[0199] LLRF LLRF_out_model2.pdb 0.79 SEQ ID NO:17
[0200] WDQV WDQV_out_model15.pdb 0.79 SEQ ID NO:14
[0201] MPLW MPLW_out_model17.pdb 0.79 SEQ ID NO:18
[0202] KYQF KYQF_out_model10.pdb 0.79 SEQ ID NO:19
[0203] YLKY YLKY_out_model7.pdb 0.78 SEQ ID NO:5
[0204] YLKT YLKT_out_model5.pdb 0.78 SEQ ID NO:6
[0205] FYQK FYQK_out_model13.pdb 0.78 SEQ ID NO:11
[0206] YQLY YQLY_out_model7.pdb 0.78 SEQ ID NO:2
[0207] YQKF YQKF_out_model14.pdb 0.78 SEQ ID NO:8
[0208] LLRF LLRF_out_model5.pdb 0.78 SEQ ID NO:17
[0209] KYQF KYQF_out_model16.pdb 0.78 SEQ ID NO:19
[0210] YQKF YQKF_out_model3.pdb 0.77 SEQ ID NO:8
[0211] YLQY YLQY_out_model18.pdb 0.77 SEQ ID NO:1
[0212] QYLY QYLY_out_model17.pdb 0.77 SEQ ID NO:4
[0213] YQLY YQLY_out_model8.pdb 0.77 SEQ ID NO:2
[0214] YQFL YQFL_out_model8.pdb 0.77 SEQ ID NO:20
[0215] FFVA FFVA_out_model6.pdb 0.77 SEQ ID NO:21
[0216] KTVY KTVY_out_model18.pdb 0.77 SEQ ID NO:22
[0217] YQLY YQLY_out_model13.pdb 0.76 SEQ ID NO:2
[0218] KYQF KYQF_out_model11.pdb 0.76 SEQ ID NO:19
[0219] FSDI FSDI_out_model14.pdb 0.76 SEQ ID NO:23
[0220] FFVA FFVA_out_model5.pdb 0.76 SEQ ID NO:21
[0221] YLKY YLKY_out_model13.pdb 0.75 SEQ ID NO:5
[0222] FFVA FFVA_out_model7.pdb 0.75 SEQ ID NO:21
[0223] SFSD SFSD_out_model14.pdb 0.75 SEQ ID NO:24
[0224] FLLY FLLY_out_model8.pdb 0.75 SEQ ID NO:7
[0225] FFVA FFVA_out_model12.pdb 0.75 SEQ ID NO:21
[0226] LLYQ LLYQ_out_model5.pdb 0.75 SEQ ID NO:25
[0227] DKTE DKTE_out_model20.pdb 0.74 SEQ ID NO:26
[0228] LLYQ LLYQ_out_model6.pdb 0.74 SEQ ID NO:25
[0229] QYLY QYLY_out_model8.pdb 0.74 SEQ ID NO:4
[0230] YYVP YYVP_out_model13.pdb 0.73 SEQ ID NO:27
[0231] YQKF YQKF_out_model13.pdb 0.73 SEQ ID NO:8
[0232] LSRY LSRY_out_model9.pdb 0.73 SEQ ID NO:16
[0233] YQLY YQLY_out_model19.pdb 0.73 SEQ ID NO:2
[0234] YLKT YLKT_out_model14.pdb 0.73 SEQ ID NO:6
[0235] FTES FTES_out_model15.pdb 0.73 SEQ ID NO:28
[0236] LSRY LSRY_out_model4.pdb 0.73 SEQ ID NO:16
[0237] GTQY GTQY_out_model13.pdb 0.73 SEQ ID NO:29
[0238] PEVF PEVF_out_model7.pdb 0.72 SEQ ID NO:15
[0239] FLGA FLGA_out_model7.pdb 0.71 SEQ ID NO:30
[0240] YTDA YTDA_out_model10.pdb 0.71 SEQ ID NO:31
[0241] YPSY YPSY_out_model18.pdb 0.71 SEQ ID NO:32
[0242] KTVY KTVY_out_model2.pdb 0.71 SEQ ID NO:22
[0243] YPSY YPSY_out_model19.pdb 0.71 SEQ ID NO:32
[0244] FTES FTES_out_model12.pdb 0.71 SEQ ID NO:28
[0245] FPKY FPKY_out_model9.pdb 0.71 SEQ ID NO:33
[0246] QYLY QYLY_out_model18.pdb 0.70 SEQ ID NO:4
[0247] The occurrence of individual tetrapeptides in the best result list can be estimated. Since most peptides are located linearly on the protein surface, the direction relative to the BZD site can be determined. In the following, F stands for Forward - the N-terminus of the peptide is located in the BZD site or in close proximity to it. R stands for Reverse - the C-terminus of the peptide is located in the BZD site - in these cases, the peptide sequence should be from C-terminus to N-terminus. Peptides with only conformer R are not peptides in the provided list:
[0248] YQLY 8F / R (SEQ ID NO: 2)
[0249] YLQY 6F / R (SEQ ID NO: 1)
[0250] YLKY 5F / R (SEQ ID NO: 5)
[0251] QYLY 5F / R (SEQ ID NO:4)
[0252] FLLY 5F / R (SEQ ID NO:7)
[0253] YQKF 4F (SEQ ID NO: 8)
[0254] FFVA 4F (SEQ ID NO: 21)
[0255] YLKT 3F (SEQ ID NO:6)
[0256] KYQF 3R (SEQ ID NO: 19)
[0257] LSRY 3R (SEQ ID NO: 16)
[0258] FTES 2F (SEQ ID NO: 28)
[0259] PEVF 2R (SEQ ID NO: 15)
[0260] YPSY 2F / R (SEQ ID NO:32)
[0261] LYQE 2F (SEQ ID NO:9)
[0262] LLRF 2R (SEQ ID NO: 17)
[0263] KTVY 2R (SEQ ID NO: 22)
[0264] FYQK 2F (SEQ ID NO: 11)
[0265] WDQV 2F (SEQ ID NO: 14)
[0266] LLYQ 2F (SEQ ID NO: 25)
[0267] DKTE 1F (SEQ ID NO: 26)
[0268] YTDA 1F (SEQ ID NO: 31)
[0269] FQSE 1F (SEQ ID NO: 10)
[0270] FSDI 1F (SEQ ID NO: 23)
[0271] PFTE 1F (SEQ ID NO: 13)
[0272] MPLW1R (SEQ ID NO: 18)
[0273] GTQY 1R (SEQ ID NO: 29)
[0274] SFSD 1F (SEQ ID NO: 24)
[0275] YQFL 1F (SEQ ID NO: 20)
[0276] FLGA 1F (SEQ ID NO: 30)
[0277] YLEQ 1F (SEQ ID NO: 3)
[0278] YLGY 1R (SEQ ID NO: 12)
[0279] YYVP 1F (SEQ ID NO: 27)
[0280] FPKY 1R (SEQ ID NO: 33)
[0281] The best findings were most consistently located in the BZD locus.
[0282] 2.3 Conclusion
[0283] By looking at the most suitable options, a tetrapeptide of the known peptide YLGYLEQLLR was found. However, other peptides were found that differed significantly in sequence but not in the value of the evaluation function. For further experimental validation, the following original peptides were selected: FQSE (SEQ ID NO: 10), WDQV (SEQ ID NO: 14), DKTE (SEQ ID NO: 26), and the negative control - FLPY (SEQ ID NO: 36).
[0284] In addition, an in silico approach was used to examine whether the FQSE (SEQ ID NO: 10) peptide might have affinity for the neurosteroid site of GABA-A.
[0285] The FQSE (SEQ ID NO: 10) tetrapeptide was initially identified by docking all possible tetrapeptides in a high-throughput combinatorial manner into the extracellular domain of the GABA-A receptor. The preferential binding pocket for this peptide was found to be the BZD site. The binding mode of FQSE (SEQ ID NO: 10) was then independently examined during a control docking run to the complete GABA-A receptor model containing its membrane-buried α-helical domain. This run demonstrated that FQSE (SEQ ID NO: 10) has a high preference for the neurosteroid binding site of GABA-A, where all the best hits from 20 independent replicates were located.
[0286] These experiments demonstrated that the FQSE (SEQ ID NO: 10) peptide binds to the GABA-A receptor in two regions: a major binding mode corresponding to the neurosteroid site and a minor binding mode corresponding to the BZD site.
[0287] Example 3: Effects of selected peptides and other test substances on zebrafish (Danio Assessment of the impact of rerio) behavior
[0288] The aim was to develop a standard protocol for evaluating the neurotropic activity of novel neuromodulatory peptides by analyzing the effects of psychoactive agents on the behavior of zebrafish (Danio rerio). Specifically, the effects of a single injection of antidepressants and anxiolytics such as fluvoxamine and diazepam on scototaxis, locomotor activity, exploratory responses, and social behavior of zebrafish were evaluated.
[0289] Materials and methods
[0290] 3.1.1. Animals maintain
[0291] Zebrafish were maintained in a flow-through ZebTEC zebrafish housing system (manufactured by Tecniplast) at 28°C, pH 6.8-7.5, osmotic pressure 550-700 osmol / liter, with a 12 / 12 lighting regimen and continuous aeration. Zebrafish were fed a specialized diet twice daily. During the experiments, the fish were fed the evening before and the evening after the experiment. All procedures involving animals were performed in accordance with European (Directive 2010 / 63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes) and Russian ("GOST 33216-2014 Guidelines for the maintenance and care of laboratory animals. Rules for the maintenance and care of laboratory rodents and rabbits") bioethical guidelines.
[0292] 3.1.2. Substances, doses and administration
[0293] Diazepam
[0294] Diazepam is a benzodiazepine anxiolytic that works by binding to the benzodiazepine sites of GABA-A receptors (Cl- channels), prolonging their open state. Thus, at low doses, diazepam has been shown to produce anxiolytic effects, while at high doses, it can cause strong sedative effects. In the experiments, diazepam was administered at doses of 1.25 mg / kg, 5 mg / kg, and 10 mg / kg.
[0295] Fluvoxamine
[0296] Fluvoxamine, a known antidepressant representing the selective serotonin reuptake inhibitor (SSRI) group, was administered to zebrafish at doses of 5 mg / kg and 10 mg / kg.
[0297] β-Casomorphin-7(BCM-7)
[0298] BCM-7 is a fragment of bovine milk beta-casein (H-YPFPGPI-OH (SEQ ID NO: 34); IUPAC: L-tyrosyl-L-prolyl-L-phenylalanyl-L-prolyl-glycyl-L-prolyl-L-isoleucine). BCM-7 is known to have opioid activity (e.g., analgesic and anxiolytic activity), mainly acting through the mu-opioid receptor (Kamiński S., et al. (2007) Polymorphism of bovine beta-casein and its potential effect on human health. J. Appl. Genet. 48: 189–198). BCM-7 was administered at a dose of 5 mg / kg in this study.
[0299] α-Casozepine-10(ACZ-10)
[0300] ACZ-10 is a fragment of bovine milk α-casein (H-YLGYLEQLLR-OH (SEQ ID NO: 35); IUPAC: L-tyrosyl-L-leucyl-glycyl-L-tyrosyl-L-leucyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-leucyl-L-arginine). According to Miclo et al., 2001 (Miclo (2001) Characterization of alpha-casozepine, a tryptic peptide from bovine alpha (s1) -casein with benzodiazepine-like activity. FASEB J. 15: 1780–2), ACZ-10 exhibits benzodiazepine-like activity, which is attributed to its three-dimensional structure that allows it to bind to the benzodiazepine site of the GABA-A receptor. ACZ-10 was administered at a dose of 0.6 mg / kg in this study.
[0301] Creative Tetrapeptide
[0302] Four selected tetrapeptide ligands for the GABA-A benzodiazepine site were tested at two dose levels - 1 mg / kg and 10 mg / kg. The peptides have the following primary structures: FQSE (SEQ ID NO: 10), DKTE (SEQ ID NO: 26), WDQV (SEQ ID NO: 14), and FLPY (SEQ ID NO: 36). Among these peptides, FQSE (SEQ ID NO: 10), DKTE (SEQ ID NO: 26), and WDQV (SEQ ID NO: 14) are exemplary tetrapeptides, while FLPY (SEQ ID NO: 36) is a negative control.
[0303] Application
[0304] The test substance was injected intraperitoneally (ip) into zebrafish using an insulin syringe (0.5 ml, 30 g) 10 minutes before the test. Saline solution (0.9% NaCl) was used as solvent. Anesthesia and fixation were completed by placing the animals in water at 10°C. The control group fish were also injected intraperitoneally with an equal volume of solvent after a precooling procedure.
[0305] 3.1.3. Equipment settings
[0306] The open field test was conducted in a 4-liter trapezoidal aquarium, and the parameters are shown in Figure 2 The bottom, back wall, and side walls of the aquarium were made of matte black plastic; the front panel (the shorter wall) was made of transparent Plexiglas. The setup for the light / dark preference test consisted of three main parts: a launch compartment, a light compartment made of white plastic, and a dark compartment made of black plastic. The setup parameters are shown in Figure 3 The bright lighting in these experiments was provided by a lamp (LED lamp PL, 11 W, luminous flux ≈ 600 Lm, about 500 Lx just above the water surface) mounted on a bracket on the upper part of the aquarium.
[0307] Use a Plexiglas container with a removable partition (such as Figure 4 ) was used as a device for studying the schooling behavior of zebrafish. A group of 5 adult Danio rerio specimens was placed in the small compartment; and the test fish were placed in the large compartment. The diffused lighting in this device was provided by the normal lighting of the room (about 200Lx).
[0308] 3.1.4. Behavioral test
[0309] 3.1.4.1. Open field test
[0310] The open field test was performed as described in Maximino et al., 2013. Video recording (background shooting) was started 20-30 seconds before the zebrafish was placed in the test aquarium. The experimental zebrafish was placed in the open field ("OF") aquarium using a net. The recording was performed for five minutes. The test was performed using the EthoVision XT software package (Noldus). The software recorded the distance covered by the animal, its speed, the number of visits to three conventional areas of the aquarium: the "bottom", "center" and "middle" (the lower, middle and upper third of the aquarium, respectively), the time spent in these areas, and the lurking of visits to the middle and surface of the aquarium.
[0311] 3.1.4.2. crowd gathering Behavioral assay
[0312] As described in Parker et al., 2014. (Parker et al. (2014) The utility of zebrafish to study the mechanisms by which ethanol affects social behavior and anxiety during early brain development. Prog. Neuro-Psychopharmacology Biol. Psychiatry. 94-100), the group behavior test was performed. The video recording was started at the same time as the zebrafish was placed in the setup and recorded for 5 minutes. The video was processed using RealTimer (OpenScience Ltd., Moskow, Russia). During the processing of the recording, the residence time and number of visits to three general areas of the aquarium wall (near the "fish school", the middle of the aquarium, and near the opposite side; the three were equal in size) were recorded.
[0313] 3.1.4.3. Light / dark box test
[0314] The light / dark box (LDB) test was performed as described by Maximino et al., 2011. Zebrafish were placed in the light compartment of the LDB using a net, while the camera was turned on and the behavior of the zebrafish was recorded for 5 minutes. The video was processed using RealTimer (OpenScience). During the recording process, the residence time and number of visits to the light and dark compartments of the experimental setup were recorded, as well as the latency to visit both compartments.
[0315] Data analysis
[0316] The data obtained during the behavioral experiments were evaluated using the STATISTICA platform. Statistical processing of the data and construction of visual representations of the results, including graphs, were performed in Graph Pad Prism 6.
[0317] The Kolmogorov-Smirnov normality test was used to assess the normality of the data distribution obtained. Nonparametric tests (Mann-Whitney test) were used to compare the parameters of the distribution that did not conform to the normal distribution. The use of paired tests was effective because paired controls were recorded for each substance. Multiple comparisons were performed using the nonparametric Kruskal-Wallis test, which was performed according to the Dunn multiple comparison test. The results are displayed on the graph in the form of average / mean, and the spread is expressed as the standard error of the mean.
[0318] 3.2. Evaluation of the effects of test substances on zebrafish behavior
[0319] 3.2.1. Diazepam
[0320] During experiments designed to evaluate the effects of diazepam on zebrafish behavior, it was found that diazepam at doses of 1.25 mg / kg, 5 mg / kg and 10 mg / kg (ip) altered the behavior of the treated zebrafish compared to control animals. At a dose of 1.25 mg / kg, a statistically significant decrease in the time spent in the compartment near the "fish school" was detected ( Figure 1A ), while other behavioral parameters did not change. Injection of 5 mg / kg diazepam caused a far more significant behavioral effect: the experimental zebrafish spent more time in the compartment near the wall on the opposite side of the "fish school" ( Figure 1B ). The time spent in the light chamber also increased significantly ( Figure 1C ). Diazepam was not shown to have an effect on zebrafish behavior in the open field test.
[0321] Diazepam at a dose of 10 mg / kg resulted in an increase in the number of transitions between the light and dark compartments in the light / dark box ( Figure 5A ) and the time (latency) to first return to the light compartment of the light / dark box decreased ( Figure 5B ). Under the influence of high doses of diazepam, zebrafish tended to cover less distance during the open field test ( Figure 5C ).
[0322] 3.2.2. Fluvoxamine
[0323] Fluvoxamine at dose levels of 5 mg / kg and 10 mg / kg resulted in behavioral changes in treated zebrafish in the OFT, but not in the "schooling" and light / dark tests. At both doses, fluvoxamine resulted in a statistically significant increase in the time spent on the surface of the aquarium in the open field ( Fig. 6A and 6B ). The time spent in light increased by about 6.8-fold at the 5 mg / kg dose and by about 7.2-fold at the 10 mg / kg dose.
[0324] 3.2.3.α-Casozepine-10(ACZ-10)
[0325] demonstrated that zebrafish that received intraperitoneal injections of ACZ-10 spent a statistically significant decrease in the time spent in the swarming compartment compared to controls ( Fig. 7A ), and the time spent on the water surface in the open field test increased by approximately two times ( Figure 7B ).
[0326] 3.2.4. β-Casomorphin-7 (BCM-7)
[0327] like Fig. 8A and 8B As shown, zebrafish receiving an intraperitoneal injection of 5 mg / kg dose of β-casomorphin (BCM-7) showed a decrease in the time spent near their sample and a slight increase in the travel length in the "schooling" test compared to the control group (trending towards a significant difference in the Mann-Whitney U-test, p≈0.07).
[0328] 3.2.5. Comparison of the effects of test substances on zebrafish behavior
[0329] In the experiments conducted, it was shown that only BCM-7 affected the average distance covered by the experimental zebrafish. The average distance covered parameter reflects the overall locomotor activity and, to a certain extent, the physical condition of the zebrafish tested. However, diazepam, fluvoxamine and ACZ-10 did not show any significant effect on the average distance covered by the experimental zebrafish. No changes were observed compared to the corresponding control group or between consecutive control groups, such as Fig. 9 shown.
[0330] The experiments described herein demonstrate that diazepam, as a typical representative of benzodiazepine anxiolytics, reduced the herding reflex at a dose of 1.25 mg / kg and reduced the severity of herding reflexes and scototaxis in the light / dark chamber at a dose of 5 mg / kg. This indicates that fish treated with diazepam had reduced anxiety levels in the described experimental setting. Diazepam at a dose of 10 mg / kg, in addition to its anxiolytic effect in the light / dark chamber, also resulted in a slight sedative effect, which was manifested by a trend toward decreased locomotor activity in the open field test. These results are consistent with those obtained in other studies describing similar effects of benzodiazepine anxiolytics (Gebauer et al. (2011) Effects of anxiolytics in zebrafish: similarities and differences between benzodiazepines, buspirone and ethanol. Pharmacol. Biochem. Behav. 99: 480-486; Bencan (2009). Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. Pharmacol. Biochem. Behav., 94(1): 75-80; Giacomini et al., (2016) Fluoxetine and diazepam acutely modulate stressinduced behavior. Behav. Brain Res. 296).
[0331] In addition, in the experiment, ACZ-10 and BCM-7 peptides were observed to have anxiolytic and positive neurotropic effects on zebrafish behavior after a single intraperitoneal injection. The inventors found changes in zebrafish behavior, which indicates that neuropeptides can produce neurotropic effects on various anxiety-depression disorders. It is worth noting that the efficacy characteristics of ACZ-10 (better known as an antianxiety drug) are closer to those of fluvoxamine rather than diazepam. At the same time, BCM-7 only showed moderate antianxiety efficacy. These results show that zebrafish is a suitable model for screening the neurotropic effects of new drugs in various anxiety-depression disorders, where new drugs are not limited to small molecules, but can also include peptides (e.g., oligopeptides).
[0332] 3.2.6. FQSE (SEQ ID NO: 10) tetrapeptide
[0333] The FQSE (SEQ ID NO: 10) peptide was studied at 1 mg / kg and 10 mg / kg doses. In the experiments described, the most significant changes in zebrafish behavior were observed at the 10 mg / kg dose. Fig. 10A As shown in the open field test, zebrafish were shown to spend a statistically significant increase in the time they spent in the upper part of the aquarium (i.e., near the surface and in the middle, rather than at the bottom). The same test showed a significant decrease in latency to leave the bottom in the zebrafish group, as shown in the open field test. Fig. 10B As shown. This result shows that the anxiety of zebrafish exposed to the FQSE (SEQ ID NO: 10) peptide at a dose of 10 mg / kg was reduced. As observed in the fluvoxamine experiments described herein, the results of the open field test on zebrafish are a good indicator of the activity of fluvoxamine. Therefore, the effects of FQSE (SEQ ID NO: 10) observed in the open field test can be interpreted as an indication of the antidepressant effect of FQSE (SEQ ID NO: 10).
[0334] like Fig.11A and 11B As shown, compared to the other tested substances (ACZ-10 and fluvoxamine), the 10 mg / kg dose of FQSE (SEQ ID NO: 10) was more effective than ACZ-10 (0.6 mg / kg), which did not affect the time spent in the upper water column, although it significantly reduced the amount of LP leaving the bottom of the test aquarium. Compared to fluvoxamine (5 mg / kg), FQSE (SEQ ID NO: 10) was slightly less effective: with the same decrease in LP leaving the bottom ( Fig. 11B ), FQSE (SEQ ID NO: 10) increased the time spent in the upper part by 35%, while fluvoxamine increased it by more than 80%. However, significant behavioral changes were observed under the action of FQSE (SEQ ID NO: 10), similar to those caused by injection of fluvoxamine.
[0335] During the light / dark box (LDB) test, fish injected with a high dose of FQSE (SEQ ID NO: 10) peptide showed a statistically significant increase in the time spent in the light compartment and a decrease in the time spent in the dark compartment ( Fig. 12A and 12B A similar effect was observed with the benzodiazepine anxiolytic diazepam at a dose of 5 mg / kg ( Fig.13A and 13BCompared to the control group, the time spent in the light compartment increased by about 140% after injection of FQSE (SEQ ID NO: 10), while the injection of diazepam (5 mg / kg) resulted in an increase of about 210%. Compared to the control group, the time spent in the dark compartment decreased by about 40% in both groups.
[0336] The reduction in Scototaxis (pursuit of dark space) is interpreted as a reduction in anxiety, since this parameter is significantly affected by the typical anxiolytic diazepam but is not affected at all by fluvoxamine.Thus, the 10 mg / kg dose of FQSE (SEQ ID NO: 10) appears to have a significant anxiolytic effect.
[0337] Fig.14A and 14B The effect of FQSE (SEQ ID NO: 10) on the behavior of zebrafish in the swarming test is shown. The swarming behavior test shows that under the influence of FQSE (SEQ ID NO: 10) (10 mg / kg), the latency to leave the "shoal" sector (the Fig. 14B ) decreased, with a trend towards an increase in the time spent outside the group area (p = 0.054, according to the Mann-Whitney U-test, Fig.14A ).
[0338] Fig.15A and 15B A comparison of the effects of diazepam, BCM-7, and FQSE (SEQ ID NO: 10) peptide on zebrafish behavior in a swarming assay is shown. The reduction in latency to leave the "school" caused by a 10 mg / kg dose of FQSE (SEQ ID NO: 10) was less than that caused by the 1.25 mg / kg and 5 mg / kg doses of diazepam, and was approximately the same level as in BCM-7, which also did not show a statistically significant effect on the time outside the swarming area ( Fig. 15B As previously mentioned, the increase in time spent outside the "fish school" caused by the FQSE (SEQ ID NO: 10) peptide could only be considered a trend toward an increase, whereas diazepam (1.25 mg / kg) caused a statistically significant change ( Fig.15A ). The herding reflex is usually interpreted as a protective mechanism, indicating an increase in anxiety in the presence of predators, exposure to anxiogenic compounds or in a novel environment. Diazepam has a consistent anxiolytic effect in this test, as it reduces the latency to leave the "school" (a fish quickly adapts and easily swims away from its conspecifics) and increases the time spent outside the schooling area.
[0339] Fig.16A , 16B, 17A and 17B show a comparison of the effects of FQSE (SEQ ID NO: 10) peptide and fluvoxamine on zebrafish behavior in the open field test. It was observed that at a dose of 1 mg / kg, the FQSE (SEQ ID NO: 10) peptide was effective in the open field test, statistically increasing the time spent near the water surface ( Fig.16A ) and the incubation period to the surface ( Fig.17A In addition, the effect of low doses of FQSE (SEQ ID NO: 10) can be compared with the effect of a 10 mg / kg dose of fluvoxamine ( Fig. 16B and 17B ), that is, FQSE (SEQ ID NO: 10) at a dose of 1 mg / kg showed a stable antidepressant effect.
[0340] Fig.18 Shown are the mean track lengths in the open field test for groups of zebrafish administered the following test substances: diazepam at doses of 1.25 mg / kg ("Diaz1.25"), 5 mg / kg ("Diazepam 5"), and 10 mg / kg ("Diazepam 10") and the corresponding control groups ("Control-diaz1.25", "Control-diaz5", "Control-diaz10"); 5 mg / kg ("Fluvoxamine 5") and 10 mg / kg ("Fluvoxamine 10”) dose of fluvoxamine and the corresponding control groups (“control-fluv5” and “control-fluv10”); 0.6 mg / kg dose of ACZ-10 (“ACZ-100.6”) and the corresponding control group (“control-ACZ-100.6”); 5 mg / kg BCM-7 (“BCM-75”) and the corresponding control group (“control-BCM-75”); 1 mg / kg and 10 mg / kg doses of the tetrapeptide FQSE (SEQ ID NO: 10) (“FQSE1” and “FQSE10”, respectively) and the corresponding control groups (“control-FQSE1” and “control-FQSE10”). Fig.18 It was shown that FQSE (SEQ ID NO: 10) had no significant effect on the locomotor activity of zebrafish at a dose of 1 mg / kg and 10 mg / kg, nor did it cause changes in the length of the track covered in the open field test.
[0341] These experiments demonstrate that the FQSE (SEQ ID NO: 10) peptide has complex anxiolytic and antidepressant effects on zebrafish behavior. The anxiolytic effects of FQSE (SEQ ID NO: 10) have been demonstrated in the light / dark box test. The increased time spent in the light compartment of the light / dark box is a result of reduced anxiety, which is further confirmed by a reduction in the flocking reflex. The antidepressant effects of FQSE (SEQ ID NO: 10) in the open field test were also observed. A 1 mg / kg dose of FQSE (SEQ ID NO: 10) showed a stable antidepressant effect in the open field test without changing the behavior of the zebrafish in other tests.
[0342] 3.2.7.FLPY(SEQ ID NO: 36) Tetrapeptide
[0343] In the experiments, FLPY (SEQ ID NO: 36) tetrapeptide was used as a negative control. The effects of FLPY (SEQ ID NO: 36) peptide on zebrafish behavior were investigated at two FLPY (SEQ ID NO: 36) doses - 1 mg / kg and 10 mg / kg. Fig.19A , 19B As shown in Figures 19C, 20A, 20B and 20C, none of the FLPY (SEQ ID NO: 36) doses caused statistically significant changes in basic behavioral parameters of the tested zebrafish. This demonstrates that the FLPY (SEQ ID NO: 36) peptide lacks antidepressant or anxiolytic effects.
[0344] 3.2.8. DKTE (SEQ ID NO: 26) tetrapeptide
[0345] The effect of DKTE (SEQ ID NO: 26) peptide on zebrafish behavior was studied at two DKTE (SEQ ID NO: 26) doses - 1 mg / kg and 10 mg / kg. Fig.21A , 21B 21C show the parameters of zebrafish behavior in the grouping test. Injection of DKTE (SEQ ID NO: 26) into the abdomen of zebrafish at a dose of 1 mg / kg resulted in a reduction in the grouping reflex, which was manifested by a statistically significant increase in the time spent near the contralateral wall of the grouping chamber by the experimental group of zebrafish ( Fig.21A ), and a statistically significant increase in the latency to visit the “fish school” ( Fig.21B The decrease in time spent in the cluster compartment for this group was trend level ( Fig. 21C ).
[0346] Fig. 22 Figure 2 shows the latency to visit the aquarium bottom in the open field test. Fig. 22As shown, the open field test demonstrated that a 1 mg / kg dose of DKTE (SEQ ID NO: 26) peptide resulted in an increase in the latency of the test zebrafish to visit the bottom of the aquarium.
[0347] Fig.23 A comparison of the effects of diazepam, FQSE (SEQ ID NO: 10) peptide, and DKTE (SEQ ID NO: 26) peptide on zebrafish behavior in a grouping assay is shown. When the effects of a 1 mg / kg dose of DKTE (SEQ ID NO: 26) peptide on grouping behavior were compared to the effects of diazepam and FQSE (SEQ ID NO: 10) peptide, it was observed that the effects of this dose of DKTE (SEQ ID NO: 26) were comparable to those of diazepam (1.25 mg / kg), as shown in Figure 2. Fig.23 At the same time, Fig.23 As shown, the effect of 1 mg / kg DKTE (SEQ ID NO: 26) on group activity was higher than that of 10 mg / kg dose of FQSE (SEQ ID NO: 10), which only showed a statistically significant trend toward increased activity. In addition, given that no efficacy was observed for the DKTE (SEQ ID NO: 26) peptide in the light / dark box test and the weak effect of the DKTE (SEQ ID NO: 26) peptide in the open field test, it can be concluded that the 1 mg / kg dose of DKTE (SEQ ID NO: 26) has an overall weaker anxiolytic effect than FQSE (SEQ ID NO: 10).
[0348] Fig.24A and 24B Locomotor activity parameters (track length and average speed) in the open field test are shown for a 1 mg / kg dose of DKTE (SEQ ID NO: 26). It was shown that a 1 mg / kg dose of DKTE (SEQ ID NO: 26) did not affect these locomotor activity parameters.
[0349] Fig.25A , 25B 25C show the behavioral parameters of zebrafish after injection of 10 mg / kg dose of DKTE (SEQ ID NO: 26). Specifically, Fig.25A shows the time spent near the surface (in the open field), Fig.25B shows the time spent in the light compartment of the light / dark box, and Fig.25CThe time spent outside the grouping area measured in the grouping test is shown. As shown, intraperitoneal injection of 10 mg / kg dose of DKTE (SEQ ID NO: 26) did not result in any statistically significant changes in zebrafish behavioral parameters in the open field, light / dark box and grouping tests. This may indicate that the dose of 10 mg / kg exceeds the effective concentration range for the DKTE (SEQ ID NO: 26) peptide.
[0350] As shown in these experiments, the DKTE (SEQ ID NO: 26) peptide at a dose of 1 mg / kg exhibited anxiolytic activity in the grouping test. Under the influence of this dose of DKTE (SEQ ID NO: 26), the reduction in the time spent outside the group area was comparable to the reduction in the same parameter caused by diazepam at a dose of 1.25 mg / kg. In the open field test, DKTE (SEQ ID NO: 26) (1 mg / kg) caused a mild antidepressant effect, which was manifested by an increase in the latency to visit the bottom. DKTE (SEQ ID NO: 26) at a dose of 10 mg / kg did not show any behavioral effects in any of the tests.
[0351] 3.2.9. WDQV (SEQ ID NO: 14) tetrapeptide
[0352] The effects of WDQV (SEQ ID NO: 14) peptide on zebrafish behavior were studied at two WDQV doses - 1 mg / kg and 10 mg / kg. Fig.26A , 26B 26A and 26C show the behavioral parameters of zebrafish injected with a 1 mg / kg dose of WDQV (SEQ ID NO: 14). As shown in these figures, at a dose of 1 mg / kg, no significant effect of the WDQV (SEQ ID NO: 14) peptide on fish behavior was observed in all three behavioral tests - open field, light / dark box and grouping test.
[0353] Fig.27A , 27B , 27C and 27D show the behavioral parameters of zebrafish after injection of 10 mg / kg dose of WDQV (SEQ ID NO: 14) in the light / dark box test. Fig.27A and 27C As shown, at a dose of 10 mg / kg, the peptide WDQV (SEQ ID NO: 14) only affected the behavior of fish in the light / dark box test. Fish from the experimental group showed an increase in the time spent in the light compartment of the light / dark box, both for the entire 5-minute period of the test and from the 3rd to the 5th minute of the test. Thus, at 10 mg / kg WDQV (SEQ ID NO: 14), a decrease in the time spent in the dark compartment of the LDB was observed, both for the entire time and for the dynamic time, as shown in FIG. Fig.27B and 27D shown.
[0354] Fig.28A and 28B The effect of WDQV (SEQ ID NO: 14) (10 mg / kg) in the light / dark box test is shown in comparison with diazepam (5 mg / kg) and FQSE (SEQ ID NO: 10) (10 mg). It was observed that the WDQV (SEQ ID NO: 14) peptide has a similar anxiolytic efficacy profile as diazepam and FQSE (SEQ ID NO: 10).
[0355] Fig.29 The figure shows the average track length in the open field test of zebrafish groups administered with the following test substances: diazepam at doses of 1.25 mg / kg ("diazepam 1.25"), 5 mg / kg ("diazepam 5") and 10 mg / kg ("diazepam 10") and corresponding control groups ("Contr-diaz1.25", "Control-diaz5", "Control-diaz10"); fluvoxamine at doses of 5 mg / kg ("fluvoxamine 5") and 10 mg / kg ("fluvoxamine 10") and corresponding control groups ("Control-fluv5" and "Control-fluv10"); ACZ-10 at a dose of 0.6 mg / kg ("ACZ-100.6") and corresponding control group ("Control-ACZ-10"); BCM-7 "BCM-75" and corresponding control group ("Control-BCM-7"); the tetrapeptide WDQV (SEQ ID NO: 1) at a dose of 10 mg / kg ID NO: 14) ("WDQV 10") and the corresponding control group ("Control-WDQV 10"). Fig.29 It was shown that at a dose of 10 mg / kg, the WDQV (SEQ ID NO: 14) peptide did not exhibit any behavioral effects, in particular the tetrapeptide had no effect on locomotor activity in the open field test.
[0356] These experiments demonstrated that the WDQV (SEQ ID NO: 14) tetrapeptide at a dose of 10 mg / kg exhibited anxiolytic effects in the light / dark box test similar to those observed after injection of diazepam (5 mg / kg) and FQSE (SEQ ID NO: 10) (10 mg / kg). However, other experiments did not reveal any effects of the WDQV (SEQ ID NO: 14) peptide (10 mg / kg) on the behavior of zebrafish. At a dose of 1 mg / kg, WDQV (SEQ ID NO: 14) also did not have any significant effects on zebrafish behavior. In summary, it can be concluded that WDQV (SEQ ID NO: 14) has a positive neurotropic effect, although it is less obvious than diazepam and FQSE (SEQ ID NO: 10) tetrapeptides, both of which show a wider range of behavioral effects.
[0357] Example 4: FQSE (SEQ ID NO: 10) Determination of neurotropic activity of peptides in mice
[0358] The purpose of this experiment was to identify the potential neurotropic effects of different doses of FQSE (SEQ ID NO: 10) peptide on the behavior of BALB / C mice after acute intraperitoneal injection. The effects of administration of FQSE (SEQ ID NO: 10) peptide on the behavior of BALB / C mice were compared with the effects of administration of diazepam on BALB / C mice. The effects of FQSE (SEQ ID NO: 10) peptide and diazepam on the behavior of mice were evaluated using the buried bead test, elevated plus maze test, Porsolt swim test (two-day modification), and open field test. These tests are techniques used to measure stress and anxiety-related behaviors in animal models to evaluate the effectiveness of potential antidepressants and anxiolytics.
[0359] In the experiments conducted in this study, BALB / C mice were subjected to open field, elevated plus maze and buried bead tests to determine the anxiolytic effects of diazepam and FQSE (SEQ ID NO: 10) peptide on mice. According to the results obtained in the open field test, elevated plus maze test and buried bead test, the administration of diazepam (by intraperitoneal injection) to mice resulted in a significant anxiolytic effect. These findings confirm that the mouse model is an effective model for testing the effects of drugs (including peptides) that bind to GABA-A receptors. In addition, in this study, the Porsolt swim test (two-day correction) was performed on BALB / C mice to determine the antidepressant effects of diazepam and FQSE (SEQ ID NO: 10) peptide on mice. FQSE (SEQ ID NO: 10) peptide in the dose range of 1 mg / kg to 20 mg / kg showed an antidepressant effect.
[0360] Materials and methods
[0361] Animal models
[0362] In this embodiment, 79 male BALB / C mice were used as subjects. The body weight of each sample was between about 18 grams and about 20 grams at the beginning of the experiment. All animals were free of species-specific pathogens (SPF status according to the FELASA list, 2014). Animals were kept under conditions where water and food were freely available. The room was equipped with air conditioning (exchange rate not less than 15r / h), with a 12h:12h light-dark cycle (lights turned on at 09:00 am), an air temperature of 20-24°±2°C (possible fluctuations were limited to no more than 2°C per day), and a humidity of 30-70%. In the study, mice were divided into six different groups, and test substances were applied to each group as shown in Table 1. Considering the grouping, the interval between the tests was one day. All procedures involving animals were performed in accordance with European (Directive 2010 / 63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes) and Russian (“Guidelines for the maintenance and care of laboratory animals GOST 33216-2014. Rules for the maintenance and care of laboratory rodents and rabbits”) bioethical guidelines.
[0363] Table 1: Experimental groups
[0364]
[0365]
[0366] After the adaptation period, the test substances were injected intraperitoneally into the mice. Behavioral parameters were measured within 30 minutes after injection. The test was performed as follows: Day 1 - open field test, Day 3 - elevated plus maze test, Day 5 - buried bead test, Day 12-13 - Porsolt swimming (two-day correction) test.
[0367] Statistical analysis
[0368] Statistical data analysis was performed using nonparametric standard (Manna-Whitney) for non-normally distributed samples or one-way analysis of variance (ANOVA) followed by Fisher's LSD test for normally distributed samples.
[0369] 4.1.3. Open field test
[0370] In the open field test, the device is a 63cm diameter venue, illuminated by strong light (500lux) (OpenScience, Russia). The following parameters were measured in a 5-minute experiment: total distance (cm), movement time (if the speed is greater than 5cm / s), immobility (if the speed is less than 0.2cm / sec), average and maximum speed, and the number of motor activities and "freezing" experiences. The same set of parameters, as well as latency and residence time, were recorded for the central sector of the venue. Defecation and rearing with hind limbs (rearing, animals stand up with hind limbs) were visually assessed (File and Wardill (1975) Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacol., 44, 53-59). The test was designed to measure the level of movement and exploratory activity.
[0371] 4.1.4. Elevated plus maze test
[0372] In the elevated plus maze test, the test site includes two open arms and two closed arms that cross in the middle. The arm length is 30cm, and the height of the closed arm side wall is 15cm. The whole device is 70cm above the ground. The open arm has a bright uniform illumination of about 400lux, and the closed arm has an illumination of about 30-40lux. The mouse is placed at the junction (center) of the four arms of the maze, facing the open arm. The following behavioral parameters are automatically recorded by the EthoVision Noldus program within 5 minutes of the experiment: total distance (cm), movement time (if the speed exceeds 5cm / s), motionlessness (if the speed is less than 0.2cm / sec), average and maximum speed, and the number of motor activities and "freezing" experiences. The same set of parameters and latency and residence time of the central sector, open arm and closed arm are measured respectively. (Made by OpenScience, Russia).
[0373] 4.1.5. Buried bead test
[0374] In the buried bead test, the apparatus is a standard T3 cage (19 cm x 29 cm x 13 cm) filled with bedding material. Standard glass beads (15 mm diameter, 5.2 g weight, any color) are used for the test. Twenty beads are evenly distributed on the surface in 4 rows of 5 beads each. The animal is placed in the test cage for 30 minutes. At the end of the time period, after the animal is carefully removed, the beads that are more than two-thirds covered by the bedding are counted.
[0375] 4.1.6. Porsolt swim test (two-day correction)
[0376] In the Porsolt swimming test, two tests were conducted over two days. The apparatus was a transparent cylinder, 30 cm high and 10 cm in diameter, filled with water (temperature of about 21-23° C.) to the 25 cm height mark. On the first day, each animal was placed in the cylinder for 10 minutes. No behavioral parameters were recorded. On the second day, the animals were placed in the cylinder for 5 minutes. The following parameters were measured: active (all four limbs with strong movements) and passive (weak movements of the hind limbs) swimming, and the duration of immobility (stopping) (Porsolt et al. (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 229 (2): 327-36). After each test, the mice were placed in a heating unit to dry.
[0377] 4.2. Evaluation of the anxiolytic effect of the test substances
[0378] The following tests were used to evaluate the anxiolytic effects of the peptides at different doses (1 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg): Day 1 - open field test, Day 3 - elevated plus maze test, Day 5 - buried bead test. Diazepam (0.75 mg / kg) was used as a comparative drug. All substances were injected intraperitoneally 30 minutes before the behavioral test in a volume of 10 μl solution per 1 gram of animal body weight.
[0379] In animal models, the anxiety state can be defined as a conflict between defensive and exploratory motivations. Thus, if the defensive motivation prevails, a highly anxious emotional state is formed, and conversely, if the exploratory motivation prevails, it can be concluded that the animal's emotional state is calm. Therefore, the antianxiety effect of a drug can be manifested as a weakening of the defensive motivation or a strengthening of the exploratory component, as well as a comprehensive multidirectional effect on these two components. In general, the effect of antianxiety drugs is defined as a shift in the conflict between defensive and exploratory motivations toward the latter.
[0380] 4.2.1. Evaluation of the effects of test substances on mouse behavior using the open field test
[0381] The open field test was used to assess the initial effects of drugs on locomotor (total distance traveled) and exploratory (hindlimb rearing, time in center, center entries) activities. Fig.30As shown, the total distance of the "diazepam" group (2542.2±179.77) was significantly higher than that of the control group (1925.6±129.31). Similar trends were shown in all four groups administered with FQSE (SEQ ID NO: 10) peptide: FQSE 1 mg / kg (2423±133.81), FQSE 5 mg / kg (2464±124.67 cm), FQSE 10 mg / kg (2441±185.97), FQSE 20 mg / kg (2478±100.41).
[0382] Fig.31 and 32 Parameters reflecting the exploratory activity of the animals are shown ("number of rearings" and "number of central entries", respectively). In the diazepam group, the number of rearings was significantly increased (10.8±2.1) compared to the control group (4.7±0.94), while the number of central entries and the time the animals spent in the central area were not significantly different between the diazepam and control groups. For the FQSE 1 mg / kg and FQSE 10 mg / kg groups, the number of rearings was significantly higher compared to the control group (11.7±2.3 and 11.7±3.6, respectively). For animals that received the peptide at doses of 1 mg / kg and 20 mg / kg, the number of central entries was significantly higher (13.1±2.26 and 11.6±2.5, respectively) compared to the control group (5.3±1.44).
[0383] 4.2.2. Evaluation of the effects of test substances on mouse behavior using the elevated plus maze test
[0384] Two groups of behavioral parameters characterizing the anxiolytic effect of administered drugs were identified in the elevated plus maze test. The first group of parameters is related to the locomotor activity of the animals. This group includes the following parameters: immobility, measured time without movement (seconds), and total distance (measured in cm). An overall increase in locomotor activity may indicate a reduction in the passive defensive motivational component (i.e., anxiolytic effect). Fig.33 The total distance parameter is shown. This parameter was shown to be significantly higher in the diazepam group (1219±91.4) compared to the control group (960±56). Injection of FQSE (SEQ ID NO: 10) peptide at doses of 1 mg / kg and 20 mg / kg also resulted in an increase in total distance (1156±48.2 and 1290±30.5, respectively), while the immobility time was reduced relative to the control value (57.7±7.05) ( Fig.34 )(36.6±3.97 and 30.1±3.07, respectively).
[0385] The second set of parameters includes arm opening time (seconds) ( Fig.35 ), open arm entry times( Fig.36), the number of risky behaviors (number of rearing and dangle events, such as Fig.37 shown) and anxiety index ( Fig.38 ). Anxiety index (AI) was calculated using the following formula:
[0386] AI = 100*(1-(arm opening time / total test time+arm opening entry times / total entry times) / 2)
[0387] The increase in time spent in the open arms and the associated decrease in anxiety index are standard measures of increased exploratory motivation and decreased anxiety. These observations suggest an anxiolytic effect of the substance.
[0388] According to the experimental results of the test described in this article, intraperitoneal injection of diazepam resulted in a significant anxiolytic effect: during the analysis of behavioral parameters in response to diazepam administration, it was shown that the "open arm time" (67.4±18.43), "open arm entry" (6.5±0.99), and "number of risky behaviors" (15±2.8) of the diazepam group were significantly higher than those of the control group (23±8.12; 3.5±0.81; 7±2.3, respectively), which led to a statistically significant decrease in the "anxiety index" of the diazepam group (73±4.7%) compared with the control group (85±3.4%).
[0389] Similar results were observed for the peptide administration groups. The "open arm time" (69.1±9.98) of the FQSE 20 mg / kg group was significantly increased compared to the control group (23±8.12). The "open arm entry" and "number of risky behaviors" were significantly higher in FQSE 1 mg / kg (7.7±0.79; 15±2.1), FQSE 10 mg / kg (6.5±1.07; 15±3.2) and FQSE 20 mg / kg (6.9±0.79; 16±2.1) compared to the control group (3.5±0.81; 7±2.3). Therefore, the "anxiety index" of the animals in these groups was also lower than the control value, and was 72±2% in the FQSE 1 mg / kg group; 72±3.8% in the FQSE 10 mg / kg group, and 69±3.3% in the peptide 20 mg / kg group.
[0390] 4.2.3. Evaluation of the effects of test substances on mouse behavior using the buried bead test
[0391] The animals perceived a shiny bead located in the experimental area as a stressor, a negative stimulus that had to be buried in the bedding so that the mice did not have to have visual and tactile contact with it. The number of buried beads decreased under the influence of drug administration during the 30-minute experiment ( Fig.39) showed that the anxiety level of the animals was reduced. According to the data obtained, the mean number of beads buried by animals in the control group was 5.2 ± 1.04, while the number of beads buried by animals in the diazepam group was significantly less - 1.2 ± 0.39. A reduction in the number of beads buried was also observed in the following groups: FQSE 5mg / kg (1.9 ± 0.99), FQSE 10mg / kg (2.6 ± 0.877) and FQSE 20mg / kg (1.4 ± 0.68).
[0392] 4.3. Evaluation of the antidepressant effect of the test substance
[0393] To evaluate the antidepressant effects of drugs, the Porsolt swim test (two-day modification) was used. These behavioral tests are the primary methods used to evaluate the depressive component of animal behavior and the effects of test drugs on it.
[0394] 4.3.1. Porsolt swim test (two-day correction)
[0395] The two-day correction allows the animals to adapt to the test conditions on the first day of the experiment, and this allows a more informed assessment of the behavioral responses on the second day. According to the literature, the longer the immobility time (the time the animal spends in a "freezing" state), the more depressed the animal is. A significant reduction in the immobility time under the influence of a drug characterizes its ability to exhibit an antidepressant effect and modulate depressive-like behavior.
[0396] According to the results of the experiments described here, intraperitoneal injection of diazepam at a dose of 0.75 mg / kg did not result in changes in any of the test parameters (duration of active and passive swimming, immobility time) ( Fig.40 , 41 , 42). In contrast, injection of the investigated peptide FQSE (SEQ ID NO: 10) ( Fig.40 ) resulted in a decrease in the total immobility time in all experimental groups: FQSE 1 mg / kg (142 ± 12.7), FQSE 5 mg / kg (115 ± 15.4), FQSE 10 mg / kg (145 ± 16.5) and FQSE 20 mg / kg (144 ± 10.2), and these results were significantly different from the control group (189 ± 11.1). In addition, for the FQSE 5 mg / kg, FQSE 10 mg / kg and FQSE 20 mg / kg groups, an increase in the duration of passive swimming was observed (151 ± 12.5, 162 ± 12.1 and 143 ± 14.6, respectively) compared to the control value (105 ± 11.1). It should be noted that the administration of the peptide at a dose of 20 mg / kg significantly increased the active swimming (when all four limbs of the animal move simultaneously) time to 27 ± 8.3 sec, while the average value of the control group was 5 ± 2 sec.
[0397] 4.4. Comparison of anxiolytic and antidepressant effects of test substances
[0398] The inventors of the present disclosure found that intraperitoneal administration (single injection) of 1 mg / kg to 20 mg / kg of FQSE (SEQ ID NO: 10) peptide 30 minutes before the experiment resulted in a significant anxiolytic-like effect based on the results obtained in three different behavioral tests (open field test, elevated plus maze test and buried bead test). Similarly, a single intraperitoneal injection of 0.75 mg / kg of diazepam to BALB / C mice 30 minutes before the behavioral test resulted in a significant anxiolytic-like effect of diazepam.
[0399] According to the results obtained in the open field test, the elevated plus maze test and the buried bead test, the administration of diazepam (by intraperitoneal injection) to mice resulted in a significant anxiolytic-like effect. These findings are consistent with the information in the scientific literature and confirm that the mouse model is an effective model for testing the effects of drugs, including peptides that bind to GABA-A receptors. The conclusions about the anxiolytic effect of the drug are based on the following data: increased motor and exploratory activity in the open field test; increased parameters "open arm time", "open arm entry" and "risk behavior" times, as well as a decrease in the "anxiety index" parameter in the elevated plus maze test; and a decrease in the number of buried beads in the buried bead test. All peptide doses used in this study resulted in an increase in the motor activity of animals in the open field test. An increase in exploratory activity (based on the "open arm entry" parameter) was observed in the FQSE 1mg / kg and FQSE 20mg / kg test groups. The elevated plus maze test showed a decrease in the "anxiety index" parameter in the FQSE 1mg / kg, FQSE 10mg / kg and FQSE 20mg / kg groups. Therefore, based on the results obtained in three different behavioral tests, it can be concluded that the peptides administered intraperitoneally at doses ranging from 1 mg / kg to 20 mg / kg 30 minutes before the experiment produced a significant anxiolytic-like effect.
[0400] In the experiments conducted by the inventors of the present disclosure, the Porsolt swimming test (two-day correction) was performed on BALB / C mice to determine the antidepressant effects of diazepam and FQSE (SEQ ID NO: 10) peptide on mice. A single intraperitoneal injection of diazepam at a dose of 0.75 mg / kg into BALB / C mice did not cause an antidepressant effect. However, according to the results of the Porsolt swimming test, a single intraperitoneal injection of FQSE (SEQ ID NO: 10) peptide in a dose range of 1 mg / kg to 20 mg / kg showed an antidepressant effect. In addition, diazepam injection resulted in sedative side effects, while intraperitoneal injection of FQSE (SEQ ID NO: 10) peptide at all dose levels in the range of 1 mg / kg to 20 mg / kg did not produce negative depressant effects on the CNS.
[0401] Example 5: Intranasal administration of the peptide FQSE (SEQ ID NO: 10) in male Sprague Dawley Rats anxiety and Role of behavioral tests in depression
[0402] The aim of the study was to evaluate the effective intranasal (in) dose of the peptide in behavioral tests of anxiety and depression in rats.
[0403] Materials and methods
[0404] 5.1.1. Animals
[0405] A total of 110 male Sprague Dawley rats (Charles River, Wilmington, MA) were used for the study. Initially, 3-5 rats were kept in polypropylene cages in a round tower (Animal Care Systems, Inc, Centennial, CO), which was located in a breeding house with controlled temperature and humidity and maintained a 12:12 light / dark cycle (6AM lights on). The rats weighed about 250-350gm at the beginning of the experiment and were at least 100 days old. Food and water were available at will throughout the study. All procedures were approved by the Animal Care and Use Institutional Committee of the University of Houston according to the guidelines of the National Institutes of Health.
[0406] 5.1.2. Drugs and test articles
[0407] Diazepam (DZ2.0, Sigma-Aldrich, St. Louis, MO, USA, 2 mg / kg, IP) and ketamine (Miller Veterinary Supply, Fort Worth, TX, 10 mg / kg, IP) were prepared in sterile saline. Five doses of FQSE (SEQ ID NO: 10) (0.01, 0.1, 0.5, 1 and 3 mg / kg, CS, Menlo Park, CA) were freshly prepared in sterile saline on each experimental day and administered intranasally (in) 30 minutes before the experiment. 15 rats were tested per group for each peptide dose, except for 20 rats in the vehicle (0) group. Each dose was administered in a random order in rats. Prior to dosing, rats were lightly anesthetized with isoflurane (2.5%, 0.5 L / min oxygen) (until loss of righting reflex), placed in the recumbent position, and then a thin plastic pipette (Fischer Scientific) was inserted into the nostrils and the peptide was administered in a volume of 15-20 μL per nostril. Each individual conducting the behavioral experiments was blinded to drug treatment.
[0408] 5.1.3. Behavioral apparatus and experimental procedures
[0409] Open Field (OF)
[0410] The open field test was conducted in an open field apparatus (17" L x 17" W x 12" H (43.2 cm x 43.2 cm x 30.5 cm; Noldus, Leesburg, VA) constructed of gray Plexiglas, with a digital camera positioned above the arena to detect different activity measures using specialized software (Ethovision, XT12). Rats were first acclimated to the test room in their home cages for 30 minutes. At the beginning of the test, the animals were placed in the center of the open field chamber and behavior was recorded for 30 minutes. Observers were not in the room during the test. The test was conducted under red light. The arena was thoroughly cleaned with LpH disinfectant between subjects.
[0411] Elevated plus maze (EPM)
[0412] First, rats were allowed to adapt to the test room in their home cages for 30 minutes. During the test, a rat was placed in a maze consisting of the following for 5 minutes: two open arms (length 45cmx width 10cm), two closed arms (length 45cmx width 10cmx height 30cm) and a central compartment (length 4cmx width 4cm) formed a plus sign, located 50cm above the ground. The test phase was recorded digitally for later analysis (Ethovision, XT12). All tests were conducted under red light. The experimenter observed the rats through a special observation window provided on the door of the behavioral test room during the test. After each animal was performed, the device was cleaned with LpH disinfectant.
[0413] Forced swim test (FST)
[0414] First, rats were acclimated to the test room in their home cages for 30 minutes. The forced swimming test was performed using a Plexiglas cylinder (10 wide and 18 high) containing water maintained at approximately 25°C. On the first day, rats were first accustomed (15 minutes) to the forced swimming apparatus by placing them in the water facing the cylinder wall. The forced swimming test was performed the next day (5 minutes). Activity was recorded by a digital camera and analyzed using dedicated software (Ethovision XT12).
[0415] Statistical analysis
[0416] Central zone time in the open field test, central zone entries, % open arm time in the EPM test, and immobility and movement time in the FST were analyzed using a 1X7 one-way ANOVA with drug dose (0, 0.01, 0.1, 0.5, 1.0, 3.0, diazepam 2.0 or ketamine 10 mg / kg) as the main factor. Paired multiple comparison procedures were performed using the Student-Newman-Keuls method or Fisher's least significant difference (LSD) post hoc test. Statistical significance was set at P < 0.05.
[0417] Results
[0418] OFT
[0419] The central zone time after administration of different drug doses is as follows Fig.43A The analysis revealed a significant main effect of drug dose (P < 0.05). Post hoc multiple comparisons of central zone time at different drug doses showed significant differences between the control (90.9 ± 11.6 s) and two FQSE (SEQ ID NO: 10) doses: 0.5 mg / kg (204.1 ± 46.6 s; P = 0.0017) and 3 mg / kg (166.2 ± 18.4 s; P = 0.038) peptides. Central zone entry after administration of different drug doses was as shown in Figure 2. Fig.43B As shown in 43C. The analysis revealed a significant main effect of drug dose (P<0.05). Post hoc multiple comparisons of central zone entries at different drug doses showed significant differences between vehicle (33.6±3.9) and four experimental groups: 0.01 mg / kg (49.1±6.5; P=0.048), 0.5 mg / kg (54.2±8.3; P=0.009), 3 mg / kg (54.1±4.6; P=0.011), and diazepam (54.3±6.2; P=0.0089). The total distance (cm) after administration of different drug doses is shown in 43C. The analysis revealed a significant main effect of drug dose (P<0.05). Fisher's LSD post hoc test yielded significant differences between vehicle (4441±292 cm) and two experimental groups: 0.5 mg / kg (5338±316.2 cm; P=0.014) and diazepam (5289±263 cm; P=0.02).
[0420] EPM
[0421] The percentage of open arm time after the EPM test is as follows Fig.44 The analysis revealed a significant main effect of drug dose (P < 0.05). Fisher's LSD post hoc test showed significant differences between vehicle (6.1 ± 1.4%), the two experimental groups: 0.01 mg / kg (10.6 ± 1.6%; P = 0.032), 0.5 mg / kg (11.3 ± 2.05%; P = 0.015), and diazepam (10.8 ± 1.11%; P = 0.028).
[0422] FST
[0423] The results of the forced swim test are as follows: Fig.45AAs shown. Analysis of immobility measures revealed a significant main effect of drug dose (P<0.001). Fisher's LSD post hoc test indicated significant differences between vehicle (231.1±7.99 s) and two drug doses: 0.5 mg / kg (157.1±7.98 s; P<0.0001) and ketamine 10 mg / kg (196.4±8.9 s; P<0.008). Ketamine was also associated with a significant decrease in immobility compared to 0.1 mg / kg peptide (238.1±9.19 s; P=0.003). No significant differences were observed between any of the other doses tested. Mobility measures such as Fig.46 Figure 24 shows the results of the present invention. The results of the present invention are shown in Figure 24B. Analysis of locomotion measures revealed a significant main effect of drug dose (P<0.001). Fisher's LSD post hoc test showed a significant difference between 0.5 mg / kg (142.9±7.98 s; P<0.0001) and vehicle (68.6±7.99 s). Locomotion was also greater after ketamine administration (103.6±8.9 s) compared to vehicle (P=0.008) and the 0.1 mg / kg peptide dose (P=0.0032). No significant differences were observed between any of the other doses tested.
[0424] 5.3. Discussion
[0425] The present study addressed the behavioral effects of different doses of the FQSE (SEQ ID NO: 10) tetrapeptide compared to administration of diazepam or ketamine.
[0426] In the OF, it was found that FQSE (SEQ ID NO: 10) treatment resulted in an increase in the distance traveled (at a dose of 0.5 mg / kg) as well as an increase in the time spent in the center (at doses of 0.5 and 3 mg / kg) and the number of center entries (at doses of 0.01, 0.5, 3 mg / kg). The behavior of the animals in the OF test reflects a balance between exploratory motivation and fear in a new environment. The decrease in thigmotaxis accompanied by an increase in locomotion indicated a reduction in anxiety in rats that received FQSE (SEQ ID NO: 10). The most significant peptide effect was observed at a dose of 0.5 mg / kg and was comparable to that of diazepam. The peptide did not cause sedation at all doses.
[0427] In the EPM, a decrease in the time spent in the open arms was observed after FQSE (SEQ ID NO: 10) treatment at doses of 0.01 and 0.5 mg / kg. The EPM test has a strong predictive reliability for screening anxiolytic drugs. The behavioral results of FQSE (SEQ ID NO: 10) treatment in this test showed that the peptide has anxiolytic-like activity at doses of 0.01 and 0.5 mg / kg.
[0428] The FS test is an effective tool for evaluating drugs with potential antidepressant-like activity. In the current study, it was observed that after administration of FQSE (SEQ ID NO: 10) at a dose of 0.5 mg / kg, a significant decrease in the time spent immobile and an increase in the time spent actively swimming were observed. These changes were similar to those observed after ketamine treatment and suggest that the peptide has an antidepressant-like effect. Rats treated with other doses of the peptide did not differ from animals receiving saline.
[0429] 5.4. Conclusion
[0430] In the current study, the effects of different doses of FQSE (SEQ ID NO: 10) on the behavior of Sprague-Dawley rats in the open field were evaluated using the elevated plus maze and forced swim tests. The behavioral changes after administration of FQSE (SEQ ID NO: 10) partially reproduced the results observed in diazepam-treated rats in the OF and EPM tests and in ketamine-treated rats in the FST. According to the behavioral paradigm, the most significant anxiolytic-like and antidepressant-like effects of the peptide were seen at doses of 0.5 mg / kg and 0.01 mg / kg. The results indicate a dose-dependent activity of FQSE (SEQ ID NO: 10), which has maximum efficacy at an intranasal dose of 0.5 mg / kg.
[0431] Example 6: FQSE (SEQ ID NO:10) Peptide in the chronic mild unpredictable stress (CUMS) model to inhibit anxiety Research on anxiety and antidepressant effects
[0432] The aim of this study was to investigate the anxiolytic and antidepressant potential of different doses of FQSE (SEQ ID NO: 10) peptide after chronic intranasal administration in the CUMS model.
[0433] Materials and methods
[0434] 6.1.1. Animals
[0435] 110 Wistar male rats from the Stolbovaya laboratory animal breeding room were used in the experiment. Animals were kept under standard conditions according to the requirements of biological laboratories (Laboratory Animal Regulations and Guidelines, Moscow, 2003). Environmentally friendly hardwood shavings were used as bedding (TU 5313-001-1897639-92). Rats had free access to food and water. Daylight simulation lasted from 7:00 to 19:00, and the illumination during the light hours was 70-90 lux. The temperature of the permanent holding room was 24°C. All procedures involving animals were carried out in accordance with European (Directive 2010 / 63 / EU of the European Parliament and the Council of September 22, 2010 on the protection of animals used for scientific purposes) and Russian ("GOST 33216-2014 Guidelines for the maintenance and care of laboratory animals. Rules for the maintenance and care of laboratory rodents and rabbits") bioethical guidelines.
[0436] All animal experiments were conducted in accordance with the rules for the humane treatment of experimental animals. For this experiment, the requirements of the following instructions were implemented: Instruction MZ RF 267 from June 19, 2003 "Rules of Laboratory Practice in the Russian Federation", "Manual of Experimental (Preclinical) Research on New Pharmacological Substances" 2005 (Second Edition), and "Guidelines for the maintenance and breeding of experimental animals in nurseries and experimental biological laboratories (VivariumsA) and their use for scientific, educational and industrial purposes", M., 2003.
[0437] After transport to the animal facility, the animals were quarantined for 2 weeks before the start of the experiments (acclimatization period).
[0438] Experimental plan
[0439] Experimental plan Fig.46 At the beginning of the experiment, the animals were placed in a separate unit for a sucrose preference test, and the anhedonia level was determined for eliminating animals with a sucrose preference index below 65% (SP1).
[0440] Animals meeting the selected criteria were divided into a naive control group (n=10) and a group subjected to chronic mild unpredictable stress (CUMS) (n=52).
[0441] 6.1.3. Stress regimen
[0442] During the stress period, animals were housed in individual units and exposed to stress conditions daily for 26 days. Two stressors were used daily in the following order:
[0443] Day 1: 10am-6pm, place rats in cold room for one hour. From 6PM to 10am, lights are switched on and off every 2 hours.
[0444] Day 2: 10am-6pm, cage tilted to 45°. No water from 6pm to 10am.
[0445] Day 3: 10am-6pm, strobe lights. Lights on overnight from 6pm to 10am.
[0446] Day 4: 10am-6pm, wet bedding. From 6PM to 10am, place animals in small cages.
[0447] Day 5: 10am-6pm, no litter. Lights turned on and off every 2 hours from 6PM to 10am.
[0448] Day 6: 10am-6pm, place a new rat in the cage (6 months old). Lights are on overnight from 6PM to 10am.
[0449] Day 7: 10am-6pm, white noise. Strobe lights on overnight from 6pm to 10am.
[0450] Days 8-26: Repeat previously used stressors in the specified order.
[0451] After the stress procedure, the animals were retested for sucrose preference (SP2) to evaluate the effectiveness of the stress and identify rats showing signs of anhedonia. As a result of the evaluation, 1 rat was excluded from the natural control group due to a low sucrose preference value (<65%). 40 animals were selected as the experimental group.
[0452] Experimental groups
[0453] All selected animals were divided into the following groups: 1) "CUMS+Vehicle", where 10 males received saline in 2) "CUMS+0.05", where 10 males were administered 0.05 mg / kg of the experimental drug dissolved in saline in, 3) "CUMS+0.5", where 10 males were administered 0.5 mg / kg of the experimental drug dissolved in saline in, 4) "CUMS+Diaz", where 10 males were administered 0.5 mg / kg / ip of diazepam, and 5) "Control", where 9 males were administered saline intraperitoneally and intranasally. The experimental substances were administered daily starting from the 58th-59th day of the experiment. Administration occurred 30 minutes before the start of the behavioral test. On days without testing, the substances were administered in the morning.
[0454] Table 2: Number of injections of the investigated substances until the start of the behavioral test
[0455] test Number of peptide injections Elevated plus maze (Days 58-59) 1 Social interaction (Days 61-62) 4 Female urine sniff test (day 65-66) 8 Novelty suppressed feeding (Days 68-69) 11 Sucrose preference (Days 73-75) 16 Porsolt forced swim test (Day 75-76) 18 Collect brain samples (end of experiment, day 79-80) 22
[0456] 6.1.5. Behavioral test
[0457] Sucrose preference test (SPT)
[0458] A test was used to determine preference for sucrose solutions to assess the state of anhedonia (denial of pleasure, a key symptom of depression). Animals were provided with 2 drinking fountains for 24 hours with free access to them. One contained water only and the other contained a 1% sucrose solution. Rats were provided with a 2% sucrose solution for 2 hours the evening before the test. During the test, the drinking fountains were swapped to avoid the development of a place preference. The drinking fountains were weighed in advance and the volume of liquid consumed was calculated based on the difference in mass. The parameters measured included the volume of plain water, sweetened water and the total volume of liquid consumed. The preference index was calculated using the following formula:
[0459] Volume of sweetened water consumed * 100% / total volume of liquid consumed.
[0460] Elevated plus maze test (EPM)
[0461] The elevated plus maze test is used to assess the level of anxiety, movement and exploratory activity in laboratory animals. The device consists of two closed arms and two open arms (arm length 45 cm) opposite to each other, and the side height of the closed arms is 10 cm. The entire device is placed on a platform 70 cm above the ground. Rats are placed in the center of the maze with their heads facing the open arms. Record the number of exits to the open arms and the time spent therein, the number of transitions between arms, rest time, the duration and number of grooming movements within 5 minutes, the number of times of stretching into the open arms of the maze, and the number of times of standing upright with hind limbs. Usually, rodents tend to stay in the dark arms. An important indicator of the antianxiety effect of drugs is the increase in the number of times and duration of exits to the open arms of the maze.
[0462] Social interaction test (SI)
[0463] In order to evaluate the social activities and depressive states of animals, a test for evaluating rodent social interaction was used. In the test, a 1-month-old young male was placed in a home cage. The duration and number of social contacts with the young male within 10 minutes, as well as the number of intimidation and aggressive contacts were recorded. Social contact is considered to be a reaction of following and sniffing young males, etc. (Vishnivetskaya et al. (2007). Effect of MAO A deficiency on different kinds of aggression and social investigation in mice. Aggress. Behav. 33 (1), 1-6). Usually, young males do not pose any danger to adult rats, so rats in a calm state show quite high social interaction indicators and low aggression. Signs of aggression are the result of behavioral deviations, and reduced social contact can indicate the presence of depressive behavior.
[0464] Novelty suppressed feeding test (NSFT)
[0465] In order to assess anxiety and food motivation, a dietary behavior test in a new environment was used. In this test, experimental animals that had previously experienced food deprivation for 24 hours were placed in a square field (50x50x40cm) for 5 minutes (Jiao et al. (2019). Influence of Xiaoyaosan on depressive-like behaviors inchronic stress-depressed rats through regulating tryptophan metabolism in hippocampus. Neuropsych. Dis. Treat. 15, 21). A snack (a food pellet) was placed in the brightly illuminated center of the field. The time to start eating and the duration of eating were recorded. Because rodents are afraid of open lighting spaces, this test is used to assess anxiety levels. Animals that show high anxiety levels usually do not approach snacks. Anti-anxiety drugs significantly reduce the time to start eating. Chronic administration of antidepressants also leads to a reduction in the latency to start eating in this test.
[0466] Female Urine Sniff Test (FUST)
[0467] The FUST test is used to assess anhedonia, sexual motivation, and exploratory behavior associated with depressive conditions in rodents (Gould et al. (2009). Mood and anxiety related phenotypes in mice. Humana Press). The test was conducted in a cage containing bedding under dim light (3 lux). In the first phase of the experiment, cotton swabs moistened with distilled water were provided to the animals for 3 minutes. The latency, sniffing time, and number of approaches to the cotton swab were recorded. After a 45-minute rest, the rats were provided with cotton swabs moistened with estrus urine of the same strain of females. The latency, sniffing time, and number of approaches to the cotton swab were also recorded. To determine preference, the index was calculated using the following formula: time spent sniffing urine * 100% / total sniffing time. Mature males showed a high interest in cotton swabs with female urine and showed high sexual motivation. This was manifested in a reduced latency to contact the moistened cotton swab and a longer duration of interaction. At the same time, a low rate of interaction with the cotton swab may indicate that exploratory behavior is disturbed and anhedonia develops, which is a major symptom of clinical depression.
[0468] Porsolt swim test
[0469] The forced swim test is a rodent behavioral test for evaluating the antidepressant efficacy of antidepressant drugs, new compounds, and experimental manipulations intended to cause or prevent depressive-like states. During the test, each animal was placed in a cylinder filled with water (temperature 24°C) to 30cm for 8 minutes. The cylinder diameter is 31cm and the height is 40cm. In the last 6 minutes, the duration of active (vigorous movement of the limbs) and passive (weak paddling of the hind limbs) swimming and the duration of immobility were recorded. The immobility parameter reflects the state of animal despair and refusal to try to escape from the experimental device. This can reflect the state of apathy and slow movement that occurs in clinical depression.
[0470] Statistical analysis
[0471] The Shapiro-Wilk criterion was used to examine the data distribution and parametric or nonparametric statistical comparison criteria were selected based on this.
[0472] Parametric analyses were performed in case of normal distribution of number of stands, social interaction time, female urine preference index, and sucrose preference using ANOVA analysis of variance and post hoc analysis with Tukey's multiple comparison criteria. Nonparametric analyses (in case of non-normal distribution) were performed using Kruskal-Wallis test and post hoc analysis with Dunn's multiple comparison test. Differences were considered significant when p < 0.05.
[0473] Results
[0474] 6.2.1.EPM
[0475] Experiments were performed to determine anxiety levels in rats, which can be increased in animals with a depressive-like phenotype.
[0476] Normality test using Shapiro-Wilk test did not prove normal distribution of data in the groups, therefore the results will be evaluated using nonparametric criteria. The results using Kruskal-Wallis criterion revealed a significant effect of the treatment factor (H(4, N = 49) = 21.5; p = 0.0002) on the time spent in the open arms. It was shown that this parameter was significantly reduced in animals of the "CUMS + veh" group compared to the control group (p = 0.04), which indicates the development of an anxious phenotype ( Fig.47A ). There were no differences between control and peptide treated animals, indicating normalization of stress levels. The 0.05 mg / kg dose of FQSE (SEQ ID NO: 10) also showed a trend towards an increase in this parameter compared to vehicle treatment (p = 0.07), which may indicate that the peptide has a mild anxiolytic effect. Animals treated with diazepam after chronic stress spent an increased amount of time in the open arms compared to stressed animals treated with vehicle (p = 0.0001) and both doses of the peptide (p = 0.05 compared to FQSE (SEQ ID NO: 10) 0.05 and p = 0.009 compared to FQSE (SEQ ID NO: 10) 0.5). Fig.47A ), which reflects its powerful anxiolytic effects.
[0477] In addition, there was a significant main effect of treatment (H(4, N=49)=12.6; p=0.013) on freezing time in the EPM test. Increased freezing was only observed in animals treated with diazepam (p=0.006 compared to the control group) ( Fig.47B ), which may be the result of the strong sedative effect of the drug.
[0478] 6.2.2.SI
[0479] The social interaction test showed that rats have interest in social contact, which can be reduced in a depressive-like state.
[0480] Normality testing using the Shapiro-Wilk test confirmed normal distribution, and therefore the results will be evaluated using parametric criteria. One-way ANOVA revealed a significant effect of treatment (F(4,44)=7.5; p=0.0001) on social contact time. Multiple pairwise comparisons of the groups using the Tukey test revealed that the duration of social contact was significantly reduced in the stressed animal group that received the solvent (p=0.0002), diazepam (p=0.01), and 0.5 mg / kg dose of FQSE (SEQ ID NO:10) (p=0.007) compared to control non-stressed rats. Although animals that received a 0.05 mg / kg dose of the peptide did not differ from control animals in this parameter, the duration of social contact was significantly higher compared to the CUMS+veh group (p=0.01) ( Fig.48 ).
[0481] 6.2.3.FUST
[0482] Normality tests confirmed normal distribution, so the results will be evaluated using parametric criteria. One-way ANOVA showed a significant effect of treatment (F(4,44) = 5,8073; p = 0.0007) on the female urine preference index. Post hoc analysis showed a decrease in the stressed animals group that received the vehicle compared to the control group (p = 0.03). Administration of the peptide at doses of 0.05 and 0.5 mg / kg resulted in an increase in the rats' preference for female urine (p = 0.003 and p = 0.001) compared to animals that had undergone stress and received the vehicle ( Fig.49 ). In this test, diazepam had no effect on the animals' behavior.
[0483] 6.2.4.NSFT
[0484] The NSFT test was performed to determine the anxiety level of the rats.
[0485] The Kaplan-Meyer multiplier estimates were used to estimate the latency to start eating, which takes into account censored variables. Fig.50 shown.
[0486] The use of the chi-square criterion revealed significant differences between the groups (Chisq = 12.1; df = 4; p = 0.01). The groups were compared using the Cox-Mantel test. It was shown that chronic stress did not lead to an increase in the latency to approach the food (F(6,8) = 1.3, p = 0.35 compared to the control group). It should be noted that in the control group, more than 60% of the animals did not approach the food, which is attributed to the high stress level in this experiment. The introduction of diazepam resulted in a significant decrease in latency compared to the control and CUMS+veh. groups (F(6,14) = 3.5, p = 0.02, and F(8,14) = 3.2, p = 0.02, respectively). Similar effects were observed in the group of rats that received the peptide at a dose of 0.05 mg / kg; a significant increase in time was observed compared to the control and CUMS+veh. groups (F(6,16)=4.2, p=0.009, and F(8,16)=3.71 p=0.01). Animals that received a dose of 0.5 mg / mg of FQSE (SEQ ID NO: 10) were no different from the control group and stressed animals that received saline.
[0487] 6.2.5.SPT
[0488] This test characterizes the degree of anhedonia in animals experiencing chronic stress.
[0489] Normality testing using the Shapiro-Wilk test did not confirm normal distribution, so nonparametric criteria will be used to evaluate the results. The results of the Kruskal-Wallis test showed that the treatment factor had a significant effect on the sucrose preference index (H(4,N=49)=11.8; p=0.018). The index of animals that underwent stress and received the solvent was significantly lower than that of control animals (p=0.017). The stressed animals that received diazepam and peptide did not show significant changes compared to the control or CUMS+veh groups ( Fig.51 ).
[0490] 6.2.6.FST
[0491] A widely used test for evaluating the potent antidepressant activity of a substance.
[0492] Normality testing using the Shapiro-Wilk test did not confirm normal distribution, so nonparametric criteria will be used to evaluate the results. The results of the Kruskal-Wallis test revealed a significant effect of treatment on immobility time (H(4,N=49)=12.2, p=0.01). A significant increase in immobility was observed in the CUMS+veh group compared to the control group (p=0.04). A dose of 0.5 mg / kg of FQSE (SEQ ID NO: 10) significantly reduced immobility time in this trial compared to the CUMS+veh. group (p=0.03)( Fig.52 ). Diazepam and peptide doses of 0.05 mg / kg did not differ from controls or the stressed group receiving saline.
[0493] Discussion
[0494] The chronic stress model resulted in the development of a persistent depressive-like condition observed in all behavioral tests used. Administration of diazepam at a dose of 0.5 mg / kg produced only anxiolytic effects in the EPM and NSFT tests and had no effect on animal behavior in the test of depressive-like condition (Table 3).
[0495] The experimental drugs studied had antidepressant-like effects in the Porsolt test, the social interaction test, and affected anhedonia levels in the female urine preference test. Both doses of the peptide had antidepressant-like effects, but not in all behavioral tests. In the FUST test, the most significant effects were observed at both doses of the peptide. The antidepressant effect of FQSE (SEQ ID NO: 10) was observed after the 4th injection.
[0496] At a dose of 0.05 mg / kg, FQSE (SEQ ID NO: 10) had anxiolytic-like effects in NSFT. It should be noted that in this assay, anxiolytic effects were observed following chronic administration of clinically used antidepressants, selective serotonin reuptake inhibitors (SSRIs).
[0497] Conclusion
[0498] This unpredictable chronic stress model leads to the development of a persistent depressive state in rats.
[0499] Administration of diazepam has significant anxiolytic and sedative effects.
[0500] FQSE (SEQ ID NO: 10) at doses of 0.05 and 0.5 mg / kg had antidepressant-like effects in various behavioral tests.
[0501] FQSE (SEQ ID NO: 10) at a dose of 0.05 mg / kg exhibited anxiolytic effects in NSFT and mild anxiolytic-like effects in EPM without signs of sedation.
[0502] Table 3: Results obtained in the chronic stress model after introduction of the investigated substances
[0503]
[0504] Example 7: FQSE (SEQ ID NO:10) in animal models of post-traumatic stress disorder (PTSD)
[0505] To date, there is no effective treatment for PTSD: first-line treatment for PTSD includes SSRIs, yet a report by the Institute of Medicine concluded that the available evidence is insufficient to support the efficacy of SSRIs or other pharmacotherapy in PTSD (Treatment of posttraumatic stress disorder: An assessment of the evidence. Washington, DC: National Academies Press. Institute of Medicine; 2008). Clearly, the discovery of new pharmacological treatments for anxiety disorders represents a huge unmet medical need.
[0506] The aim of the study was to evaluate the effect of FQSE (SEQ ID NO: 10) peptide in a PTSD model.
[0507] Materials and methods
[0508] 7.1.1. Animals and housing
[0509] A total of 120 male Sprague Dawley rats (Charles River, Wilmington, MA) were used for the study. Initially, 3-5 rats were kept in polypropylene cages in a round tower (Animal Care Systems, Inc, Centennial, CO), which was located in a breeding house with controlled temperature and humidity and maintained a 12:12 light / dark cycle (6AM lights on). The rats weighed about 250-350gm at the beginning of the experiment and were at least 100 days old. Food and water were available at will throughout the study. All procedures were approved by the Animal Care and Use Institutional Committee of the University of Houston according to the guidelines of the National Institutes of Health.
[0510] 7.1.2. Animals and housing
[0511] Doxazosin (DOX, Sigma-Aldrich, St. Louis, MO, USA, 1 mg / kg, IP) was prepared in sterile saline. DOX has been previously shown to be effective in treating some PTSD symptoms in veterans (Rodgman et al. (2016). Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. J. Clin. Psychiat., 77(5), e561-565).
[0512] Two doses of FQSE (SEQ ID NO: 10) (0.05 and 0.5 mg / kg, CS, Menlo Park, CA) were freshly prepared in sterile saline each experimental day and administered intranasally 30 minutes before testing. Each dose was administered in a random order between groups. Prior to dosing, rats were lightly anesthetized with isoflurane (2.5%, 0.5 L / min oxygen) (until loss of righting reflex), placed in the recumbent position, and a fine plastic pipette (Fischer Scientific) was inserted into the nostrils and the peptide was administered in a volume of 15-20 μL per nostril. Doxazosin was administered using the same procedure as isoflurane, but the drug was administered IP. Individuals undergoing behavioral testing were blinded to drug treatment.
[0513] 7.1.3. Behavioral apparatus and experimental procedures
[0514] The predator odor stress exposure and conditioned place aversion protocols were based on previously published studies (Edwards et al. (2013). Traumatic stress reactivity promotes excessive alcohol drinking and alters the balance of prefrontal cortex-amygdala activity. Transl. Psychiatry, 3(8), e296; Roltsch et al. (2014). Predator odor stress alters corticotropin-releasing factor-1 receptor(CRF1R)-dependent behaviors in rats. Neuropharmacology, 79, 83-89; Whitaker et al. (2015). Blunted hypothalamo-pituitary adrenal axis response to predator odor predicts high stress reactivity. Physiol. Behav., 147, 16-22). Using a place conditioning apparatus (place conditioning apparatus, MED Associates, Fairfax, VT) consisting of two compartments (8x8x11in) connected by a smaller middle compartment (5x8x11in) with different visual (wall color) and tactile (floor texture) cues, rats were exposed to odorless (sterile saline) or predator odor (bobcat urine, PMart, Sandy Point, ME). The compartments were separated by automatic gates. An unbiased conditioning method was used so that mice did not prefer one room to another. Between 8-10am (AM), rats were placed in the middle compartment and the gate was raised, and allowed to explore the conditioning apparatus for 15 minutes (adaptation). The time and activity in each compartment were recorded by infrared sensors and tabulated using commercially available software (MED Test, version 4.2.0.0, MED Associates, Fairfax, VT). Between 2-4pm (PM), rats were allowed to explore the conditioning apparatus again and record time and activity (baseline before conditioning). After 24 hours, rats were randomly assigned to one chamber and exposed to saline (AM) while confined to the conditioning compartment for 15 min. On the same evening (PM), rats were confined to the opposite compartment and exposed to predator odor (or no odor) for 15 min.During pairing, a 2x2 inch square piece of filter paper in a weigh boat was soaked in 5 mL of saline or bobcat urine and placed under the grid floor of the chamber. The day after predator odor stress, rats were placed in the central compartment and allowed to explore the entire apparatus for 15 minutes. Rats had no access to direct contact with bobcat urine. The entire apparatus was cleaned with disinfectant after each conditioning session.
[0515] Statistical analysis
[0516] Statistical analysis was performed by subtracting the time in the odor-paired compartment from the baseline measurements of 117 rats. The time in the distribution chamber between the odor-free and odor-exposed groups to which the vehicle was administered was analyzed using an independent t-test. Potential differences between the unexposed odor group and the exposed odor group were analyzed using a one-way ANOVA with drug dose as the main factor. Significant main effects were obtained after paired multiple comparison procedures (Student Newman-Keuls method). Significance was set to P<0.05.
[0517] Results
[0518] Fig.53A The odor-free and odor-exposed groups treated with VEH are shown. The analysis confirmed that predator odor exposure produced significant (t(27)=2.690, P=0.012) conditioned place aversion 24 hours after exposure. Fig.53B As shown, ANOVA revealed no significant differences in the treatment groups after exposure to predator odor (P = 0.746). Time analysis of the groups exposed to predator odor revealed a significant main effect of drug dose (F(3,57) = 2.780, P = 0.050). Post hoc multiple comparisons yielded a significant difference between the highest peptide dose (FQSE (SEQ ID NO: 10) 0.5) and VEH (P = 0.036) ( Fig.53C ) and a trend towards significant difference between the low peptide dose (FQSE (SEQ ID NO: 10) 0.05) and the high peptide dose (P = 0.159).
[0519] Conclusion
[0520] This report describes the effects of intranasally administered peptide test articles in an animal model of PTSD. The main findings include: 1) confirmation of predator odor-induced conditioned place aversion as previously described, 2) no apparent adverse effects of the drug or peptide, and 3) significant attenuation of predator odor-induced place aversion in rats administered the highest dose of peptide.
[0521] Predator odor-induced place aversion is robust as an animal model of PTSD and replicates previous studies (Edwards et al. (2013). Traumatic stress reactivity promotes excessive alcohol drinking and alters the balance of prefrontal cortex-amygdala activity. Transl. psychiatry, 3(8), e296). Analysis of the group that received DOX and peptide and was not exposed to predator odor showed normal behavior, as no significant effects were found on the time spent in the randomly paired chambers. There was also no difference in total activity between the groups (not shown). Fig.53C As shown, the highest dose of the peptide (FQSE (SEQ ID NO: 10) 0.5) completely attenuated the place aversion induced by the predator odor. DOX, a drug that has been shown to be effective in humans with PTSD (Rodgman et al. (2016). Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. J. Clin. Psychiat., 77 (5), e561-565), also attenuated the place aversion induced by the predator odor, but no significant difference was found with VEH using the statistical model adopted. In summary, the data support further development of peptide test substances as potential treatments for PTSD.
[0522] Example 8: Intranasal administration of FQSE (SEQ ID NO: 10) Effects of the "learned helplessness" model of depression on rats for the study of the effects on endocrine parameters
[0523] The aim of the study was to investigate the potential antidepressant and anxiolytic effects of intranasally administered peptide GABA-AR modulator FQSE (SEQ ID NO: 10) on behavioral and endocrine parameters in rats in the "learned helplessness" (LH) depression model.
[0524] Materials and methods
[0525] 8.1.1. Animals
[0526] The study was performed in 45 adult male Wistar rats 220-250 g (mean weight 230 g) from the "Collection of laboratory mammals of different taxonomic affiliations" of IPh RAS, supported by the biological resource collection project of FANO, Russia, kept under standard conditions. All procedures involving animals were performed in accordance with European (Directive 2010 / 63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes) and Russian ("GOST 33216-2014 Guidelines for the maintenance and care of laboratory animals. Rules for the maintenance and care of laboratory rodents and rabbits") bioethical guidelines.
[0527] 8.1.2. Test substances
[0528] The peptide GABA-A modulator FQSE (SEQ ID NO: 10) (LC) was administered intranasally (in) at a dose of 0.5 mg / kg or 2.5 mg / kg daily for 10 days. To prepare a solution of the FQSE (SEQ ID NO: 10) peptide, a 0.3% bicarbonate buffer (containing 3 g of sodium bicarbonate NaHCO3 per 1 liter of ddH2O, pH 8; to prepare the solution, the buffer was collected through a (Millipore) filter with a 0.45 μm Millex syringe). The solution for administration at 2.5 mg / kg in a volume of 20 μl (single administration) contained 0.575 mg FQSE (SEQ ID NO: 10), and the solution for administration at 0.5 mg / kg intranasally in a volume of 10 μl (single administration) contained 0.115 mg FQSE (SEQ ID NO: 10). Weigh on an analytical balance with an accuracy of 0.0001 g and prepare the solution with a 0.5 ml margin. In the experiment, a freshly prepared FQSE (SEQ ID NO: 10) solution was used; the next day, this solution was stored in a refrigerator at +4°C.
[0529] 8.1.3. Comparison of drugs
[0530] Maprotiline (Lyudiomil), a tetracyclic antidepressant, is a monoamine reuptake inhibitor and was used as a positive control. Animals received daily intraperitoneal (ip) injections of maprotiline for ten days (M9651, Merck, 4.5 mg / kg, dissolved in saline: 200 μl per administration).
[0531] 8.1.4. Learned Helplessness (LH) Model
[0532] The classical paradigm of "learned helplessness" (LH) is used as an experimental model of depression (Seligman et al. (1975). Learned helplessness in the rat. J. Comp. Physiol. Psychol., 88 (2): 534-541). According to modern concepts, the state of "learned helplessness" fully reflects the anxiety-depression syndrome, reproducing the main signs of endogenous depression in a person, including helplessness, despair and the severity of the effects of characteristic endocrine disorders. In order to develop LH, rats are subjected to uncontrollable and unavoidable aversive stress (electrical skin stimulation). In a closed space of a cage of 13x16x26cm in size with a conductive floor, the animals are stimulated with an electric current (1mA, 1Hz, 15sec), and intervals of different durations are used between the application of the current to the chamber floor so that each rat receives 60 stimulations in one hour, which leads to the development of a persistent depressive-like state. The stimulation is automatically performed using a software randomizer.
[0533] 8.1.5. 《 Open Field Test (OF)
[0534] The open field test is a classic method for assessing the level of motor activity and exploratory behavior of rodents under novel stress-generating conditions. The test was conducted in a 90×90×45 cm cage without a roof, the floor of which was laid out in 15×15 cm squares and illuminated from above by a 60 W lamp. On the 5th day after stress in the LH model, the rats were placed in the center of the OF. The following parameters were measured within 5 minutes: latency to start moving, number of crossing squares (lateral, middle and central), duration of rearing with hind limbs and immobility time.
[0535] 8.1.6. Elevated plus maze test (EPM)
[0536] The EPM test can characterize the behavior of rodents under variable stress conditions, which makes it possible to evaluate the anxiety level of animals and the anxiolytic effect of drugs. On the 6th day after experimental exposure, rats were tested one by one for 5 minutes in the EPM device, which was located at a height of 75 cm above the ground and consisted of 2 open arms with lighting and 2 closed arms with outlets. The time spent by animals in and out of the closed arms (in the open arms and in the center), the number of transitions between arms, and the number of stretching postures were evaluated. Normally, animals tend to stay in the closed arms, and antianxiety treatment leads to an increase in the time spent in the open arms of the maze (Pellow et al. (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 14(3), 149-167; Walf et al. (2007). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc., 2(2), 322-328).
[0537] 8.1.7. Porsolt forced swim test, one-day modification (FS)
[0538] The Porsolt swimming test (FS) is a standard test for detecting the potent antidepressant-like properties of a substance by assessing the motor activity of rats placed in a glass cylinder. The cylinder has a diameter of 30 cm and a height of 90 cm, of which 2 / 3 is filled with water and the temperature is 26±1°C. In a one-day modification of the Porsolt test (Porsolt et al. (1977). Behavioral despairin mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther., 229 (2), 327-336; Slattery et al. (2012). Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat. Protoc., 7 (6): 1009-14), the animal is placed in the cylinder and the following parameters are measured for 5 minutes: time of active and passive swimming, time spent immobile.
[0539] 8.1.8. Dexamethasone test (DXMT)
[0540] Taking into account the circadian specificity of HPA axis function in rats (Zhukov (1993) The dexamethasone suppression test in genetically different rats exposed to inescapable and escapable electric shocks. Psychoneuroendocrinology, 18(7):467-474), stress-induced glucocorticoid (corticosterone, human cortisol analog) release and its suppression by the introduction of synthetic glucocorticoids were assessed on days 9-10 after LH development in a two-day dexamethasone test according to the protocol.
[0541] On the first day of the experiment (DXMT1) at 10:00 AM, animals were injected intraperitoneally with normal saline, and peripheral blood samples were collected at 04:00 PM on the same day to determine basal levels of hormones (causing stress), and blood was re-collected 30 minutes after the rats were removed from the cage and received the initial sample to measure hormone stress levels.
[0542] In order to study the sensitivity of the HPA system to feedback signals, rats were injected with dexamethasone (10 μg / kg, intraperitoneally) at 10 am the next day (DXMT2). The procedure of taking blood from the tail vein was repeated after 6 hours and 6.5 hours. The corticosterone content in two parallel samples was determined by enzyme-linked immunosorbent assay using the kit "Corticosterone-ELISA" ("Hema", RF).
[0543] Experimental data were processed by calculating the mean and standard error of the mean in the subgroup of animals studied, n=9 for each point.
[0544] Experimental design
[0545] The laboratory rats were divided into 5 experimental groups with 9 animals in each group:
[0546] "Control" - injection control group received intranasal administration of solvent (0.3% bicarbonate buffer) daily for 10 days. "LH" - a group of animals subjected to stress, in which a depressive state of "learned helplessness" developed. The LH group was not drug-treated; the development of experimental depression was studied. "LH+FQSE (SEQ ID NO: 10) 0.5" - pharmacologically corrected LH group, which received intranasal administration of 0.5 mg / kg dose of FQSE (SEQ ID NO: 10) daily for 10 days. "LH+FQSE (SEQ ID NO: 10) 2.5" - pharmacologically corrected LH group, which received intranasal administration of 2.5 mg / kg dose of FQSE (SEQ ID NO: 10) daily for 10 days. "LH+Map." - comparative drug group. Maprotiline was injected intraperitoneally at a dose of 4.5 mg / kg daily for 10 days to develop experimental depression.
[0547] Table 4: Overall scheme of experiments, drug administration and detection (described in the text).
[0548]
[0549]
[0550] Statistical analysis
[0551] For normally distributed data, one-way analysis of variance (ANOVA) with post hoc Tukey test was used. For non-normally distributed data, Kruskal-Wallis test was used, followed by Dunn's test for multiple comparisons. The significance threshold was 0.05. Data are expressed as mean ± standard error of the mean, or as median and interquartile range with minimum and maximum values.
[0552] Results
[0553] 8.2.1.OF
[0554] The LH group was characterized by a significant increase in freezing compared to the control group (which corresponds to motor inhibition in patients with depression). This was particularly evident in the center of the maze during the initial phase (p=0.01, Fig.54 In addition, the time spent on vertical exploratory activities was significantly reduced (p = 0.03, Fig.55A ), indicating anxiety and reduced exploratory activity of the animals. When the animals were placed in the center of the OF, chronic administration of FQSE (SEQ ID NO: 10) 2.5 mg / kg (i / n) and maprotiline 4.5 mg / kg (i / p) resulted in a significant decrease in freezing time compared to the LH group (p = 0.04 and p = 0.044, respectively, Fig.54 ). Daily administration of maprotiline resulted in a 2.3-fold reduction in the number of animals showing immobility after LH; in the FQSE (SEQ ID NO: 10) treated groups, this index was also reduced: 1.75-fold in the 2.5 mg / kg group and 1.4-fold in the 0.5 mg / kg group, however, the mean immobility time of all animals in these groups was not significantly different from that in the LH group.
[0555] A significant decrease in vertical activity was also found in the group of animals subjected to LH and receiving a 0.5 mg / kg dose of the peptide (p=0.01, Fig.55A ). The "LH+Map" and "LH+FQSE(SEQ ID NO: 10)0.5" groups did not differ from either the control group or the LH group, which could indicate a partial correction of the negative effects of unavoidable stress by these substances. In all experimental groups, the animals' motor activity did not change ( Fig.55B ).
[0556] 8.2.2.EPM
[0557] In the EPM test, open arm entries were almost completely absent in the control and LH groups. This result may indicate the high level of novelty and stress of this test. At the same time, animals treated with Map or FQSE (SEQ ID NO: 10) appeared more often in the arms, but these differences did not reach statistical significance ( Fig.56A There was also no difference between the groups in the number of closed-sleeve stretches ( Fig.56B ).
[0558] 8.2.3.FS
[0559] In the forced swim test, administration of the antidepressant maprotiline after stress conditioning resulted in a significant reduction in the time spent immobile compared with the control and LH groups (p = 0.02 and p = 0.03, respectively, Fig.57A ), and active swimming time increased (p = 0.01 and p = 0.02, respectively, Fig.57B ). The introduction of FQSE (SEQ ID NO: 10) at a dose of 0.5 mg / kg but not 2.5 mg / kg resulted in a decrease in immobility and, therefore, an increase in active swimming at a trend level compared to the control group (p=0.09 and p=0.08, respectively).
[0560] 8.2.4.DXMT
[0561] Studies of basal levels of corticosterone (CS) in rat plasma showed a trend toward increased levels of the hormone in animals that were stressed and received saline injections compared to animals in the control group (p=0.07). This result suggests hyperactivation of the HPA axis. Meanwhile, rats treated with Map and two doses of FQSE (SEQ ID NO: 10) did not differ from unstressed animals and had significantly lower CS levels compared to the LH group (p<0.02), suggesting that the animals were less stress-responsive ( Fig.58 Interestingly, in a previous study, the use of high doses of the antidepressant lyudiomil (maprotiline) to prevent experimental depression in this model (Rybnikova et al. (2008). The possible use of hypoxic preconditioning for the prophylaxis of post-stress depressive episodes. Neurosci. Behav. Physiol., 38(7), 721-726) resulted in a reduction in blood corticosterone levels below control levels.
[0562] The dexamethasone test is a hallmark of primary depression. According to clinical data, in healthy subjects, when dexamethasone is introduced, the level of cortisol decreases due to the negative feedback loop that inhibits the secretion of cortisol and ACTH. In patients with endogenous depression, such a decrease in cortisol levels is less significant because the negative feedback mechanism is disturbed in this disease. The weak effect of dexamethasone on the level of cortisol in the blood (positive test result) indicates the presence of endogenous depression.
[0563] The DXM test revealed an impaired regulation of the pituitary-adrenal system in the negative feedback of glucocorticoids in the LH group of rats. Injection of dexamethasone into these animals did not actually reduce the basal or stress levels of CS, compared with an inhibition of more than 50% in control rats ( Fig.59 , Table 2). It was found that the introduction of Map and FQSE (SEQ ID NO: 10) at a dose of 0.5 mg / kg but not 2.5 mg / kg resulted in a significant suppression of the stress-induced increase in CS in the blood after DXM administration ( Fig.59 , Table 5), which may indicate the normalization of HPA system inhibition in these groups of rats.
[0564] Administration of FQSE (SEQ ID NO: 10) at a dose of 2.5 mg / kg had a less pronounced effect on the suppression of stress hormone levels caused by exogenous glucocorticoids: the Δ of the LH+FQSE (SEQ ID NO: 10) 2.5 group was two times lower than that of the control group, but at the same time it exceeded this value of the LH group (Table 2, Δ(FR-DXM)).
[0565] Table 5: Extent of inhibition of corticosterone stress release by introduction of exogenous steroids
[0566]
[0567]
[0568] 8.3. Conclusion
[0569] The results of the study showed that ten-day intranasal administration of the peptide GABA-A modulator FQSE (SEQ ID NO: 10) had dose-dependent anxiolytic-like (effect on time spent in open arms in EPM, immobility time in OF) and antidepressant-like (DXMT, reduction in immobility time in FS test) effects, and apparently it prevented the overactivation of the hypothalamic-pituitary-adrenocortical hormone system and the interference of feedback mechanisms in its regulation, which manifested in the animal's response to stress.
[0570] Therefore, the peptide GABA-A modulator FQSE (SEQ ID NO: 10) exhibits stress protective properties and demonstrates effectiveness in correcting post-stress anxiety. These data, combined with the absence of significant behavioral side effects at the doses studied, suggest the promise of further research into FQSE (SEQ ID NO: 10) and its potential use in anxiety-depression.
[0571] Example 9: Intranasal administration of FQSE (SEQ ID NO:10) neurotropic effects in the chronic restraint stress model Research
[0572] The objectives of the study were to evaluate the behavioral effects of administration of FQSE (SEQ ID NO: 10) and to analyze the relative levels of BDNF, p-p70S6k, p-ERK (1 and 2), p-GSK3β, and p-PKC proteins in brain structures of rats treated with FQSE (SEQ ID NO: 10) after chronic restraint stress (CRS).
[0573] Materials and methods
[0574] 9.1.1. Animals
[0575] Experiments were conducted in male Sprague-Dawle rats (n=50) aged three to four months. Animals were housed in a breeding room at the institute with free access to food and water and natural daily light alternation. All procedures involving animals were conducted in accordance with European (Directive 2010 / 63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes) and Russian ("GOST 33216-2014 Guidelines for the maintenance and care of laboratory animals. Rules for the maintenance and care of laboratory rodents and rabbits") bioethical guidelines.
[0576] 9.1.2. Chronic restraint stress model
[0577] To simulate a depressive state, the experimental animals were placed in individual restraints ("Open Science", Russia) for 6 hours per day for 14 days (hereinafter referred to as "Chronic restraint stress = CRS"). To study the neurotropic effects of FQSE (SEQ ID NO: 10), the animals were divided into 5 groups, 10 in each group. The groups were as follows: Group 1, control non-stressed animals, received 10 μl (a pair of 5 μl doses) of saline intranasally; Group 2, stressed animals, received 10 μl of saline intranasally (CRS+Veh); Group 3, stressed animals, received 5 mg / kg dose of fluoxetine (FO) intraperitoneally (CRS+FO, positive control); Group 4, stressed animals, received 0.3 mg / kg dose of peptide drug in 10 μl saline intranasally (CRS+FQSE (SEQ ID NO: 10) 0.3); Group 5, stressed animals, received 3 mg / kg dose of peptide drug in 10 ml saline intranasally (CRS+FQSE (SEQ ID NO: 10) 3). Drug administration was performed daily 30 minutes before placing the rats in restraints. The dose of FQSE (SEQ ID NO: 10) was selected based on the results of the preliminary study.
[0578] 9.1.3. Behavioral test
[0579] Fourteen days after the start of the experiment, the changes in animal motor activity and emotional state were assessed in the open field (OFT) and the Porsolt forced swim test (FST). In all cases, the animals were injected with drugs 30 minutes before the test. The OF test design is a square box with a side length of 90cm and a height of 35cm. The device floor is divided into 25 squares. Measure horizontal and vertical movement activities for three minutes. Calculate the total number of times across the squares, as well as the length of the travel distance and the number of times of standing upright with the hind limbs. FST is carried out in a glass cylinder, which is 40cm high and 19cm in diameter, and the water temperature is 24°C. In the 8-minute experiment, the time spent actively (active swimming + climbing) and inactive swimming (immobile + passive swimming) is calculated. The recording and analysis of behavioral experiments are carried out using the animal behavior video monitoring system "AnyMaze".
[0580] 9.1.4. Brain sample preparation
[0581] At the end of the behavioral examination, the rats were decapitated and their brains were extracted for subsequent Western blot analysis. A total of 51 homogenized brain tissue samples from Sprague-Dawley rats (3-4 months old) were received from the customer. 25 samples were homogenized from the cerebral cortex and 26 samples were homogenized from the hippocampus isolated from the rat brain. The amount of homogenized tissue in each sample was less than 50 mg. Homogenization was performed in a buffer (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1% NP-40, 0.1% SDS) at a ratio of 1 ml buffer per 100 mg sample. It was incubated on ice for 30 minutes. The sample was then centrifuged at 12000 g, +4 ° C for 15 minutes.
[0582] Experimental design
[0583] Analysis of total protein levels in the samples studied was provided using trichloroethane according to standard methods (Ness et al. (2015). Western blot optimized exercise: an efficient and more environmentally friendly approach in the lab classroom. Biochem. Mol. Biol. Educ., 43(5), 358-365).
[0584] All necessary steps are provided to analyze protein levels of BDNF, p-p70S6k (Thr421 / Ser424), p-ERK (1 and 2), (Thr202 / Tyr204), p-GSK3β (Ser9), p-PKC (PKCγThr514), and GAPDH reference proteins in study samples using western blotting.
[0585] The following procedures were performed:
[0586] Proteins were separated by electrophoresis at 10 V / cm in 12% denaturing polyacrylamide gels (PAGE: 0.375 M Tris-HCl, pH 8.8, 0.1% SDS, 12% acrylamide) according to Laemmli. The Thermo Scientific High Quality Protein Kit was used as a marker.
[0587] The proteins were transferred from the gel to a nitrocellulose membrane (PVDF 0.45 μm) in transfer buffer (25 mM Tris, 190 mM glycine, 10% EtOH, pH 8.3) at room temperature overnight. The quality of the transfer was assessed by staining all bands on the membrane with the nonspecific AmidoBlack dye (if necessary).
[0588] PBS-T solution (8mM Na2HPO4, 150mM NaCl, 2mM KH2PO4, 3mM KCl, 0.05% 20, pH 7.4) and blocked (with skim milk powder or BSA, depending on the antibody) for 60 min at room temperature.
[0589] The membrane was washed and incubated overnight at +4°C with primary antibodies against the target protein at the manufacturer's recommended dilution. Afterwards, the membrane was washed again and incubated with secondary antibodies conjugated to horseradish peroxidase for 1 hour. The membrane was labeled with Thermo Scientific SuperSignal TM West Dura Extended Duration Substrate chemiluminescent substrate staining Analysis of the stained membranes was performed on the ChemiDoc detection and imaging system (Bio-Rad, USA).
[0590] The integrated areas of the spots obtained were calculated as a quantitative assessment and then normalized to the amount of protein in the sample.
[0591] Statistical analysis
[0592] Data were processed using one-way ANOVA and post hoc Fisher criterion in Statistica 10 for comparisons between groups. In the case of deviation from normal distribution, the Kruskal-Wallis ANOVA test and post hoc Dunn's multiple comparison test were used. Statistically significant differences were considered at p ≤ 0.05, and data are expressed as mean ± SE.M.
[0593] Results
[0594] 9.2.1. Behavioral effects of FQSE (SEQ ID NO: 10) in the CRS model
[0595] 9.2.1.1.OF
[0596] Total distance traveled was unchanged either after stress exposure or after drug treatment: no significant differences in horizontal activity were observed between the groups ( Fig.60 ).
[0597] 9.2.1.2.FST
[0598] Stress or FO treatment had no effect on the duration of active swimming of the animals. However, rats that had undergone stress and received a 3 mg / kg dose of FQSE (SEQ ID NO: 10) actively swam longer than animals from the "CRS+Veh" group ( Fig.61A ).
[0599] In the subgroup of animals that had undergone stress and received vehicle injection, the duration of low activity behavior was longer. Administration of the peptide at a dose of 3 mg / kg significantly reduced the time spent in passive swimming in the FST compared to "CRS+Veh" ( Fig.61B ). The introduction of FO had no effect on the behavior of the rats in this experiment.
[0600] 9.2.2. Discussion on the Behavior of FQSE (SEQ ID NO: 10) in the CRS Model
[0601] Chronic predictable stress (CPS) is one of the main tools for modeling the anxiety-depression phenotype in rodents. However, chronic immobility stress is often noted to be a weak stressor. The degree of reproducibility of this model varies from laboratory to laboratory. In this study, it was planned to evaluate the behavior of rats in response to immobility stress after chronic administration of the peptide FQSE (SEQ ID NO: 10).
[0602] In the open field test, no changes in horizontal locomotor activity (MA) were detected in stressed animals. The peptides had no effect on locomotor activity.
[0603] In the Porsolt swim test, stress did not lead to changes in the time spent in active swimming. However, there was a significant effect on the duration of low activity behavior (total time of passive swimming and immobility). Administration of 3 mg / kg of the peptide abolished this effect. There was a shift in the ratio of active and passive swimming towards a reduction in inactive swimming.
[0604] 9.2.3. Conclusion
[0605] According to the literature, CPS leads to a decrease in exploratory activity in the open field test. It also leads to an increase in immobility in the Porsolt swimming test (Bowman et al. (2002). Effect of Chronic Restraining Stress and Estradiol on Open Field Activity, Spatial Memory and Monoaminergic Neurotransmitters in Ovariectomized Rats. Neurology, 113 (2), 401-410; Guedri et al. (2017). Chronic Stress Deterrence Induced Neurobiologie Changes and Histological Changes in Rats. Toxicol. Environ. Sci., 9 (2), 123-129). The results show that the stress effect has a weak effect on animal behavior. In the open field test, the administration of 0.3 and 3 mg / kg doses of peptides had no effect on the mood of the corresponding stimulants. The dose of 3 mg / kg had an antidepressant-like effect compared to the stress+vehicle group, which may indicate that chronic administration of FQSE (SEQ ID NO: 10) has a positive neurotropic effect.
[0606] 9.2.4. Western Blot Analysis Results and Discussion
[0607] Examples of blots obtained are Fig.62 As shown. According to the results obtained for the GAPDH reference gene ( Fig.63A , 63B ), no statistically significant differences were observed in any of the experimental groups, indicating consistent protein distribution in the samples.
[0608] The stress effect led to an increase in p-ERK-1 (60% increase), p-ERK-2 (100% increase), p-GSK3β (40% decrease) and p-PKC (53% decrease) in the hippocampus, whereas in the cerebral cortex this effect itself did not affect the levels of the studied proteins. The results obtained could indicate a mild stress (low-grade stress) in the model used. Fig.64A ) and hippocampus ( Fig.64B ) showed no correlation with stress or fluoxetine administration. Meanwhile, both doses of FQSE (SEQ ID NO: 10) (0.3 mg / kg and 3 mg / kg) resulted in a 20% to 40% decrease in BDNF levels in the cortex and a 40% decrease in BDNF levels in the hippocampus.
[0609] This change corresponds to the action of allosteric modulators of GABA-A receptors. It was shown that the administration of benzodiazepines leads to a decrease in BDNF levels in the hippocampus, hypothalamus and cerebral cortex of adult male rats (Kellogg et al. (2000). Sex-specific effects of intrauterine GABA receptor manipulation on pre-and postnatal BDNF expression in rats. Dev. Brain. Res., 121 (2), 157-167; Chan et al. (2017). Sex Differences in Brain Neurotrophic Factor Signals and Functions. J. Neurosci. Res., 95 (1-2), 328-335). The same effect was observed in the mouse cerebral cortex (Huopaniemi et al. (2004). Adaptive plasticity induced by diazepam is revealed by profiling the specific expression of the α1GABAA receptor. J. Neurochem., 88 (5), 1059-1067). It also reduces the serum level of BDNF protein (Ventrilla et al. (2013). Serum levels of brain neurotrophic factors in various neurological diseases. Biomed Res. Int., 2013). However, it should be noted that there are no studies on the interaction between GABA-A and BDNF (Kim et al. (2017). Brain neurotropic factor and GABAergic transmission in neurodegeneration and neuroregeneration. Neural Regen. Res., 12 (10), 1733).Some papers have noted BDNF transfer in response to GABA-A stimulation, which is associated with embryonic or developing neurons (Porcher et al. (2011). Regulation of positive feedback between the signaling of the γ-aminobutyric acid receptor type A (GABAA) and the release of brain neurotrophic factor (BDNF) in developing neurons. J. Biol. Chem., 286 (24), 21667-21677; Porscher et al. (2018). Mechanism of BDNF modulation in GABAergic synaptic transmission in healthy and diseased brains. Front. Cell. Neurosci., 12, 273). The nature of the changes in BDNF levels in response to GABA-A stimulation may depend on the type of neurons and brain regions studied, the mode and duration of GABA-A modulators, and the type of experimental model used (Kimet. (2017). Brain neurotropic factor and GABAergic transmission in neurodegeneration and neuroregeneration. Neural Regen. Res., 12 (10), 1733). At the same time, the data obtained as a result of this study allow the following hypothesis within a high range of probability: the changes in BDNF levels in response to the administration of FQSE (SEQ ID NO: 10) indicate the modulation of the GABA system.
[0610] The phosphorylation level of p-p70S6k (Thr421 / Ser424) was significantly higher in the cerebral cortex ( Fig.65A ) or hippocampus ( Fig.65B In response to two doses of FQSE (SEQ ID NO: 10), protein levels increased by 80% in the cortex and 170% to 200% in the hippocampus.
[0611] S6 kinase is one of the main effectors of the mTORC1 signaling cascade. It is associated with increased protein biosynthesis activity (Mao et al. (2018). The role of mTOR in glucose and lipid metabolism. Int. J. Mol. Sci., 19 (7), 2043). GABA A Activation of the receptor leads to inactivation of the mTORC1 cascade, especially the increase of p-p70S6k (Thr421 / Ser424) (Thanapreeda Watai et al. (2013). Influence of GABA on brain protein synthesis mediated by the mammalian target on therapamycin pathway. Biosci. Biotechnol. Biochem., 120808; Weston et al. (2012). Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J. Neurosci. Res., 32 (33), 11441-11452). Activation of S61 and mTROC1 has antidepressant effects and has been studied on ketamine. In this case, the antidepressant effect of ketamine was neutralized by the use of rapamycin, indicating an important role for mTROC1 in mediating this effect (Dwyer et al. (2015). Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior. Proc. Natl. Acad. Sci., 112 (19), 6188-6193). It can therefore be concluded that the high level of S6k phosphorylation in response to the introduction of FQSE (SEQ ID NO: 10) indicates the activation of the mTORC1 cascade, which may be initiated through the regulation of GABA-A receptors.
[0612] In the hippocampus, p-ERK1 protein phosphorylation was shown ( Fig.66B ) and p-ERK2( Fig.66B ) levels increased by 60% and 100%, respectively, in response to stress. Both doses of FQSE (SEQ ID NO: 10) resulted in normalization of p-ERK1 and p-ERK2 levels to intact control levels.
[0613] Some literature shows that individual stress models show increased phosphorylation of p-ERK1 and 2 in the brain (Kim et al. (2018). Social support rescues acute stress-induced cognitive impairments by modulating ERK1 / 2phosphorylation in adolescent mice. Sci. Rep., 8 (1), 1-13; Hebert et al. (2005). Single and repeated immobilization stress differentially trigger induction and phosphorylation of several transcription factors and mitogen-activated protein kinases in the rat locus coeruleus. J. Neurochem., 95 (2), 484-498), which supports the results of this study. It is also known that allosteric modulators of GABA-A (especially benzodiazepines) can inhibit the phosphorylation of the p-ERK system (Kim et al. (2012). Hippocampal extracellular signaling-regulated kinase signaling has a role in passive avoidance memory retrievalinduced by GABA receptor modulation in mice. Neuropsychopharmacology, 37(5), 1234).
[0614] Therefore, the properties of FQSE (SEQ ID NO: 10) correspond to the characteristics of the allosteric modulator GABA-A. However, it should be noted that in other models described in the literature, depressive states and severe chronic stress are associated with inhibition of p-ERK1 / 2 and the MAPK kinase cascade. The antidepressant effect, especially that of ketamine, is associated with the activation of this system (Réus et al. (2014). MAPK signaling correlates with the antidepressant effects of ketamine. J. Psychiatr. Res., 55, 15-21). The data obtained clearly demonstrate the effect of FQSE (SEQ ID NO: 10) on the MAPK signaling cascade, and a certain direction of change can be observed in the mild stress model.
[0615] p-ERK1 (Thr 202) levels in the cerebral cortex showed no association with any of the effects studied ( Fig.66A ). Cortical levels of p-ERK2 (Tyr204) did not change in response to stress, but were decreased in response to fluoxetine and a 0.3 mg / kg dose of FQSE (SEQ ID NO: 10) relative to stress and control levels ( Fig.67A ). This may be related to GABA-A receptor regulation. Since stress does not affect ERK1 / 2 phosphorylation levels in the cortex, the findings need to be verified in different stress models.
[0616] In the cerebral cortex, the level of the phosphorylated form of p-PKC (Thr514) showed no change after stress, fluoxetine, or 0.3 mg / kg administration of FQSE (SEQ ID NO: 10) ( Fig.68A ). However, administration of 3 mg / kg of FQSE (SEQ ID NO: 10) resulted in a 51% decrease in p-PKC. This effect may be due to the decrease in BDNF levels in this group, which is attributed to the involvement of p-PKC in the cascade triggered by TrkB (Duman et al. (2012). Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci., 35(1), 47-56). A 3 mg / kg dose of FQSE (SEQ ID NO: 10) resulted in a more significant decrease in BDNF compared to a 0.3 mg / kg dose ( Fig.64A). This could explain the ineffectiveness of lower doses on p-PKC levels. In addition, a reduction in p-PKC levels could indirectly indicate inhibition of the mTORC2-dependent cascade (which has an antagonistic effect on mTORC1 activation), for which p-PKC is an effector (Mao et al. (2018). The role of mTOR in glucose and lipid metabolism. Int. J. Mol. Sci., 19(7), 2043). However, the above results do not warrant any definitive conclusions about the effects of FQSE (SEQ ID NO: 10) on p-PKC.
[0617] CRS caused a significant decrease in p-PKC in the hippocampus ( Fig.68B ), which corresponds to a depressive state (Thiels et al. (2000). Protein phosphatase-mediated regulation of protein kinase C during long-term depression in the adult hippocampus in vivo. J. Neurosci., 20 (19), 7199-7207; Shelton et al. (2009). Protein kinases A and C in post-mortemprefrontal cortex from persons with major depression and normal controls. Int. J. Neuropsychoph., 12 (9), 1223-1232). At the same time, neither fluoxetine nor the peptide FQSE (SEQ ID NO: 10) promoted the normalization of its levels: the values in these groups were not statistically different from those in the control group. It should be noted that the lack of activation of p-PKC and FQSE (SEQ ID NO: 10) in the hippocampus can be considered a positive effect.
[0618] It is known that high activity of p-PKC is associated with phosphorylation of benzodiazepine-specific sites in GABA-A receptors (especially γ2 subunits), which reduces the affinity of modulators to receptors and inhibits their effects (Gao et al. (2005). Activation of protein kinase C reduces benzodiazepine potency at GABAA receptors in NT2-N neurons. Neuropharmacology, 48 (3), 333-342; Qi et al. (2007). Protein kinase C ∈ regulates γ-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of γ2 subunits. J. Biol. Chem., 282 (45), 33052-33063). The above mechanism may reveal the increase in tolerance to benzodiazepines. Activation of p-PKC during chronic administration leads to GABA-A receptor phosphorylation and reduced sensitivity to these drugs (Vinkers et al. (2012). Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv. Pharmacol. Sci., 2012). The absence of PKC activation in this experiment best indicates that providing FQSE (SEQ ID NO: 10) does not activate the self-tolerance mechanism.
[0619] The level of protein p-GSK3β was shown to be independent of any effect in the cortex ( Fig.69A ). Hippocampus( Fig.69B ) showed a 40% decrease in response to stress, while showing no response to the administration of fluoxetine or FQSE (SEQ ID NO: 10).
[0620] In summary, it can be concluded that the nature of FQSE (SEQ ID NO: 10) levels in the various proteins tested matches the characteristics of a positive allosteric modulator of the GABA-A receptor. Reduced levels of BDNF and ERK1 / 2 phosphorylated forms are characteristic of benzodiazepines. High levels of p70S6k phosphorylation in the cortex and hippocampus in response to FQSE (SEQ ID NO: 10) administration indicate activation of the mTORC1 cascade and correspond to a significant antidepressant effect. Increased p70S6k phosphorylation can affect behavior, as observed in a significant increase in active swimming and drift time and a decrease in passive swimming time compared to rats in the control group. The observations from the Porsolt test may be the result of activation of the mTORC1 cascade (Chen et al. (2015). AMPA receptor–mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: Insertion of AMPA receptor may play a role. Front. Behav. Neurosci., 9, 162). This effect may also indicate GABA-A receptor modulation, during which the mTORC1 cascade begins and an increase in p-p70S6k (Thr421 / Ser424) levels should be observed.
[0621] However, it has to be mentioned that the analyzed markers are actually participants of a general cascade regulated by a large number of factors. Therefore, it is not possible to unequivocally state a specific regulation of the GABA-A receptor mediated by FQSE (SEQ ID NO: 10).
[0622] 9.2.5. Conclusion
[0623] Stress resulted in significant changes in the levels of the proteins p-ERK-1, p-ERK-2, p-GSK3β and p-PKC in the hippocampus. However, this did not affect the levels of the studied proteins in the cerebral cortex. The results obtained could indicate a mild stress mode (low-grade stress) in the model used.
[0624] Administration of two doses (0.3 mg / kg and 3 mg / kg) of FQSE (SEQ ID NO: 10) resulted in a decrease in BDNF levels in both the cortex (20-40%) and hippocampus (40%). This corresponds to the characteristics of an allosteric modulator of the GABA-A receptor. BDNF can be used as a marker of GABA-A receptor modulation in further experiments.
[0625] Example 10: For in vitro studies [ 3 H]FQSE(SEQ ID NO: 10) radioactivity at the specific binding site Ligand binding assay
[0626] 10.1. Research Purpose
[0627] Stage 1. When 50 μl of the test compound is added to the incubation medium to a final concentration of 10 -10 -10 -4 M, the unlabeled FQSE (SEQ ID NO: 10) peptide was evaluated relative to [ 3 H]-SR95531 (antagonist of GABAA receptor) binding IC50 value.
[0628] Phase 2. Determination of the binding site of the FQSE (SEQ ID NO: 10) peptide in brain structures (using tritium radiolabeled peptide) in the following experiment:
[0629] Isolation of plasma membranes with GABAA receptors from the cerebral cortex (Ito's modified method (Ito et al. (1992)). Effects of bicuculline on [ 3 H]SR 95531binding indiscrete regions of ratbrains. Neurochem.res., 17(4), 307-313; Hawkinson et al. (1996). Steroid inhibition of[ 3 H]SR 95531binding to the GABAA recognition site.Eur.J.Pharmacol.,304(1-3),141-146)).
[0630] Isolate whole brain plasma membranes with a+ / b-GABAA receptor sites (according to the improved method of Maldifassi et al. (2016). Molecular mode of action of CGS 9895 at α1β2γ2GABAA receptors. J. Neurochem., 138(5), 722-730; Ramerstorfer et al. (2011). The GABAA receptor α+β-interface: novel target for subtype selective drugs. J. Neurosci., 31(3), 870-877).
[0631] The plasma membrane of the brain was isolated by other methods.
[0632] Phase 3. In a ligand replacement experiment with different "classical" GABAA receptor ligands, rat cerebral cortical membranes were used to determine the binding site of the FQSE (SEQ ID NO: 10) peptide in brain structures (using tritium radiolabeled peptides):
[0633] Incubate at room temperature for 25 minutes;
[0634] Increase incubation time;
[0635] Pre-incubation with a known "cold" ligand and subsequently added labeled peptide (assuming that binding of the "hot" peptide to intact membranes will be reduced because the "cold" ligand will occupy its site - indirectly determining competition).
[0636] Stage 4. Calculate the value of 10 -10 -10 -4 M concentration range (with [ 3 H]flunitrazepam and [ 3 H]diazepam-related) added unlabeled peptides to assess in vivo binding of the BZD site of the GABAA receptor;
[0637] Phase 5. Using different protocol modifications to evaluate multiple substance pairs that bind to different sites on the GABAA receptor [ 3 H]-FQSE (SEQ ID NO: 10) specific binding to rat cortical membranes.
[0638] Stage 6. To obtain 3 [H]-FQSE (SEQ ID NO: 10) binding site data with negative control: the membranes were separated by a specific method (NMDA, addition of ligand MK-801) different from that obtained in the previous experiments and the absence of the binding site for the peptide was checked in this protocol.
[0639] Materials and methods
[0640] Studies were performed on Wistar male rats (250-300 g). The animals were decapitated and the brains removed, placed on ice, and analyzed according to generally accepted protocols (Glowinski et al. (1966). Regional studies of catecholamines in the rat brain-I: the disposition of [ 3 H]norepinephrine,[ 3 H]dopamine and 3H]dopain various regions of the brain. J. Neurochem., 13(8), 655-669) Isolate brain structures for radioreceptor analysis. All procedures involving animals were performed in accordance with European (Directive 2010 / 63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes) and Russian ("GOST 33216-2014 Guidelines for the maintenance and care of laboratory animals. Rules for the maintenance and care of laboratory rodents and rabbits") bioethical guidelines.
[0641] 10.2.1. Series 1. Isolation of plasma membranes with GABAA receptors from the cerebral cortex.
[0642] According to the improved method (Ito et al. (1992). Effects of bicuculline on[ 3 H]SR95531binding in discrete regions of rat brains.Neurochem.res.,17(4),307-313;Hawkinson et al.(1996).Steroid inhibition of[ 3 H]SR 95531binding to theGABAA recognition site. Eur. J. Pharmacol., 304 (1-3), 141-146) prepared membrane samples containing rat GABAA-cerebral cortex receptors. After decapitation, the tissue was immediately frozen in liquid nitrogen and stored in a low-temperature refrigerator at -80°C. On the day of the experiment, the frontal cortex was homogenized at 1:20 W:V in an ice-cold buffer (0.32M sucrose; pH 7.1) in a Teflon glass Potter homogenizer. The homogenate was then centrifuged at 1,000g for 10 minutes. The supernatant was re-centrifuged at 20,000g for 20 minutes. The precipitate was resuspended in 20 ml of cold distilled water and centrifuged at 8000g for 20 minutes. The supernatant was re-centrifuged at 48,000g for 20 minutes. The precipitate was suspended in 0.05M Tris-citrate buffer (pH 7.1) and centrifuged at 48,000g for 20 minutes. The resulting membrane was partially frozen and stored at -80°C. On the day of the experiment, the membrane was suspended in 40 volumes of 0.05M Tris-citrate buffer (pH 7.1) and centrifuged at 48,000g for 20 minutes. The precipitate was suspended in 40 volumes of 0.05M Tris-citrate buffer (pH 7.1) and incubated at 24°C for 30 minutes. It was then centrifuged again at 48,000g for 20 minutes. The final precipitate was resuspended in fresh buffer.
[0643] 10.2.2. Radioligand analysis of GABAA receptors
[0644] The incubation mixture (final volume 0.5 ml) contained 50 μl [ 3 H]SR 95531, 250 μl buffer and 200 μl membrane protein suspension, 50 μl unlabeled SR 95531 ligand (gabazine) or unlabeled FQSE (SEQ ID NO: 10) peptide was added for non-specific binding. The reaction mixture was incubated at 40°C for 1 hour.
[0645] 10.2.3. Series 2. Determination of the binding sites of the peptides under investigation in brain structures (using tritium radiolabeled FQSE(SEQ ID NO: 10) peptide).
[0646] According to various modified techniques (Ito et al. (1992). Effects of bicuculline on[ 3 H]SR95531binding in discrete regions of rat brains.Neurochem.res.,17(4),307-313;Hawkinson et al.(1996).Steroid inhibition of[ 3H]SR 95531binding to the GABAArecognition site.Eur.J.Pharmacol.,304(1-3),141-146;Asano et al.(1979).Identification of inosine and hypoxanthine as endogenous ligands for thebrain benzodiazepine-binding sites.Proc.Nat.Acad.Sci.,76(2),977-981;Maldifassi et al.(2016).Molecular mode of action of CGS 9895atα1β2γ2GABAAreceptors.J.Neurochem.,138(5),722-730;Ramerstorfer et al.(2011).The GABAAreceptorα+β-interface: a novel target for subtype selective drugs. J. Neurosci., 31(3), 870-877) isolates the plasma membrane. The isolated membranes were then subjected to radioligand analysis in vitro using [3H]FQSE (SEQ ID NO: 10) and its unlabeled form. Thus, specific FQSE (SEQ ID NO: 10) binding percentages relative to total binding ranging from 0% to 47% were obtained. For further studies, the technique with the highest specific binding percentage was selected. The protocol for the technique is described below.
[0647] 10.2.4. Plasma membrane isolation and radioligand analysis.
[0648] After decapitation, the tissue was immediately frozen in liquid nitrogen and stored in a low-temperature freezer at -80°C. On the day of the experiment, brain tissue (cortex, about 300 mg) was homogenized in a Teflon-glass Potter homogenizer in a buffer (50 mM Tris-HCl, pH 7.4) at 1:25 W:V. The homogenate was centrifuged at 40,000 g for 20 minutes. The obtained precipitate was homogenized in a buffer (50 mM Tris-HCl; pH = 7.4) and centrifuged again at 40,000 g for 20 minutes. A similar procedure was performed again. The precipitate was resuspended in 15 ml of the same buffer and used for radioligand analysis.
[0649] The incubation mixture (final volume 0.5 ml) contained 50 μl [ 3H] FQSE (SEQ ID NO: 10), 200 or 250 μl of buffer (50 mM Tris-HCl, pH = 7.4) and 200 μl of membrane protein suspension, 50 μl of unlabeled FQSE (SEQ ID NO: 10) was added for nonspecific binding.
[0650] Afterwards, the optimal incubation pattern was experimentally selected for the binding of FQSE (SEQ ID NO: 10) to its own binding site in rat cortex by variation of time and temperature: the reaction mixture was incubated at room temperature (RT) for 25 minutes (Table 6).
[0651] Table 6: Different experimental conditions for incubation in radioligand analysis. * - selected incubation conditions.
[0652]
[0653] When the incubation mode was selected, the composition of the buffer was changed by adding various salts - NaCl, KCl, KH2PO4, CaCl2, MgCl2. As a result, the percentage of specific binding decreased to 63%.
[0654] Furthermore, using this modification of the plasma membrane extraction, the ligand pairs of known receptor sites (Table 7) were investigated. 3 H]FQSE (SEQ ID NO: 10) binding to its own specific binding site to determine its properties.
[0655] Table 7: Ligand pairs for various receptors [ 3 H] In vitro effects of binding of FQSE (SEQ ID NO: 10) to FQSE (SEQ ID NO: 10) binding cortical sites.
[0656]
[0657]
[0658]
[0659] 10.2.5. Liquid scintillation spectrometry
[0660] At the end of the incubation, the samples were filtered through GF / C glass fiber filters (Whatman) pre-wetted with 0.3% polyethyleneimine for 2 hours at room temperature. Each tube was washed twice with cold buffer and then the filter was washed twice with the same volume of buffer.
[0661] The filter was air-dried and transferred to a scintillation bottle. 5 ml of toluene-based scintillation fluid (4 g PPO, 0.2 g POPOP per liter of toluene) was poured into the filter. The radioactivity of the sample was measured on a Tri-Carb 2900TR counter (Perkin Elmer) with a counting efficiency of 42-46%. Protein concentration was determined by the standard Lowry method (1951).
[0662] 10.2.6. Series 3. Ligand replacement experiments using different "classical" GABAA receptor ligands. Yes Fixed brain structure Binding sites of the peptides studied (using tritiated FQSE (SEQ ID NO: 10) peptide).
[0663] For protocols for sample preparation and radioligand binding assays, see 9.2.3.
[0664] Table 8: List of “classical” GABAA ligands
[0665]
[0666]
[0667] 10.2.7. Series 4. Radioligand analysis of GABAA receptors (benzodiazepine site).
[0668] The incubation mixture (final volume 0.5 ml) contained 50 μl [ 3 H] flunitrazepam, 250 μl buffer and 200 μl of the protein suspension of the membrane, 50 μl of unlabeled diazepam ligand or unlabeled FQSE (SEQ ID NO: 10) peptide were added for nonspecific binding.
[0669] The liquid scintillation spectrometry procedure and processing of results were performed as described in 10.2.5.
[0670] The first modification of the in vitro radioligand assay for benzodiazepine receptors was as follows: incubation at 40°C and 24°C for 30 min; for nonspecific binding, the following combination of unlabeled substances was used: 1) diazepam 10 -6 M+FQSE10 -4 M; 2) Diazepam 10 -6 M+FQSE10 -5 M; 3) Diazepam 10 -6 M (control).
[0671] The second modification was similar to that described above, but also included a pre-incubation period lasting 25 minutes during which unlabeled FQSE (SEQ ID NO: 10) was added, and then only during the incubation period. 3 H]-flunitrazepam with the addition of diazepam.
[0672] 10.2.8. Series 5. Various substances that bind to different sites on GABAA receptors [ 3 H]-FQSE (SEQ ID NO: 10) Effect of specific binding to rat cortical membrane.
[0673] For protocols for sample preparation and radioligand binding assays, see 9.2.3.
[0674] Table 9: List of GABAA ligands
[0675]
[0676]
[0677] 10.2.9. Series 6.[ 3 H]-FQSE (SEQ ID NO: 10) binding site negative control.
[0678] 10.2.9.1. Isolation of Plasma Membranes with Hippocampal NMDA Receptors.
[0679] An improved method was used to isolate the hippocampal plasma membrane (Zhou et al. (1997). (2S, 4R) -4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors. J. Pharmacol. Exp. Ther., 280 (1), 422-427., LePage et al. (2005). Differential binding properties of [ 3 H]dextrorphan and 3H]MK-801inheterologously expressed NMDA receptors.Neuropharmacol.,49(1),1-16). After decapitation, the tissue was immediately frozen in liquid nitrogen and stored in a low-temperature freezer at -80°C. On the day of the experiment, the hippocampus was homogenized in a Potter homogenizer in 10 volumes of buffer No. 1 (5mM HEPES, 4.5mM Tris, 0.32M sucrose, pH 7.6) with "Teflon-glass". The homogenate was diluted in 50 volumes of buffer No. 2 (5mM HEPES, 4.5mM Tris, pH 7.6) and centrifuged at 1000g for 10 minutes in an Optima L-70K ultracentrifuge (Beckman Coulter). The supernatant was discarded and centrifuged again at 25000g for 20 minutes. This operation was performed twice to increase protein yield. The resulting precipitate was resuspended in 50 volumes of buffer No. 2 and centrifuged at 8000g for 20 minutes. The supernatant and upper brown sediment layer were poured off and centrifuged at 25000g for 20 minutes. The precipitate was resuspended in 50 volumes of buffer No. 3 (5mM HEPES, 4.5mM Tris, 1mM Na4EDTA, pH7.6) and centrifuged 3 times at 25,000g for 20 minutes each time. The resulting precipitate was resuspended in 50 volumes of buffer No. 2 and centrifuged at 25,000g for 20 minutes. The final precipitate was resuspended in 5 volumes of buffer No. 2 and frozen in liquid nitrogen in a cryovial. On the day of analysis, the tissue was thawed, diluted in 10 volumes of buffer No. 2, and centrifuged at 25,000g for 20 minutes. The precipitate was resuspended in the required amount of buffer No. 2.
[0680] 10.2.10. Radioligand Analysis of NMDA Receptors.
[0681] The incubation mixture (final volume 0.5 ml) contained 50 μl [ 3 H] (+) MK-801, 250 μl buffer and 200 μl of the protein suspension of the membrane, 50 μl of unlabeled ligand ((+) MK-801, 1 mM for nonspecific binding) were added. The reaction mixture was incubated at room temperature for 2 hours.
[0682] 10.2.11. Analysis and presentation of results.
[0683] By adding 50 μl of the test compound to the culture medium to a final concentration of 10 -10 -10 -4 M, to determine the IC50 value for the binding of the labeled ligand. The volume of the incubation mixture was 500 μl. To construct the curve of radioligand displacement, 3 replicates were performed for each concentration of the test substance.
[0684] 10.2.12. Statistical analysis.
[0685] For analysis of radioligand binding results, the programs GraphPad Prism 4 and Statistica 6.0 were used. Results are expressed as mean ± SE.M.
[0686] 10.3. Results.
[0687] 10.3.1. Series 1.
[0688] FQSE (SEQ ID NO: 10) did not affect [ 3 H]SR 95531 binds specifically to the GABAA receptor, which indicates that the investigated compound does not interact directly with the GABA site of the GABAA receptor: IC50 values greater than 100 μmol / L ( Fig.70 ).
[0689] 10.3.2. Series 2.
[0690] The IC50 of the specific FQSE (SEQ ID NO: 10) binding site was found to be 2 ± 0.1 μM ( Fig.71 ). In the entire concentration range used, the substances studied did not affect the specific binding of the labeled peptide (IC50>100 μM for all ligands), which means that the receptor of the selected ligand is not the binding site for the peptide studied ( Fig.71 ).
[0691] 10.3.3. Series 3.
[0692] 10.3.3.1. Incubate at room temperature for 25 min.
[0693] The substances investigated did not affect the specific binding of the labeled peptide over the entire concentration range used: IC50 values greater than 100 μmol / L ( Fig.72 ).
[0694] 10.3.3.2. Increase the incubation time.
[0695] In this series of experiments, the incubations were also carried out at room temperature, but the duration was extended to 50 minutes, 1 hour, and 1 hour and 30 minutes. Of the substances studied, only diazepam and pregnenolone affected the specific binding of the labeled peptide ( Fig.73 , Table 10).
[0696] Table 10: Potential of diazepam and pregnenolone to competitively bind to the specific binding site of FQSE (SEQ ID NO: 10) in rat cortex (IC50, μmol / L). Results are expressed as mean ± SE.M.
[0697]
[0698] 10.3.3.3. Preincubation protocol.
[0699] Experiments were performed with 2 modifications of pre-incubation and incubation duration:
[0700] Preincubation - 20 min, incubation - 25 min;
[0701] Preincubation – 1 h, incubation – 30 min.
[0702] In two variations of the incubation protocol, the combined [ 3 The amount of [H]FQSE (SEQ ID NO: 10) was reduced only after preincubation with diazepam or pregnenolone (p<0.05, t-test) (Table 11).
[0703] Table 11: Effect of preincubation with diazepam and pregnenolone on 3
[00143] Effect of the amount of [H]FQSE (SEQ ID NO: 10) binding sites. The control level (100%) was calculated in probes pre-incubated without adding any unlabeled ligand.
[0704]
[0705] 10.3.4. Series 4.
[0706] Specific binding was calculated as the difference between total binding and nonspecific binding. The results obtained at this stage are shown in Table 12.
[0707] Table 12: Effect of FQSE (SEQ ID NO: 10) on the binding of benzodiazepines to the corresponding GABAA receptor sites. Specific binding values were accepted for the control level (100%), for which only diazepam was used in the nonspecific binding in the corresponding modification of the radioligand assay.
[0708]
[0709] It was shown that FQSE (SEQ ID NO: 10) in all modifications of the radioligand binding assay did not affect the binding of BZD to the GABAA receptor specific site.
[0710] 10.3.5. Series 5.
[0711] For the second part of the experiment, different incubation times were used - 25 and 50 minutes at room temperature (these protocols were used according to the results obtained in the previous experiments). In the entire concentration range used, the ligands studied (Table 9) had no effect on the specific binding of the labeled peptides, with IC50 values >100 μmol / L ( Fig.74 ).
[0712] In the second stage, incubation was performed at room temperature, but the order of adding the components to the incubation mixture was different: first, 10 -4 or 10 -5 The membrane protein suspension and unlabeled GABAA receptor ligand were added to the buffer at a concentration of 1 M and after 1 h of preincubation, [ 3 H]-FQSE (SEQ ID NO: 10). The incubation lasted for 25 minutes. The time intervals shown were selected based on data obtained in previous experiments. If one of the substances under investigation binds to the FQSE (SEQ ID NO: 10) site, the bound [ 3 H]-FQSE (SEQ ID NO: 10) will decrease, which can indicate the affinity of the binding site of the ligand under investigation to the binding site of FQSE (SEQ ID NO: 10).
[0713] In this experimental modification, none of the test substances altered the bound [ 3 H]-FQSE (SEQ ID NO: 10) (p<0.05, t-test) (Table 13).
[0714] Table 13: Effect of preincubation with the investigated substances 3 [H]-FQSE (SEQ ID NO: 10) The control level (100%) was calculated in the probe pre-incubated without adding any unlabeled ligand.
[0715]
[0716] 10.3.6. Series 6.
[0717] Obtained 3 [H]-FQSE (SEQ ID NO: 10) binding site. For this purpose, membranes with NMDA receptors were isolated using the specialized techniques described in the methods section. The specific binding of the corresponding ligand MK-801 on these membranes was verified.
[0718] As a result of in vitro radioligand analysis of NMDA receptors, a displacement curve of IC50 = 0.007 + 0.0004 μmol / L was obtained. 3[H]-FQSE (SEQ ID NO: 10) and unlabeled FQSE (SEQ ID NO: 10) were subjected to radioligand analysis on the same membrane, which showed that there was no binding site for the peptide studied (the difference between total and nonspecific binding was 11%).
[0719] 10.4. Conclusion
[0720] Determination of rat cortical membrane 3 H]-FQSE (SEQ ID NO: 10) peptide specific binding site, IC50 = 2*10 - 6 M.
[0721] FQSE (SEQ ID NO: 10) peptide does not interact with [ 3 H]-SR 95531 competes for the GABA site of the GABAA receptor.
[0722] [ 3 The specific binding site of [H]-FQSE (SEQ ID NO: 10) is different from the binding sites of the following substances: known GABA-receptor ligands (muscimol, bicuculline, gabazine, CGS-9895) and dopamine (seroperidol, sulpiride, spiperone, 7-OH-DPAT), serotonin (ketanserin), acetylcholine (nicotine), glutamate (glutamate, glycine, Ro-256981, LY-354740, MK-801, spermine, arkain) receptors.
[0723] Diazepam and pregnenolone have been shown to have an effect on [ 3 H]-FQSE (SEQ ID NO: 10) binding site partial affinity (IC50 ~ 10 -4 M).
[0724] FQSE (SEQ ID NO: 10) has no effect on the binding of benzodiazepines to the corresponding GABAA receptor site.
[0725] [ 3 The specific binding site of [H]-FQSE (SEQ ID NO: 10) is different from the binding sites of the following known GABAA receptor ligands: isotetrahydronicotinic acid, SCS, Bretanezil, SL651498, MK0343, THDOC, TB21007, gaboxadol, FGIN-1-27, allopregnanolone.
[0726] Obtained 3H]-FQSE (SEQ ID NO: 10), which confirms the existence of a specific binding site for the peptide.
[0727] Example 11: Study of FQSE (SEQ ID NO: 10) Effect of peptide administration
[0728] The purpose of this study was to evaluate the potential neurotropic effects of intraperitoneally administered FQSE (SEQ ID NO: 10) peptide using the bicuculline model.
[0729] To evaluate the mechanism of action of the peptides in this study, the bicuculline model was used. Bicuculline is a natural alkaloid compound extracted from the leaves of Dicentre cucullaria, a plant of the Fumariaceae family, and is essentially a competitive antagonist of GABA-A receptors. When administered intravenously at a dose of 0.1-0.4 mg / kg, it causes convulsions in mice that last for several hours, which is attributed to Ca2 + Dependent potassium channels are destroyed (Khawaled (1999). Bicuculline block of small-conductance calcium-activated potassium channels. Pflügers Archiv, 438 (3): 314-321). During intraperitoneal administration of the drug at a dose of 5 mg / kg, no convulsions were observed, but behavioral tests showed that the activity of drugs belonging to the group of GABA-A modulators was greatly reduced compared with the values observed for these compounds without bicuculline, which confirmed the functional effect of the studied substances on GABA-A receptors (Mizushige (2013). Aromatic amino acid-leucine dipeptides exhibit anxiolytic-like activity in young mice. Neurosci. lett., 543: 126-129). It can be proposed that the FQSE (SEQ ID NO: 10) peptide used in the current study belongs to the group of GABA-A modulators.
[0730] The study objectives were to evaluate the effects of ip administration of FQSE (SEQ ID NO: 10) peptide on the behavior of BALB / C mice in the elevated plus maze (EPM), Porsolt forced swim test (FST) using the bicuculline model.
[0731] Materials and methods
[0732] Animal models
[0733] In this embodiment, 48 male BALB / C mice were used as subjects. The weight of each sample at the beginning of the experiment was between about 18 grams and about 20 grams. All animals were free of species-specific pathogens (according to the SPF status of the FELASA list, 2014). Animals were kept under conditions where water and food were freely available. The room was air-conditioned (exchange rate was not less than 15r / h), with a 12h:12h light-dark cycle (lights turned on at 09:00am), an air temperature of 20-24°±2°C (possible fluctuations were limited to no more than 2°C per day), and a humidity of 30-70%. All procedures involving animals were carried out in accordance with the European (Directive 2010 / 63 / EU of the European Parliament and the Council of September 22, 2010 on the protection of animals for scientific purposes) and the Russian ("GOST33216-2014 Guide for the maintenance and care of laboratory animals. Rules for the maintenance and care of laboratory rodents and rabbits") bioethical guidelines. For this study, mice were divided into four different groups and the test substances were administered to each group as shown in Table 2.
[0734] Table 14: Experimental groups
[0735]
[0736] All substances were administered intraperitoneally 30 minutes before the behavioral test in a volume of 10 μl solution per 1 g of animal body weight, with FQSE (SEQ ID NO: 10) peptide at a dose of 20 mg / kg and bicuculline at 5 mg / kg. No more than one test was performed per day. List and order of planned tests: Day 1 - elevated plus maze test, Days 8-9 - Porsolt swim (two-day correction) test.
[0737] Statistical analysis
[0738] Statistical data analysis was performed using nonparametric criteria (Manna-Whitney) for non-normally distributed samples or one-way analysis of variance (ANOVA) followed by Fisher's LSD test for normally distributed samples.
[0739] 11.1.3. Elevated plus maze test
[0740] In the elevated plus maze test, the test site includes two open arms and two closed arms that cross in the middle. The arm length is 30cm, and the closed arm side wall height is 15cm. The whole device is 70cm above the ground. The open arm has a bright uniform illumination of about 400lux, and the closed arm has an illumination of about 30-40lux. The mouse is placed at the junction (center) of the four arms of the maze, facing the open arm. The following behavioral parameters are automatically recorded by the EthoVision Noldus program within 5 minutes of the experiment: total distance (cm), movement time (if the speed exceeds 5cm / s), motionlessness (if the speed is less than 0.2cm / s), average and maximum speed, and the number of motor activities and "freezing" events. A set of identical parameters of the central sector, open arms and closed arms, as well as latency and duration of stay are measured respectively. (Made by OpenScience, Russia). In EPM, the main behavioral parameters characterizing the anxiolytic effect of drug administration compared with the control group are "open arm time", "open arm entry" and "anxiety index". The anxiety index (AI) was calculated by the following formula: AI = 100*(1-(open arm time / total trial time + open arm entries / total entries) / 2). An increase in open arm time and open arm entries and the associated decrease in the anxiety index are standard indicators of increased motivation to explore and decreased anxiety. These parameters can indicate the anxiolytic effect of a substance.
[0741] 11.1.4. Porsolt swim test (two-day correction)
[0742] In the Porsolt swimming test, two tests were conducted over two days. The apparatus is a transparent cylinder, 30 cm high and 10 cm in diameter, filled with water (temperature of about 21-23°C) to the 25 cm high mark. On the first day, each animal was placed in the cylinder for 10 minutes. No behavioral parameters were recorded. On the second day, the animals were placed in the cylinder for 5 minutes. The following parameters were measured: active (strong movements of the limbs) and passive (weak movements of the hind limbs) swimming, as well as the duration of immobility (immobility) (Porsolt et al. (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 229 (2): 327-36). After each test, the mice were placed in a heating unit to dry. FST (two-day correction) is used to evaluate the antidepressant-like properties of drugs. This test is one of the main methods for evaluating the depressive component of animal behavior and studying the effects of drugs on it.
[0743] The experimental studies were conducted in accordance with the following: GOST 33215-2014 rules on equipment premises and organizational procedures when working with laboratory animals; GOST 33216-2014 rules for working with laboratory rodents and rabbits; translation of Directive 2010 / 63 / EU of the European Parliament and of the Council of the European Union on the protection of animals used for scientific purposes, Rus-LASA, 2012.
[0744] 11.2 Results
[0745] 11.2.1. Evaluating the Effects of Test Substances on Mouse Behavior Using the Elevated Plus Maze Test
[0746] FQSE (SEQ ID NO: 10) peptide administration increased the time spent in the open arms (60.9 ± 13.31 vs. 32.4 ± 6.77 s in the control group) ( Fig.75A ) and open arm entry ( Fig.75B )(4±0.65 compared to 2.2±0.48 in the control group. Changes in these parameters resulted in a decrease in "AI" in FQSE (SEQ ID NO: 10) treated animals compared to controls (73±3.8 vs. 85±2.7%, respectively) ( Fig.75C The results obtained showed that the test substance at a dose of 20 mg / kg had a significant anxiolytic-like effect.
[0747] We did not observe any difference in the EPM test between the experimental groups treated with bicuculline at a dose of 5 mg / kg. Co-administration of the peptide with bicuculline also did not reduce the anxiety-like behavior of the mice.
[0748] The results obtained indicate that the test substance at a dose of 20 mg / kg has significant anxiolytic-like effects. These effects of FQSE (SEQ ID NO: 10) were absent when the peptide was co-administered with bicuculline (a competitive antagonist of GABA-A receptors), which may indicate a functional role of FQSE (SEQ ID NO: 10) through interaction with GABA-A receptors.
[0749] 11.2.2. Evaluation of the Effects of Test Substances on Mouse Behavior Using the Porsolt Forced Swim Test
[0750] FQSE (SEQ ID NO: 10) peptide treatment resulted in an increase in the time spent in active swimming (103.7 ± 16 s) compared to the control group (57.1 ± 17.62 s) ( Fig.76 ), which can be regarded as the antidepressant-like effect of the test compound.
[0751] In this test, bicuculline alone did not affect the behavior of the mice. These results are consistent with previous studies. In Mizushige's work (Mizushige et al. (2013). Characterization of Tyr-Leu-Gly, a novel anxiolytic-like peptide released from bovine αS-casein. FASEBJ., 27 (7), 2911-2917), ip administration of bicuculline at a dose of 5 mg / kg did not affect the parameters of the animals in the FST. Mice that received FQSE (SEQ ID NO: 10) and bicuculline also did not show any changes in the time spent actively swimming. These results may indicate that bicuculline can attenuate the effects of the peptide and that the antidepressant-like properties of FQSE (SEQ ID NO: 10) may be related to the interaction with the GABA-A receptor.
[0752] Conclusion
[0753] Intraperitoneal injection of 20 mg / kg dose of FQSE (SEQ ID NO: 10) peptide into BALB / C mice 30 minutes before behavioral testing resulted in significant anxiolytic-like and antidepressant-like effects.
[0754] Injection of 5 mg / kg bicuculline into BALB / C mice 30 minutes before behavioral testing did not affect the behavior of mice in the EPM and FS tests.
[0755] Co-administration of FQSE (SEQ ID NO: 10) and bicuculline significantly reduced the manifestation of anxiolytic-like and antidepressant-like properties of the peptide, which may indicate a possible mechanism by which the drug functions through interaction with GABA-A receptors.
[0756] Example 12: New peptide FQSE (SEQ ID NO: 10) Effects on neuroinflammation in vitro using primary glial cells cell
[0757] The aim of the study was to evaluate the potential effects of FQSE (SEQ ID NO: 10) peptide on LPS-induced neuroinflammation in primary murine glial cells in vitro.
[0758] 12.1. Methods
[0759] The cells were divided into 10 groups and subjected to the following treatments.
[0760] Control cells
[0761] +LPS (500 ng / mL, 24 hours)
[0762] +LPS+FQSE(SEQ ID NO:10), 0.04μM
[0763] +LPS+FQSE(SEQ ID NO:10), 4μM
[0764] +LPS+FQSE(SEQ ID NO:10), 40μM
[0765] +LPS+FQSE(SEQ ID NO:10), 400μM
[0766] +FQSE (SEQ ID NO: 10), 0.04 μM
[0767] +FQSE (SEQ ID NO: 10), 4 μM
[0768] +FQSE (SEQ ID NO: 10), 40 μM
[0769] +FQSE (SEQ ID NO: 10), 400 μM
[0770] 12.1.1. Parameters of analysis
[0771] Expression levels (mRNA, qPCR) of the following inflammatory biomarkers: IL-6, Il-1b, TNFa, IKKb.
[0772] 12.1.2 Experimental procedures
[0773] Whole brains from 1-2 day old newborn C57 / Bl6 mice were collected, without meninges, and placed in HBSS modified medium (Gibco 14190144) without calcium or magnesium, and processed according to the manufacturer's instructions of Miltenyi Biotech. All procedures were approved by the Animal Care and Use Committee of Wayne State University Institutions according to the guidelines of the National Institutes of Health. The supernatant was discarded, and the pellet was resuspended in 1-2 mL Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12, without phenol red (DMEM / F-12), (Gibco 21041025), which was enriched with 10% inactivated fetal bovine serum (FBS) (ThermoFischer 10082147) and 1% antibiotic-antimycotic (ThermoFischer 15240062). After homogenization, cells were incubated in a Nunc filter-capped microcentrifuge containing 10 mL of culture medium [DMEM / F-12; 10% FBS; 1% antibiotic-antimycotic].TM Cell culture treatment bottle (ThermoFischer, 178905), in 5% CO2 incubator (Galaxy 170R, Eppendorf) at 37 ℃ growth. The cells are kept in culture for 8-10 days, and part of the culture medium (70%) is replaced every 48-72 hours. When 80% confluence, the cells are incubated at 37 ℃ for 2 hours in a shaking incubator at 200rpm to separate oligodendrocytes and neurons from glial cell cultures. The suspended cells are discarded, and the adhered cells are washed with 1mL of Dulbecco'sPhosphate-Buffered Saline (Dulbecco'sPhosphate-Buffered Saline, DPBS) (Gibco 14190144) without calcium or magnesium. Then, 5mL 1x trypsin (ThermoFischer 15400054) is added, and the cells are kept in an incubator (5% CO2, 37 ℃) for 15 minutes. After this step, an equal amount of complete medium was added to stop the trypsin action, and the cells were centrifuged at 1000 rpm for 10 min at room temperature. The cells were then cultured in 24-well plates (80,000 cells / well) and treated 48 hours after seeding.
[0774] Cells were treated for 24 hours with the following conditions: LPS [250 ng / ml] and drug FQSE (SEQ ID NO: 10) alone [400 μM, 40 μM, 4 μM, 0.04 μM]. In addition, all concentrations of drug FQSE (SEQ ID NO: 10) with LPS [400 μM + LPS, 40 μM + LPS, 4 μM + LPS, 0.04 μM + LPS] were used. N = 3-4 samples per group. Complete medium was used as a control.
[0775] After exposure, cells were washed with 1 ml cold DPBS and immediately harvested with 1 ml Trizol and subsequently used for RNA extraction. The gene expression of TNF-α, IL-1b, IL-6, and IKKb was analyzed.
[0776] Results
[0777] The qPCR measurement results of TNFa, IL-1b and Il-6 expression levels are shown in Fig.77As shown. FQSE (SEQ ID NO: 10) demonstrated a significant dose-response effect on TNFa expression. At 400 μM, it effectively inhibited LPS-induced TNFa expression, however, the effect of lower FQSE (SEQ ID NO: 10) concentrations was not statistically significant. Under chronic stimulation with potential stressors weaker than LPS, lower concentrations of FQSE (SEQ ID NO: 10) can still have an anti-inflammatory effect. This hypothesis is supported by the fact that FQSE (SEQ ID NO: 10) (even at 0.04 μM) is able to reduce basal TNFa and IL-6 expression levels in non-activated glial cells.
[0778] FQSE (SEQ ID NO: 10) demonstrated high efficacy in inhibiting LPS-induced IL-1b and IL-6 expression over a wide dose range.
[0779] Expression of NFKb downstream signal transduction gene IKKb ( Fig.78 ) was not related to FQSE (SEQ ID NO: 10), however the expression level of said gene was relatively weak in all treatments. In addition, it is worth mentioning that no significant changes in the expression of IKKb in response to LPS were detected, indicating that this gene seems to be an irrelevant marker in this model.
[0780] Conclusion
[0781] FQSE (SEQ ID NO: 10) inhibits LPS-induced expression of proinflammatory cytokines TNF-α, IL-1b, and IL-6 in primary glial cells, which may indicate its role in regulating neuroinflammation.
[0782] The data obtained are highly correlated with previous Western blot results, in which FQSE (SEQ ID NO: 10) was found to be able to normalize stress-induced ERK1 / 2 (MAPK pathway participant) phosphorylation levels. The suppressed expression of proinflammatory cytokines observed in this study can also be considered as a result of GABAa-triggered MAPK inhibition (Lee et al. (2013). Neurotransmitters and microglial-mediated neuroinflammation. Curr. Prot. Pept. Sci., 14 (1), 21-32).
[0783] Example 13: FQSE (SEQ ID NO: 1) in rat brain regions after intranasal administration ID NO: 10) Distribution research
[0784] The pharmacokinetic study objective was to determine the distribution of FQSE (SEQ ID NO: 10) in rat brain regions following intranasal administration.
[0785] Study Design
[0786] The tritiated peptide FQSE (SEQ ID NO: 10) was administered intranasally (in) at a dose of 500 μg / kg diluted in saline. The administered sample contained 2000 μKi of the tritiated peptide [ 3 H] FQSE (SEQ ID NO: 10). 6 minutes after administration, test samples of brain, blood and urine were obtained.
[0787] Choice of animal species
[0788] Animal studies provide complete toxicity information for substances intended for human use. This study is part of a complex pharmacokinetic and pharmacological study of drugs intended to treat neurodegenerative diseases. Wistar male rats were selected for the study.
[0789] Number of animals
[0790] The number of animals used in the study - 5 Wistar male rats, was sufficient for the significance of the data for the effects tested.
[0791] Method of administration and dosage selection
[0792] The substance was administered once, as a single intranasal administration (bolus).
[0793] Dose preparation
[0794] The study was conducted using the tritiated peptide FQSE (SEQ ID NO: 10). For this purpose, rats were administered a dose of 500 μg / kg (approximately 150 μg) of 2000 μKi [ 3 H] FQSE (SEQ ID NO: 10). The solution administered to the animals was prepared using saline solution. The volume of the solution for intranasal administration in rats was 20 μl.
[0795] After the dose is prepared, keep at 4-2°C for 3 hours before administration.
[0796] Animal husbandry
[0797] The animals were housed on litter in polycarbonate cages type 3 (825 sq.cm); the cages were covered with steel grid feeders. For the litter, a commercial litter LIGNOCEL (JRS, Germany) made of specially prepared wood chips was used. The litter was regularly checked for microbial contamination. The experimental data were kept in the laboratory files.
[0798] Complete mixed feed "Chara" (Range of Agro products, Russia) for experimental animals was freely provided to feeders in the cage covers. Microbiological contamination of feeding materials was regularly analyzed. The results of the analysis, as well as data on the composition and quality of the producer's feed, were recorded in the laboratory files.
[0799] Purified drinking water is freely available in standard drinking bottles. Water samples are tested for microbiological contamination at regular intervals. Test results are submitted in current laboratory files.
[0800] The animals were kept under controlled environmental conditions (18-26°C and 30-70% relative humidity). Temperature and humidity were constantly monitored in each experimental room. A 12-hour light cycle and at least 10 room air changes per hour were maintained in the rooms where the animals were housed.
[0801] Animals were allowed to adapt to the laboratory for at least 3 days before dosing. During this period, the appearance of the animals was checked every day. Animals with abnormalities found during the inspection were excluded from the experimental group.
[0802] Each animal was assigned an individual number, marked by ear puncture and fixed to a cage tag. All procedures involving animals were performed in accordance with European (Directive 2010 / 63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes) and Russian (“Guidelines for the maintenance and care of laboratory animals GOST 33216-2014. Rules for the maintenance and care of laboratory rodents and rabbits”) bioethical guidelines.
[0803] 13.1 Methods
[0804] Peptide administration to animals and blood collection
[0805] In rat experiments, the product FQSE (SEQ ID NO: 10) was administered as a single, bolus, intranasal injection. Initially, rats were anesthetized with chloral hydrate (300 mg / kg) and injected intranasally with 500 μg / kg of chloral hydrate over 10 minutes in a 20 μl volume containing 2000 μKi of the labeled peptide [ 3 The product FQSE (SEQ ID NO: 10) was administered in a sterile saline solution (0.9% NaCl) to prepare the FQSE (SEQ ID NO: 10) solution intended for administration to animals. Rinses were sacrificed within 6 minutes after product administration. Organ biopsies were rinsed in saline solution for 5-7 seconds, transferred to weighed plastic vials, weighed and frozen with liquid nitrogen. Sterile saline solution (0.9% NaCl) was used to prepare the FQSE (SEQ ID NO: 10) solution intended for administration to animals.
[0806] Preparation of tissue samples
[0807] Frozen and weighed tissue samples in plastic tubes were freeze-dried for 2 days before preparing the tissue for high performance liquid chromatography (HPLC) determination. To prepare the peptide extract, sequential extraction of the organic diluent, evaporation under reduced pressure and centrifugation were performed. The freeze-dried blood sample was heated at 65°C for 30 minutes, after which the sample was dispersed in the same plastic vial and the horizontal knife was rotated at a speed of 5000 rot / min. The sample was first extracted with 90% water-acetonitrile containing 1% trifluoroacetic acid. Then, 10 μg of the peptide FQSE FQSE (SEQ ID NO: 10) intended to identify the peptide fraction in the chromatogram was added to the extraction water-acetonitrile solution. After centrifugation, the solution containing the tritiated peptide and plasma components was dried under reduced pressure, re-extracted with methanol and re-centrifuged. The resulting solution containing the tritiated peptide and plasma components was dried under reduced pressure, re-extracted with a 0.1% aqueous solution of heptafluorobutyric acid and further centrifuged. In order to verify the method of sample preparation, a peptide containing 10 μKi [ 3 10 μl of a solution of [H]FQSE (SEQ ID NO: 10) was administered to 200 μl of fresh rat blood, after which the sample was processed according to the protocol. As a result of the analysis, 95% of the initial labeled peptide [ 3 H] FQSE (SEQ ID NO: 10).
[0808] 13.2 Results
[0809] Quantitative analysis of the peptide HPLC was performed on a Kromasil C18 column (4x150 mm), with a methanol gradient (0-40%), and with 0.08% TFA and 0.02% HFBA (heptafluorobutyric acid). Fractions containing the peptide FQSE (SEQ ID NO: 10) were collected and their radioactivity was measured by liquid scintillation counting. The distribution of the peptide (SEQ ID NO: 10) in tissues is shown in Table 15.
[0810] Table 15: Intranasal administration of 500 μg / kg dose of 2000 μKi [ 3 Distribution of peptide FQSE (SEQ ID NO: 10) in rat brain tissue within 6 minutes after administration of [H]FQSE (SEQ ID NO: 10). Concentrations are expressed as mean ± error of the mean.
[0811]
[0812]
[0813] It was found that the greatest affinity of the peptide FQSE (SEQ ID NO: 10) after intranasal administration was in the olfactory bulb, where the content was significantly higher than in other brain regions. It was also found that higher levels of the peptide FQSE (SEQ ID NO: 10) were present in the prefrontal cortex, hippocampus and hypothalamus compared to other brain regions. The concentration of the peptide FQSE (SEQ ID NO: 10) in tissues was lower than in the blood: 6 minutes after intranasal administration, the concentration of FQSE (SEQ ID NO: 10) in the brain was about 1 / 5-1 / 10 of its blood concentration.
[0814] 13.3 Conclusion
[0815] It was found that the greatest affinity of the peptide FQSE (SEQ ID NO: 10) was found in the olfactory bulb, where the content was significantly higher than in other brain regions. It was also shown that higher levels of the peptide FQSE (SEQ ID NO: 10) were present in the prefrontal cortex, hippocampus and hypothalamus compared to other brain regions. These results indicate that the peptide FQSE (SEQ ID NO: 10) is able to cross the blood-brain barrier.
[0816] Equivalent
[0817] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are also intended to be encompassed within the scope of the following claims.
[0818] Incorporated by Reference
[0819] All patents and publications cited herein are incorporated by reference in their entirety.
[0820] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
[0821] As used herein, all headings are for organizational purposes only and are not intended to limit the disclosure in any way. The contents of any individual section may apply equally to all sections.
[0822] As referred to herein, unless otherwise specified, all composition percentages are by weight of the total. As used herein, the word "include" and its variants are intended to be non-restrictive, so that the items listed in the list do not exclude other similar items that can also be used for the compositions and methods of the present technology. Similarly, the terms "can" and "may" and their variants are intended to be non-restrictive, so that the description that an embodiment can or can include certain elements or features does not exclude other embodiments of the present technology that do not include those elements or features. In addition, the term "substantially" means that the feature, parameter or value does not need to be precisely implemented, but there may be deviations or changes, including, for example, tolerances, measurement errors, measurement accuracy limitations, manufacturing tolerances, and other factors known to those skilled in the art, and the amount does not hinder the effect to be provided by the characteristic, parameter or value. In the description presented herein, the term "about" or "approximately" refers to a range of values within plus or minus 10% of the specified number.
[0823] Although the open-ended term "comprising," as a synonym for terms such as includes, contains, or having, is used herein to describe and claim the invention, the invention or embodiments thereof may alternatively be described using alternative terminology such as "consisting of" or "consisting essentially of.
[0824] As used herein, the words "preferred" and "preferably" refer to embodiments of the technology that provide certain benefits in certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, listing one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the technology. Sequence Listing <110> Lactocore, Inc. MALYSHEV, Anton DORONIN, Igor BABKIN, Gennady A. Kuchumov (Askar) <120> Synthetic neuromodulatory peptides <130> LACT-001PC / 121851-5001 <150> US 62 / 818,458 <151> 2019-03-14 <160> 36 <170> PatentIn version 3.5 <210> 1 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 1 Tyr Leu Gln Tyr 1 <210> 2 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 2 Tyr Gln Leu Tyr 1 <210> 3 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 3 Tyr Leu Glu Gln 1 <210> 4 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 4 Gln Tyr Leu Tyr 1 <210> 5 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 5 Tyr Leu Lys Tyr 1 <210> 6 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 6 Tyr Leu Lys Thr 1 <210> 7 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 7 Phe Leu Leu Tyr 1 <210> 8 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 8 Tyr Gln Lys Phe 1 <210> 9 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 9 Leu Tyr Gln Glu 1 <210> 10 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 10 Phe Gln Ser Glu 1 <210> 11 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 11 Phe Tyr Gln Lys 1 <210> 12 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 12 Tyr Leu Gly Tyr 1 <210> 13 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 13 Pro Phe Thr Glu 1 <210> 14 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 14 Trp Asp Gln Val 1 <210> 15 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 15 Pro Glu Val Phe 1 <210> 16 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 16 Leu Ser Arg Tyr 1 <210> 17 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 17 Leu Leu Arg Phe 1 <210> 18 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 18 Met Pro Leu Trp 1 <210> 19 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 19 Lys Tyr Gln Phe 1 <210> 20 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 20 Tyr Gln Phe Leu 1 <210> twenty one <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> twenty one Phe Phe Val Ala 1 <210> twenty two <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> twenty two Lys Thr Val Tyr 1 <210> twenty three <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> twenty three Phe Ser Asp Ile 1 <210> twenty four <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> twenty four Ser Phe Ser Asp 1 <210> 25 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 25 Leu Leu Tyr Gln 1 <210> 26 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 26 Asp Lys Thr Glu 1 <210> 27 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 27 Tyr Tyr Val Pro 1 <210> 28 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 28 Phe Thr Glu Ser 1 <210> 29 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 29 Gly Thr Gln Tyr 1 <210> 30 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 30 Phe Leu Gly Ala 1 <210> 31 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 31 Tyr Thr Asp Ala 1 <210> 32 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 32 Tyr Pro Ser Tyr 1 <210> 33 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 33 Phe Pro Lys Tyr 1 <210> 34 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 34 Tyr Pro Phe Pro Gly Pro Ile 1 5 <210> 35 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 35 Tyr Leu Gly Tyr Leu Glu Gln Leu Leu Arg 1 5 10 <210> 36 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 36 Phe Leu Pro Tyr 1
Claims
1. Use of a composition comprising a synthetic neuromodulatory peptide in the preparation of a medicament for treating mood disorders, wherein the mood disorder is depression or anxiety, and the neuromodulatory peptide is defined by general formula I: R1R2R3R4(I) in: R1 is F, R2 is Q, R3 is S, and R4 is E; R1 is W, R2 is D, R3 is Q, and R4 is V; or R1 is D, R2 is K, R3 is T, and R4 is E.
2. The use according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
3. The use of claim 1 or 2, wherein the composition further comprises a delivery vehicle.
4. The use according to claim 3, wherein the delivery vehicle is selected from liposomes, nanoparticles and polysaccharides.
5. The use according to claim 4, wherein the polysaccharide is selected from cyclodextrin, chitosan, cellulose and alginate.
6. The use according to claim 1 or 2, wherein the composition is formulated for intranasal administration.
7. The use according to claim 6, wherein the composition comprises at least one nasal mucosal protease inhibitor.
8. The use according to claim 7, wherein the inhibitor is selected from bestatine, comostate amylase, leupeptin, aprotinin, bacitracin, amastatine, boroleucine, puromycin, bile salts and fusidic acid.
9. The use according to claim 1 or 2, wherein the composition is formulated for administration by inhalation.
10. The use of claim 9, wherein the administration by inhalation is performed using a dry powder intranasal device.
11. The use according to claim 1 or 2, wherein the composition is formulated for intravenous administration.
12. The use according to claim 1 or 2, wherein the composition is formulated for oral administration.
13. The method of claim 1, wherein the depression is selected from major depressive disorder, dysthymia, explosive depression, refractory depression and depression associated with Parkinson's disease, depression associated with post-traumatic stress disorder, postpartum depression, bipolar disorder or bipolar depression and treatment-resistant depression (TRD).
14. The method of claim 1, wherein the anxiety disorder is selected from the group consisting of separation anxiety disorder, selective mutism, specific phobia (SP), social anxiety disorder (SAD), panic disorder, agoraphobia, substance / medication induced anxiety disorder and anxiety disorder attributed to another medication condition, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), social phobia, agitation in Alzheimer's disease, aggression in Alzheimer's disease, and obsessive compulsive disorder (OCD).
15. The use of claim 1 or 2, wherein the treatment further comprises administering an antidepressant, wherein the antidepressant is optionally selected from the group consisting of: serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, combined-acting SSRI / SNRI, serotonin-2 antagonists / reuptake inhibitors, antidepressants with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, antidepressants with serotonin / norepinephrine / dopamine reuptake inhibition, antidepressants with norepinephrine and dopamine reuptake inhibition, 5-HT-1alpha antagonists, 5-HT-1beta antagonists, 5-HT1A receptor agonists, 5-HT1A receptor agonists and antagonists, 5-HT2 receptor Antagonists, viloxazine hydrochloride, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor enhancers, substance P antagonists / neurokinin-1 receptor antagonists, non-peptide substance P antagonists, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin releasing factor receptor antagonists, antiglucocorticoid drugs, glucocorticoid receptor antagonists, cortisol blockers, nitric oxide synthesis inhibitors, phosphodiesterase inhibitors, enkephalinase inhibitors, GABA-A receptor agonists, free radical traps, atypical MAOIs, selective MAOI inhibitors, hormones, folinic acid, leucovorin, tramadol, and tryptophan in combination with an antipsychotic drug, wherein the antipsychotic drug is selected from the group consisting of atypical antipsychotics and dopamine system stabilizers.
16. The use of claim 1 or 2, wherein the treatment further comprises administering an additional depression therapeutic agent optionally selected from one or more of the following agents: CYMBALTA oral, LEXAPRO oral, EFFEXOR XR oral, ZOLOFT oral, CELEXA oral, TRAZODONE oral, PROZAC oral, WELLBUTRIN XL oral, CITALOPRAM oral, PRISTIQ oral, AMITRIPTYLINE oral, SAVELLA oral, VIIBRYD oral, PAXIL CR oral, WELLBUTRIN oral, PAXIL oral, SERTRALINE oral, REMERON oral, NORTRIPTYLINE oral, VENLAFAXINE oral, FLUOXETINE oral, BUPROPION HCL oral, MIRTAZAPINE oral, RITALIN oral, PAROXETINE oral, WELLBUTRIN oral SR oral, DOXEPIN oral, METHYLPHENIDATE oral, SYMBYAX oral, ESCITALOPRAMOXALATE oral, PAMELOR oral, IMIPRAMINE oral, BRINTELLIX oral, DULOXETINE oral, NARDIL oral, FETZIMA oral, EMSAM TRANSDERMAL, PARNATE oral, PEXEVA oral, BRISDELLE oral, CLOMIPRAMINE oral, ANAFRANIL oral, TOFRANIL oral, FLUVOXAMINE oral, ZYBAN oral, DESIPRAMINE oral, SARAFEM oral, PROZAC WEEKLY oral, APLENZIN oral, METHYLIN oral, NEFAZODONE oral, QUILLIVANT XR oral, TOFRANIL-PM oral, NORPRAMIN oral, REMERON SOLTAB oral, BUPROPION HBR oral, OLEPTRO ER oral, DESVENLAFAXINE SUCCINATE oral, BUPROBAN oral, IMIPRAMINE PAMOATE oral, VILAZODONE oral, MILNACIPRAN oral, PAROXETINE MESYLATE oral, SURMONTIL oral, MAPROTILINE oral, PROTRIPTYLINE oral, PHENELZINE oral, MARPLAN oral, OLANZAPINE-FLUOXETINE oral, TRANYLCYPROMINE oral, SELEGILINETRANSDERMAL, AMOXAPINE oral, FORFIVO XL oral, ISOCARBOXAZID oral, DESVENLAFAXINE oral, KHEDEZLA oral, LEVOMILNACIPRAN oral, VORTIOXETINE oral, and DESVENLAFAXINE FUMARATE oral.
17. The method of claim 1 or 2, wherein the treatment further comprises administering an additional anxiety treatment agent optionally selected from one or more of the following agents: a benzodiazepine selected from alprazolam (XANAX), clonazepam (KLONOPIN), diazepam (VALIUM), lorazepam (ATIVAN), oxazepam (SERAX), and chlordiazepoxide (librium); a beta blocker selected from propranolol (INDERAL) and atenolol (TENORMIN); a tricyclic antidepressant selected from imipramine (TOFRANIL), desipramine (NORPRAMIN, PERTOFRANE), nortriptyline (AVENTYL or PAMELOR), atenolol (TENORMIN); imipramine (ELAVIL), doxepin (SINEQUAN or ADAPIN), clomipramine (ANAFRANIL); monoamine oxidase inhibitors (MAOIs) selected from phenelzine (NARDIL), tranylcypromine (PARNATE); selective serotonin reuptake inhibitors (SSRIs) selected from fluoxetine (PROZAC), fluvoxamine (LUVOX), sertraline (ZOLOFT), paroxetine (PAXIL), escitalopram oxalate (LEXAPRO), citalopram (CELEXA); serotonin-norepinephrine reuptake inhibitors (SNRIs) selected from venlafaxine (EFFEXOR), venlafaxine extended release (EFFEXOR XR) and duloxetine (CYMBALTA); mild sedatives; and anticonvulsants selected from valproate (DEPAKOTE), pregabalin (LYRICA) and gabapentin (NEURONTIN).
18. The use according to claim 17, wherein the mild sedative is buspirone (BUSPAR).
Citation Information
Patent Citations
Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101065014A
Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101432011A
Peptide
WO2008108285A1
Peptide with antidepressant activity and therapeutic effect against alzheimer's disease
WO2018199803A1
EP21667-21677
